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ABSTRACT
Cancer research is centered on the discovery of new biomarkers that could unlock
the obscurities behind the mechanisms that cause cancer or those associated with its
spread (i.e., metastasis). Circulating tumor cells (CTCs) have emerged as attractive
biomarkers for the management of many cancer-related diseases due primarily to the
ease of securing them from a simple blood draw. However, their rarity (~1 CTC per mL
of whole blood) makes enrichment analytically challenging. Microfluidic systems are
viewed as exquisite platforms for the clinical analysis of CTCs due to their ability to be
used in an automated fashion, minimizing sample loss and contamination. This has
formed the basis of the reported research, which focused on the development of
microfluidic systems for CTC analysis. The system reported herein consisted of a
modular design and

targeted

the

analysis of CTCs using pancreatic ductal

adenocarcinoma (PDAC) as the model disease for determining the utility of the system.
The system was composed of 3 functional modules; (i) a thermoplastic CTC selection
module consisting of high aspect ratio (30 µm x 150 µm) channels; (ii) an impedance
sensor module for label-less CTC counting; and (iii) a staining and imaging module for
phenotype identification of selected CTCs. The system could exhaustively process 7.5
mL of blood in <45 min with CTC recoveries >90% directly from whole blood. In
addition, significantly reduced assay turnaround times (8 h to 1.5 h) was demonstrated.
We also show the ability to detect KRAS gene mutations from CTCs enriched by the
microfluidic system. As a proof-of-concept, the ability to identify KRAS point mutations
using a PCR/LDR/CE assay from as low as 10 CTCs enriched by the integrated
microfluidic system was demonstrated.

The clinical utility of the polymer-based
xxiii

microfluidic device for the analysis of circulating multiple myeloma cells (CMMCs) was
demonstrated as well. Parameters such as translational velocity and recovery of
CMMCs were optimized and found to be 1.1 mm/s and 71%, respectively. Also
demonstrated was on-chip immunophenotyping and clonal testing of CMMCs, which
has been reported to be prognostically significant. Further, a pilot study involving 26
patients was performed using the polymer microfluidic device with the aim of correlating
the number of CMMCs with disease activity. An average of 347 CMMCs/mL of whole
blood

was

recovered

from

blood

volumes

xxiv

of

approximately

0.5

mL.

CHAPTER 1. MATERIALS AND MICROFLUIDICS: ENABLING THE CLINICAL
UTILITY OF CIRCULATING TUMOR CELLS
1.1 Introduction
CTCs are exfoliated cells from primary or secondary neoplasms that have been
implicated in metastasis. [1] Studies based on mouse models indicate that growing or
regressing tumors shed ~3.2 to 4.1 x 10 6 cells per day per g of tissue. [2] [3] Although a
great number of these cells turn out to be apoptotic, [4, 5] there exists a certain
aggressive population that under particular micro-environmental conditions, may
acquire mesenchymal characteristics, evade the body’s immune surveillance system
and infiltrate distant organs giving rise to metastasis. [6, 7] Recent findings have
suggested CTCs exist in circulation as single cells or aggregates (CTM-circulating
tumor microemboli) of which the latter have been found to be associated with increased
metastatic potential (see Figure 1.1). [8, 9] Clinical studies based on CTCs have
associated the frequency of occurrence of these cells with poor progression free and
overall survival for metastatic

breast, colorectal and prostate cancer. [10-12]

Consequently, they have been viewed as attractive new cancer biomarkers for
managing many cancer diseases. CTCs have been suggested to serve as surrogates
for tumor biopsy tissue allowing for less invasive sampling, which is especially beneficial
for cancers that are anatomically inaccessible, such as pancreatic tumors. They can
also be a source of material for understanding basic tumor biology, such as genotype or
protein profile investigational studies or for drug targeting/discovery applications. [13-15]
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Figure 1.1 CTCs escape immune surveillance and result in metastatic malignancy.
(Reproduced from Elshimali et al. [16] with permission)
Ninety percent of all cancer-related deaths are due to metastatic disease.
Unfortunately, many conventional methods for cancer diagnosis, such as imaging with
the appropriate contrast agents, are not sensitive enough to detect micro-metastatic or
pre-metastatic conditions, where treatment interventions can result in improved overall
survival compared to therapies administered after the onset of metastatic disease. A
number of studies have indicated that CTCs can be used for detection of pre-metastatic
conditions besides being restricted to managing metastatic disease only. [17-19]
Various technologies have been used to isolate and enumerate CTCs from
blood, however, in spite of the rapidly evolving technology there are still challenges.
CTCs are a very rare population in blood, which is populated with a variety of cell types
in

much

higher

abundance

than

CTCs.

Further,

CTCs

are

phenotypically

heterogeneous with a short half-life; 1 – 2.4 h in circulation. [20, 21] In addition, CTC
enrichment can be complicated by the fact that their genotype and phenotype profiles
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are likely to be modified dynamically once exfoliated due to EMT-like (EpithelialMesenchymal Transition) processes. [21-23] There is currently no single antigenic
marker that is uniformly expressed on all CTCs that can effectively be used to identify
the various sub-populations of CTCs that may be present in circulation and be key
effectors in the metastatic cascade. [24] Enrichment strategies (>109) are therefore
necessary to obtain various CTC sub-populations possibly found in circulation and also,
secure pure populations of these CTCs so as to enable downstream characterization of
such sub-populations via genotyping or the propagation of these cells for biological
studies.
CellSearch™ (Veridex LLC) is the only system cleared by the FDA as a
diagnostic tool for the enrichment and enumeration of CTCs, but only for metastatic
breast, colon and prostate cancers. This system is based on antibody functionalized
magnetic particles that specifically bind to CTCs expressing unique antigen(s), such as
the epithelial cell adhesion molecule, EpCAM. Upon application of a magnetic field,
CTCs bound to the magnetic particles are extracted and further identified with tumor
specific phenotypic markers. The technology has been clinically validated by several
studies. [11, 25] Advantages of CellSearch include; its ability to predict progression free
and overall survival of breast cancer patients; and it is a semi-automated process that
has facilitated use in several centers where clinical trials are currently being carried out.
[26] However, it suffers from low purity (0.01-0.1%) and low clinical sensitivity with
recent reports indicating very low CTC median yields (1 CTC/7.5 ml) in some cancers.
[27, 28]
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Newer platforms, such as microfluidics, have demonstrated higher purities and
clinical yields. [29-34] Microfluidic devices are attractive platforms for the analysis of
CTCs for several reasons: (i) They can be configured to select CTCs based on several
different modalities including biological cell properties, such as expression of antigens
specific to the CTC type or physical cell properties, such as cell size or deformability; (ii)
microfluidic devices operate in a closed architecture minimizing the potential of sample
contamination artifacts that may provide false positive results, especially in clinical
laboratory settings; (iii) microfluidics can be produced in a high production mode and at
low-cost. For example, devices can be produced in thermoplastics using microreplication, the same technology used to produce CDs and DVDs; (iv) CTC selection
devices can be integrated to other steps to fully automate sample processing negating
the need for operator intervention and thus, minimizing false negative or false positive
results. [35, 36] [34]
Challenges with microfluidics include the high surface-to-volume ratio associated
with these devices requiring special attention to engineer surfaces that reduce nonspecific adsorption artifacts, especially when dealing with clinical samples such as
whole blood. Also, microfluidics are many times incompatible with high throughput
processing; for typical volume flow rates of 300 nl/min (50 x 50 µm 2 microchannel crosssection, 0.2 cm s-1 linear velocity), 3,333 min (55.5 h) would be required to exhaustively
process 1 mL of sample.
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Figure 1.2 Enrichment of circulating tumor cells (CTCs) from the peripheral blood of
cancer patients is based on physical or biological properties of CTCs. (A) Physical
properties include size (membrane filter devices), deformability (microfluidic system in a
chip), density (Ficoll centrifugation), and electric charge (dielectrophoresis). (B)
Biological properties include expression of cell surface markers and invasive capacity.
Cell surface markers include an epithelial cell adhesion molecule (EpCAM) for positive
selection and CD45 for negative selection; anti-EpCAM or anti-CD45 antibodies
conjugated with magnetic beads, used to enrich CTCs in a magnetic field; and anti EpCAM antibodies on microposts or columns of nanobeads. Invasive capacity refers to
adherence and invasion of fluorescent matrix. Abbreviations: glyco A, glycophorin A (a
131-amino-acid protein present at the extracellular surface of the human red blood cell);
CAM, cell adhesion matrix; fluo-CAM, fluorescent cell adhesion matrix; RBC, red blood
cells. (Reproduced from Alix-Panabières et al. [38] with permission)
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CTC enrichment from blood is based on two criteria that differentiate CTCs from
normal hematopoietic cells: (i) Biological properties, such as surface and cytoplasmic
protein expression, viability, and invasion capacity. CTCs can be directly targeted, in
which case, this is referred to as positive selection while the converse, negative
selection clears hematopoietic cells to obtain CTC fractions indirectly; (ii) physical
properties such as size, density, cell membrane electric potential, and deformability (see
Figure 1.2). [37, 38]
Assessment of CTC enrichment technologies is based on 5 important figures-ofmerit: (i) Throughput, defined as the maximum volume processing rate; (ii) recovery, an
indicator of the number of target cells selected from the input sample with respect to the
seed level of the target in that same sample; (iii) purity, which is defined as the ratio of
CTCs selected to the total number of cells enriched; (iv) clinical sensitivity, which refers
to the ability of the assay to correctly identify those patients with the disease; and (v)
clinical specificity, which refers to the ability of the assay to correctly identi fy those
patients without the disease. [39, 40] While throughput is primarily a function of the
mechanical properties of the device, purity is in most cases material dependent whether
the selection modality is based on biological or physical properties of the CTC. Clinical
sensitivity and specificity are a complex function of the biological and physical
properties of the CTC, but also on the topographical features of the device.
Material considerations play an important role in the development of devices
targeted for CTC enrichment, especially for microfluidic-based devices. For example,
many CTC selection platforms utilize immunomagnetic selection that employ magnetic
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beads decorated with antibodies directed against antigens unique to the CTC. The
magnetic susceptibility of these particles must be sufficient to collect with high efficiency
all CTCs, even those with low expression levels of the target antigen. In addition,
devices with biocompatible surfaces are required so as to maintain CTC integrity and
viability as well as minimize non-specific adsorption of hematopoietic cells to their
surfaces. From a commercial perspective, material selection can determine the cost and
manufacturability of the CTC device. The manufacturing modality is highly dictated by
the type of material used; for example thermoplastics can be produced in high
production modes and at low cost using micro-replication. These considerations are
important in order to facilitate the use of devices in clinical-based settings, where a high
turnover is expected for cancer screening and diagnosis and the fact that devices are
used for only one assay and then, discarded to minimize false positive results. [41, 42]
As noted, material properties play an integral role in determining the performance
characteristics of a device irrespective of the selection modality employed (i.e.,
biological or physical). For selection based on the CTC’s biological properties, device
surface properties are dictated by the pendant functional groups found on the substrate
material both in terms of number density and type. These functional groups and their
surface density determine the surface load of affinity agents, such as antibodies used
for CTC enrichment. Typically, high loads of antibodies are required to select with high
efficiency CTCs, especially those with low antigen expression. The topography of the
surface is critical as well, because it can increase the contact area between the CTC
and selection surface for devices using affinity selection; large contact areas enhance
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recovery of CTCs even with low antigen expression levels. Optical transparency of the
substrate is an important consideration as well because efficient enumeration of the
CTCs utilizes immunofluorescence, where low-levels of fluorescence must be detected.
In addition, the substrate material must accommodate the fluorescence microscope
used to image the CTCs, such as the refractive index and cover slip thickness to
provide high image quality of the CTCs. For devices and assays based on IMAC
(immunomagnetic assisted cell sorting), the magnetic susceptibility of the beads is
critical for effective enrichment of CTCs from complex sample matrices. For CTC
microfluidic devices based on physical selection, such as micro-filters, the material
selection is based upon the ability to generate reproducible and accurate pore or filter
structure dimensions optimized for CTC selection while at the same time minimizing
non-specific adsorption of hematopoietic cells.
While many CTC reviews have appeared in the literature, the primary goal of
these reviews have been to focus on the enrichment protocols employed to select CTCs
and/or clinical studies. [38, 43-46]

This review is unique in that it will provide an

overview on the interplay of materials and microfluidics for CTC enrichment.
Specifically, we will discuss the role of material considerations on the performance
metric(s) of the microfluidic selection mechanism for CTC analysis including, recovery,
throughput, purity and clinical sensitivity/specificity.
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1.2 Substrates Commonly Used by Microfluidics for CTC Enrichment
Material options for any microfluidic device depend on several factors such as
machinability, optical transparency, inertness

to

the

assay conditions, thermal

tolerances and a surface conducive to modification. [42, 43, 47, 48] Silicon, glass,
polymers and magnetic beads are commonly employed in CTC enrichment microfluidic
devices. Here we will look at how these materials have been selected for the fabrication
of various CTC enrichment devices and the material property effects on CTC
enrichment.
1.2.1

Silicon and Glass Materials for CTC Enrichment Microfluidic Devices

Silicon and glass and their hybrids are the most commonly used materials for
CTC enrichment microfluidic devices primarily because of their well-established surfacemodification chemistries.

Silicon is a semiconductor material that has been well

characterized in terms of its physical and chemical properties as well as micromachining
techniques used to form structures relevant for the device’s operation. Silicon has been
used in both for the affinity and size selection of CTC using microfluidic devices. [31, 4951] Characteristics that make silicon an attractive material for CTC enrichment are its
solvent compatibility and well established surface chemistries for ligand attachment. In
the case of size selection, silicon offers good mechanical stability, especially in the
construction of different filter structures such as pores, slots and traps for high
throughput blood processing. [49, 50]
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Silicon can also be used as a master in soft lithography for the fabrication of
PDMS microfluidic devices for CTC enrichment. [52-54] Microfabrication of silicon can
be carried out using photolithography followed by wet etching, plasma etching or
reactive ion etching. [55] More specifically, deep reactive ion etching (DRIE) has been
utilized to create micropost structures as deep as 50 to 100 µm for CTC selection
devices based on affinity capture, [31] and the GEDI (geometrically enhanced
differential) devices, [29] both of which utilize affinity capture of CTCs. Nanostructured
silicon nanopillar (SiNP) devices for CTC capture were fabricated using a wet etching
method implementing a micro-electrochemical redox reaction involving HF and silver
nitrate. [56]
Filter-based microfluidic devices for CTC enrichment have also used silicon as
the substrate material for the generation of pore or filtering structures.

One such

example was the multi-obstacle architecture device that utilized silicon-on-glass (SOG)
to create high-aspect ratio microfilter structures for CTC isolation. Basically, lapping and
chemical/mechanical polishing (CMP) were performed on the silicon layer, which
determined the optimal height of the structures (50 µm). Glass was bonded onto the
silicon using anodic methods. As a consequence, CTC visualization was enabled
through the use of optical microscopy with high aspect ratio structures generated for
CTC isolation. [50] In another report, the authors produced uniform depth honeycomb
structures on a silicon micro-sieve (see Figure 1.3) to generate a CTC enrichment
device. The fabrication strategy employed a SOI (silicon-on-insulator) wafer instead of
silicon to prevent DRIE over-etching due to the embedded silicon dioxide layer. After the
10

structures were formed, the embedded SiO2 layer was then removed by dielectric
reactive ion etching. [49]

Figure 1.3 (A) SEM image of a silicon microsieve filter with uniform honeycomb pore
structures fabricated using silicon on insulator technology (SOI), (B) SEM image of the
backside of the microsieve membrane showing the supporting rings. The dimension of
the silicon microsieve and membrane area is 7.5 mm and 5 mm in diameter,
respectively. (C) Composite fluorescent images of enriched MCF-7 cells (red and blue)
and leukocytes (green and blue) stained with fluorescent labeled antibodies against
membrane antigens EpCAM (red) and leukocyte marker CD45 (green). All nuclei were
stained with DAPI. Scale bar: 30 μm (20×). (Reproduced from Lim et al. [49]with
permission).

Glass microfluidic devices are particularly favored due to their well-defined
surface chemistry and outstanding optical properties. These properties are highly
desired for maximizing signal output during the fluorescence imaging phases of the
assay to allow for immunophenotyping of the cells. In fact, a number of CTC microfluidic
devices consist of hybrid forms of two materials, such as glass and silicon or glass and
PDMS where glass is primarily used as a cover plate for high resolution imaging
purposes. For example, a herringbone device, which consisted of a PDMS substrate
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bonded to a glass cover plate, enabled high-resolution imaging for in situ FISH assays
and RNA ISH analysis of WNT2 gene expression of CTCs enriched by the device from
both human and patient-derived xenograft models. [57] [32]
There are some challenges involved with the fabrication of both glass and siliconbased microfluidic devices. First, glass is limited to the production of low aspect ratio
structures due to the isotropic nature of wet etching producing shallow structures. [47,
58] While this can be alleviated using DRIE dry etching techniques, it makes the
fabrication protocol more costly compared to wet-etching microstructures. Also, both
materials involve at least 5 fabrication steps with some requiring harmful and toxic
agents, such as acids for wet etching. This necessitates the need to use clean room
facilities, which also adds to the cost of producing devices, which can be problematic for
scenarios where in vitro diagnostics are required such as CTC assays, which require
one-time use operation. Device cost is compounded by low manufacturing yields when
using DRIE as well. [59, 60]
1.2.2
Polymer
Enrichment

Substrates

for

Microfluidic

Devices

used

for

CTC

To ensure clinical accessibility of microfluidic devices for CTC diagnostics, low-cost
and high fidelity large-scale production of single-use devices is critical. [61, 62] For this,
polymers, such as poly (methylmethacrylate), PMMA, cyclic olefin copolymer, COC,
poly(carbonate), PC, or poly(dimethyl siloxane), PDMS, are well suited. Microfluidic
devices fabricated in silicon [62-66] require time-consuming photolithography and
etching (wet or dry) to microstructure components required for each device adding to
device cost and reduced production rates. Alternatively, reverse polarities of the desired
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microstructures can be patterned into silicon substrates [62, 67-69] or spin-coated
photoresist layers [70-78] that can be used as molding masters. PDMS can be cast
against a mold master and cured to form the desired microstructures; this curing
process requires from 45 min to 24 h. [62, 67-79] The elastomeric PDMS is then peeled
from the master and the microstructured PDMS sealed against a glass cover plate; both
are treated with oxygen plasma and irreversibly bonded to yield the sealed device. After
removing the PDMS, the molding master is free for repetitive uses and the time and
expense of lithography for producing each device eliminated. [62, 67-79] However, this
process requires several hours of curing time and thus, is difficult to effectively compete
with the throughput capabilities offered by hot embossing or injection molding, where
thermoplastic replicas can be produced within a few seconds with high fidelity. [34, 61,
70, 80, 81]
Thermoplastics, such as PMMA and COC for selection of CTCs and PC have been
hot embossed from a metal molding master. In many cases, the master can be
mechanically machined into brass using micrometer-sized milling bits and thus, no
clean room is required. [61, 80] Alternative strategies, such as UV or X-ray LiGA
(lithography, electroplating, and molding) offer the ability to fabricate sub-micrometer
structures with high fidelity. [79, 82] Hot embossing consists of heating a thermoplastic
substrate to above its glass transition temperature (Tg) and under controlled pressure,
transferring the master’s microstructures into the heated substrate, then cooling and
releasing the patterned substrate. [61, 79, 80] Figure 1.4 shows pictures of a
micromilling machine used to produce mold masters and a hot embossing machine
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used to micro-mold devices from the metal masters generated via micromilling.
Similarly, injection molding can be used to create devices via micro-replication and
requires pellets of the thermoplastic to be passed through a heated barrel with the
molten thermoplastic forced through a nozzle and into a cavity produced by the molding
master. The thermoplastic then solidifies following cooling transferring the master
mold’s structures into the polymer. [79] While set up costs for injection molding are
higher than that associated with hot embossing, production rates for injection molding
are typically much higher than that associated with hot embossing.

Figure 1.4 (A) Kern micromilling machine (MMP) is a computer numerically
controlled (CNC) milling machine that is used to pattern microstructures on
metal mold inserts using very small milling bits (down to 25 µm diameter) rotated
at very high speeds in the range of 40,000 – 200,000 rpm. Mold inserts can then
be used as masters for the production of microstructures on polymer substrates
(B)
Hex03 hot embossing equipment capable of molding polymer parts
containing features with micro- and nano-dimensions including high aspect ratios
(>10 : 1) through a combination of heat and pressure. It is commonly used to
produce polymer microfluidic chips for biomedical applications.
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Because both hot embossing and injection molding use a top-down fabrication
approach leaving open-faced microstructures, sealing the patterned thermoplastic must
be undertaken to form the final device. Sealing strategies can employ simple
approaches such as the use of commercially available adhesive coverslips.[83]
However, the fluidic pressure of processing whole blood within micrometer-sized
channels necessitates strong sealing of the coverslip to the substrate to prevent device
failure. Thus, thermal fusion bonding has been employed due to the high tensile
strength bonding between the substrate and coverslip it generates. Here, a thin (125 –
500 µm) coverslip composed of the same thermoplastic as that used for the substrate is
pressed against the patterned substrate and the pair is heated to near their glass
transition temperature, which allows the polymer chains to rearrange, bond, and seal
the microfluidic device with similar tensile strengths as PDMS-to-glass bonding. [34, 61,
80, 81]
Whichever fabrication modality is used, the polymer substrate must possess the
following characteristics to serve as a viable substrate for fluidic devices targeted for the
selection of CTCs: (i) Functional scaffold for the surface attachment of the affinity agent
(antibody, peptide, aptamer); (ii) optically transparent and void of autofluorescence; and
(iii) surfaces that show minimal amounts of non-specific adsorption of blood cells to their
surfaces to provide high purity of the enriched CTC fractions; and (iv) biocompatible
surfaces so as not to compromise the viability of isolated CTCs for on-chip culturing or
drug delivery studies. Point (i) is particularly important for CTC selection modality using
biological CTC selection because of the need for covalently attaching is high.
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Strategies for immobilizing affinity agents to polymers are diverse amongst
current CTC

technologies

but for either PDMS or thermoplastics, successful

immobilization of the affinity agents has been demonstrated by introducing reactive
functional groups onto the substrate. For example, PDMS surfaces use alkoxysilane
molecules,[63, 67, 84] while thermoplastics depend on generating carboxylic acid
moieties for amide coupling of affinity agents; the activating source for generating these
functional scaffolds typically use UV or ozone. [61, 80, 81] [34] Furthermore,
thermoplastic UV/ozone modifications require the thermoplastic to be sufficiently
transparent to provide uniform modification throughout the CTC selection conduit. [81]
A polymer’s optical qualities also impacts the identification or enumeration
process of the isolated CTCs via immunofluorescence.[62] PDMS’s optical transparency
is nearly glass-like making it ideal for fluorescence visualization.[85] Both unmodified or
UV/ozone modified PMMA and COC thermoplastics have comparable fluorescence
backgrounds to glass, [85, 86] and thus, they are certainly compatible with
immunofluorescence identification of CTCs. [61, 80, 81] [34] PC, however, has a much
higher fluorescence background,[86] and following UV/ozone modification for the
attachment of affinity agents, the polymer’s autofluorescence overwhelms CTC
fluorescence, disqualifying it in many cases for CTC isolation and immunofluorescence
analysis. [81]
Lastly, the hydrophobicity of native PMMA, [87] COC, [88] and PDMS [89] lends
to issues related to biocompatibility. But, modifications of the polymer using, for
example, oxygen plasma treatment of PDMS or UV/ozone treatment of thermoplastics,
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[81] is necessary to improve the material’s biocompatibility. In the case of PDMS,
hydrophobic recovery can affect the surface’s biocompatibility (adherent cells were
~98% viable after 24 h [90]), while for thermoplastics, hydrophobic recovery is not as
pervasive, but thermal processing above the Tg of the material can enhance this
process.[81] UV/ozone treated COC exhibited the same biocompatibility as PDMS, [90]
but the UV/ozone treated PMMA exhibited elevated cytotoxicity (~89% viability after 24
h [90]) due to the leaching of peroxide and oligomeric and monomeric methyl
methacrylate by-products following the UV/ozone activation process. [81, 90]
Further aspects of thermoplastic biocompatibility are more subtle. Firstly, if CTC
culturing is attempted on-chip, the CTCs must be provided with an adequate supply of
carbon dioxide and oxygen to maintain pH; [90] the gas permeability (permeability
constants given in Table 1.1) of elastomeric PDMS is far greater than most
thermoplastics, [91-96] thereby requiring continuous flow of fresh media to cells cultured
within thermoplastic devices. [90] Secondly, on-chip monitoring of cellular response to
drugs can be biased by adsorption of small, hydrophobic molecules to the polymeric
substrate; this effect has been shown to occur in PDMS [90, 97, 98] and PMMA [90]
(detailed values are shown in Table 1.1).
As a final note, thermoplastics can be used for the fabrication of filters for sizebased selection of CTCs from other mononucleated blood cells. [99, 100] Commerciallyavailable PC filters are track-etched; [101] this process produces pores randomly
distributed across the filter and larger, fused pores through which rare CTCs may pass.
Consequently, clogging is common and recoveries are poor (50-60%). [102, 103]
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Table 1.1 Various polymer materials used in CTC enrichment devices
Quality

Specific Criteria (ref)
Master Mold
Fabrication [79]

Manufacturability

(Material) [79]
Time for Replication
[79]

COC

Lithographic

PMMA

PC

Micromilling or LIGA

(Si or
photoresist)
Mediocre
(hours)

(Brass or Nickel)
Mass-Production (seconds)

Immobilization of
Affinity Agents

Functionalization [84]

Excellent

Excellent

Moderate

(Method) [84]

(alkoxysilane)

(UV/ozone)

(UV/ozone)

Immunofluorescence
Visualization

Autofluorescence [85,
86]

Very Low

Low

Low

Very High

Cytotoxicity [90]

Excellent

Excellent

Moderate

Excellent

(Viability after 24 h)
Adsorption of
Hydrophobic [90]
†
Molecules (7-EC ) [90]
‡*
CO2 Permeability
13
(P × 10 )
‡*
O2 Permeability
13
(P × 10 )

(98%)

98%

89%

98%

20%

0%

20%

0%

3489

1.77

2.33

22.23

695

0.765

0.0653

2.96

Biocompatibility

†

PDMS

Poor/Moderate
(UV/ozone)

7-EC ≡ 7 ethoxycoumarin. Similar results were found for testosterone.

‡

Permeability constant (P) units: (
).
* References [93-96].
Measurements were done at standard pressure and the temperatures were 25 °C for COC and PC and 35 °C for
PDMS and PMMA.
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To this end, microfabrication techniques utilizing photoresists and reactive ion etching
have been used to construct 2-D and 3-D filters with controlled pore sizes and spacing.
Three-D filters offer lower fluidic stress on filtered CTCs for the isolation of live rather
than fixed cells. [99, 100, 104] Parylene C has also been used as a polymeric substrate
for these filters due to its mechanical flexibility, biocompatibility, and optical
transparency for immunofluorescence CTC enumeration. [99]
1.2.3

Magnetic Materials for CTC Enrichment using Microfluidic Devices

The use of magnetic particles for CTC isolation is ubiquitous largely because the
CellSearch technology remains the only FDA approved assay for CTC enrichment and
analysis. In this section, we will focus on several technologies that utilize magnetic
particles and discuss how the nature of the particles affects the CTC enrichment
process.
Magnetic particles have been researched for over two decades, resulting in the
commercialization of an array of products, including those catered specifically for the
isolation of CTCs. Many other commercially available products or slight modifications
thereof are used for CTC isolation. [105] The choice of magnetic particles for CTC
enrichment is predicated on the requirement of only low strength magnets (such as
inexpensive neodymium magnets generating on the order of a T) necessary to remove
these magnetic particles and their payload from solution (achieving saturation
magnetization in fields on the order of tens to hundreds of mT). [105-108] There are
material properties that should be assessed when considering magnetic particles for the
isolation of CTCs, especially when utilized in conjunction with a microfluidic device. [68]
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To process a blood sample using CellSearch, a pre-processed blood sample is
dosed with a ferrofluid consisting of ~100 nm iron oxide nanoparticles [108] coated with
a polymer to improve solubility [109] with the particles functionalized with anti-EpCAM
antibodies. [110] After incubation, cells bound to these magnetic nanoparticles are
isolated by applying an external magnetic field. [105, 106, 110] Rigorous evaluations of
the CellSearch technology have shown a recovery of ~85%; [110, 111] however, the
purity is poor (<0.01-0.1%) complicating further characterizations of the isolated CTCs.
[112-115] Because the interaction of the nanoparticles with cells occurs by diffusion,
shear forces are not induced that could disrupt weak, nonspecific interactions of
contaminant cells; the use of shear forces to improve purity is a fundamental construct
of the MagSweeper. [115, 116]
The MagSweeper utilizes a magnetic stirring rod with a non-adherent, 25 µm
thick plastic sheath to isolate cells that have been labeled with 4.5 µm magnetic beads
in a similar fashion as that of CellSearch. By sweeping through a diluted blood sample
contained in a well, the MagSweeper captures labeled cells under shear stress, thereby
detaching nonspecifically and weakly adhering cells to achieve higher purities compared
to CellSearch. Of 50 MCF-7 cells, a metastatic breast cancer cell line, spiked into a
diluted blood sample, 62 ±7% were isolated with a purity of 51 ±18%. [115] A second
generation MagSweeper device was compared directly with CellSearch for patients with
metastatic prostate cancer. The MagSweeper exhibited similar recoveries to that of
CellSearch, but with lower purity. [116] The lower purity may have been attributed to
either different blood preparation steps or the use of custom-labeled 1.5 µm magnetic
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beads; [116] the authors previously iterated that antibody specificity and micro-bead
quality was critical for assay purity because contaminating cells are generally attached
to the magnetic beads rather than to the sheathed magnetic rod itself. [115]
A challenge in terms of clinical utility of the MagSweeper is its incompatibility with
whole blood. The high viscosity, cell density, and protein content of whole blood caused
magnetic micro-beads to aggregate, precipitate, and/or prevent antibody-antigen
complexation. [117] Thus, additional workflow was necessary to process blood samples,
for example removal of RBCs or dilution. [68, 111, 115-117]
For nanoparticle-based technologies, CTC isolation from whole blood has been
demonstrated using 30 nm, iron oxide nanoparticles functionalized with amphiphilic
polymers (providing stability in whole blood matrices) and capture antibodies. From
unprocessed, unfractionated whole blood, cultured SK-BR3 cells were isolated with a
73.6% recovery and 33.2% purity. [117] However, to our knowledge, clinical
demonstrations of using magnetic nanoparticles in unprocessed whole blood have not
been demonstrated.
Compared to magnetic micro-beads, iron oxide nanoparticles offer several
advantages: (i) The nanoparticle solution is quasi-homogenous, improving the kinetics
of cell-particle interactions; and (ii) more of the cell’s surface is reactive (by
approximately two to three orders of magnitude) due to the nanoparticle’s enhanced
surface area to volume ratio. [117] However, there are limitations as to the use of
nanoparticles, many of which arise from cellular uptake of the nanoparticlesXu, Aguilar
[117] This imparts unavoidable cell contamination due to cellular uptake, reduction in
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CTC viability, and alteration of the CTC’s molecular profile. [109, 118] Even with
CellSearch, it has been shown that many CTCs isolated are apoptotic. [119, 120] In
comparison, great care was taken to ensure that the MagSweeper did not induce any
statistically significant change in the viability of the selected CTCs and had minimal
effects on single cell transcriptomes. [116] In contrast to the free solution mixing of
functionalized magnetic particles with their target cells, the Ephesia microchip utilizes
magnetic micro-beads in a unique format (see Figure 1.5). A PDMS casted
microchannel was sealed over a glass coverslip previously patterned with magnetic ink
by micro-printing. Upon the application of a magnetic field, the magnetic inks
concentrated the magnetic field lines vertically and 4.5 µm antibody-coated magnetic
micro-beads self-assembled into high aspect ratio pillars that were used for CTC
isolation. [105, 121] The Ephesia chip achieved >94% recovery with 78 – 97% purity for
the isolation of cultured Raji (B-lymphocyte) cells mixed with different numbers of Jurkat
(T-lymphocyte) cells (minimum ratio of 1 Raji cell to 100 Jurkat cells). Furthermore, Blymphocytes were isolated from blood and fine needle aspirate patient samples; good
correlation with flow cytometry was observed for cell morphology and antigen
expression. [105] The Ephesia chip is compatible with mass-production modalities such
as

those

used

for the

production of thermoplastic

devices

and

the

batch

functionalization of micro-beads simplifies the practical aspects of functionalizing
individual devices. [105] A concern with the Ephesia chip was that it was designed for
processing very low sample volumes (10 µL). The stability of the micro-bead pillars
limited linear velocities of up to 0.1 mm/s, corresponding to a volumetric throughput of
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Figure 1.5 (A) Principle of magnetic self-assembly. A hexagonal array of magnetic
ink is patterned at the bottom of a microfluidic channel. Beads coated with an
antibody are injected in the channel. Beads are submitted to Brownian motion. The
application of an external vertical magnetic field induces the formation of a regular
array of bead columns localized on top of the ink dots. (B) Two levels PDMS
integrated microchip. Channels were filled with colored water. Delivery and
separation channels for the cells appear in yellow. Inlets ports appear in orange.
The separation channel is the longer vertical branch. The area bearing magnetic
posts is marked by the dotted white box. Channels in the upper PDMS layer,
controlling the opening and closing of the inlet channels, appear in blue. The green
wire is a thermocouple for in situ control of the temperature in the system. (Scale
bar: 0.5 cm.) (C) Magnetically assembled array of columns of 4.5 μm beads coated
with anti-CD19 mAb (specifically retaining Raji B-Lymphocytes). Typical column
shapes are shown in the insets. (Scale bar: 80 μm.) (D) Optical micrograph of the
columns after the passage of 1,000 Jurkat cells. No cell can be seen. (Scale bar: 80
μm.) (E) After the passage of 400 Raji cells, numerous ones are captured and
rosetted on the columns. (Scale bar: 80 μm.) (Reproduced from Saliba et.al [122]
with permission from the Proceedings of the National Academy of Sciences of the
United States of America (PNAS))
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3.6 µL/h. The low throughput was also partly due to the constrained size of the
microfluidic channel (40 x 250 µm, W x D). [105]
1.3 Biological and Physical Properties for CTC Enrichment
CTCs possess intrinsic properties that differentiate them from hematopoietic cells,
the major component of peripheral blood. These properties can be placed into two
broad categories. Biological properties, which are primarily focused on tumor associated
surface antigen expression, viability and invasion capacity while physical properties take
into account cell size, density, electrical charges and deformability. A plethora of
microfluidic technologies have adopted different formats that target either biological or
physical or both properties for CTC enrichment. In the following sections, we will
discuss microfluidic devices based on biological or physical selection and how material
properties affect the performance of these devices.

1.3.1

Microfluidics for CTC Enrichment Based on Biological Properties

These mainly employ affinity-based assays for CTC enrichment. These assays use
specific but non-covalent interactions between a ligand (antibody, aptamers, and
peptide) to a tumor specific membrane protein. CTC selection involves a solid phase
(glass, silicon, polymers) in which the recognition element is covalently tethered to the
surface of a fluidic conduit. [39] The correct choice of a solid surface and the application
of suitable surface chemistry that is compatible with a diverse set of proteins and at the
same time maintaining their native conformation and biological function are necessary.
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Blood samples are passed through the appropriately prepared conduit to invoke the
CTC selection process. The following strategies are considered in order to maximize
interactions of the blood-borne CTCs and the surface immobilized ligands: (i)
geometrical configurations of the fluidic conduit that affect the fluid dynamics; (ii) the
nature of the surface chemistry of the solid phase; and (iii) attachment chemistry of the
bound ligand.
1.3.1.1

Immobilization Strategies

Critical to a positive or negative CTC selection assay is the immobilization of a
biologic capture element, be it a protein (antibody, Ab), aptamer, or peptide, to the
surface of a microfluidic channel. For the enrichment of CTCs from a clinical sample,
which have varying levels of antigenic expression, [123] it is critical that a maximum
number of active capture elements be immobilized onto a surface. As the surface
density of these active elements increases, so does the adhesion force (FA) of an
isolated CTC to the capture surface as noted by equation (1):

(

where

)

(

),

(1)

is the cell’s contact area to the surface, kB is Boltzmann’s constant, θ is the

absolute temperature, NR is the receptor density (the CTC’s antigen expression level), lb
is the extent of stretch to reach before breaking the antigen/Ab association, NL is the
surface density of active mAbs, KD is the antigen/Ab dissociation constant, and η is an
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adjustable fitting parameter. Increasing FA by ensuring a large N R (active capture
element surface density) prevents a captured CTC from being removed from the
surface by hydrodynamic shear force, especially when antigen expression of the CTC
(NL) is low. [61, 63, 81, 124] Critical to efficient CTC capture, then, is a strategy by
which selection elements are immobilized in high densities. Attachment of the selection
element can use either passive adsorption or covalent attachment techniques.
For passive adsorption, reduction of Ab activity by physisorption is well known; it
has been shown that 90% of Abs lose their activity through this process.[125] For this
reason, few researchers directly adsorb CTC capture elements to their surfaces.
However, an example has been documented; adsorption of epithelial antibodies and
selection proteins onto halloysite coated microtubes to induce CTC capture along the
microtube surface. [126, 127] In the majority of other cases where passive adsorption
has been employed, a scaffolding protein such as an avidin protein, [116, 128]
biotinylated BSA (subsequently following by an avidin protein), [71] or protein G [127]
have been passively adsorbed first. Then, either biotinylated Abs are bound to the
avidin decorated surface via strong avidin-biotin linkages or unmodified Abs are bound
to the surface using protein G. In the latter case, protein G binds Abs specifically to the
Ab’s Fc region, thereby ensuring the Ab is optimally oriented with its Fab regions
(antigen binding regions) exposed to solution for binding CTCs. This is not true for
avidin linkages, because biotinylation may occur with any reactive residue present in the
Ab (i.e., on the Fc or Fab regions); [129] this results in a surface of Abs with nonuniform orientation where only those with Fab regions exposed to solution are capable
26

of CTC capture (effective reduction of NR in Eq. (1)). [130] Considering the costs of
avidin proteins and protein G (as well as the analogous protein A) are comparable and
the benefits of controlled Ab orientation are well established for bioassays in general,
[131] the use of protein G in place of an avidin moiety is wise due to a higher
percentage of effectively active Abs. In either case, the passive adsorption of biologic
CTC recognition elements is attractive due to simplicity (no additional linkers or coupling
agents are required).
For the covalent attachment of Ab to selection surfaces, functional scaffolds must
first be generated to which the Abs may be coupled via covalent bonds, typically
involving primary amine groups present within the Fc or Fab regions of the Abs. For
glass/PDMS substrates, the use of 3-mercaptopropyltrimethoxysilane (MPTMS) is
commonly used to generate sulfhydryl surface groups after which a sulfhydryl-amine
crosslinker, (N-(γ-maleimidobutyryloxy) succinimide ester, GMBS), is employed. [63, 67,
73, 132] The succinimide ester of GMBS permits covalent amide linkages to lysine
and/or arginine (primary amine) residues on the Abs. [84] The use of MPTMS and
GMBS on glass/PDMS substrates has exclusively been used to immobilize neutravidin
for subsequent introduction of biotinylated Abs. [63, 67, 73, 132] Alternatively,
researchers

utilizing

magnetic

nanoparticles coated with a polymer containing

carboxylic acid moieties have directly immobilized peptides and Abs via the succinimide
ester (generated

via

the

ubiquitous 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide

(EDC) and N-hydroxysuccinimide (NHS) crosslinking reagents) rather than proceed
through the neutravidin intermediate. [117, 133] As the neutravidin bridging strategy
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does not guarantee Ab orientation and adds several steps to the workflow and cost by
the use of additional reagents, direct tethering between surface-confined carboxylic acid
groups and Abs is an attractive approach.
Myung, et al. used EDC and NHS crosslinking to activate carboxylated PAMAM
dendrimers (7th generation), which were immobilized on a PEGylated surface and
immediately reacted them with epithelial antibodies. These dendrimers served two
purposes: (i) To increase the surface’s antibody load by multivalency per unit surface
area; and (ii) to decrease the antibody/antigen dissociation constant (by six orders of
magnitude), again by multivalent cell adhesion. However, the capture efficiency
enhancements observed under flow were modest, 1.5 to 2.2 fold improvements
compared to a PEGylated surface only. [134] However, a 1.1 to 1.7 fold improvement
for the PEGylated surface relative to a bare surface, where the antibodies were
covalently attached to an epoxy modified surface, was observed. [134]
The use of PEG monolayers is well known in bioassays as they reduce
nonspecific adsorption artifacts (enhancing the purity of isolated CTCs) and protein
denaturation (retaining capture antibody activity) by entropic resistance to PEG-protein
interactions. [104, 131] But, PEG coatings [133, 135] as well as polymeric linkers [136]
or amphiphilic triblock polymers, [117] can improve solubility of inorganic nanoparticles
permitting functionalization of the nanoparticles for targeting CTCs and increasing in
vivo circulation time. [104, 137-139]
It is also possible to directly and covalently tether CTC selection Abs (or
recognition element in general) via an amide linkage to microchannel surfaces molded
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into thermoplastics. Here, thermoplastic-based microfluidic devices for the analysis of
CTCs must contain surface-confined carboxylic acids for EDC/NHS coupling of the
selection Ab to the microchannel wall. The generation of carboxylic acids by UV/ozone
treatment in three different thermoplastics has been reported (PMMA, PC and COC).
[140] For this process, the polymer’s optical transparency to the 254 nm activating light
was critical for high density carboxylic acid generation throughout the microchannel’s
depth; PMMA’s absorption of the modifying radiation decreased carboxylic acid
generation, especially in microchannels possessing high aspect ratios. COC’s superior
optical transmissivity permitted higher carboxylic acid surface yields, and this was
shown to directly impact CTC selection from whole blood in terms of both efficiency and
purity (see Figure 1.6). [81]
Lastly, we address the use of aptamers for CTC selection and their attachment to
microfluidic device channels. In one case, an RNA aptamer with a pendant amino group
on its 5’ end was immobilized to a PMMA surface in the same manner as an antibody,
utilizing EDC and NHS coupling agents for covalent attachment. In another aptamer
immobilization strategy, the researchers employed a biotinylated primer sequence
bound to the surface via passively adsorbed avidin that annealed a circular DNA
template containing an aptamer sequence.
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Figure 1.6 Box plots presenting count of CTCs and WBCs selected in UVPMMA (5 PDX (Patient Derived Xenograft models)) and UV-COC (4 PDX) chip
from mice blood samples. Data are normalized to 1 mL. Lower and upper
edges of box show 25th and 75th percentiles, respectively. Solid line in box
represents median, and solid diamond represents mean. Error bars show
maximum and minimum values. (Reproduced from Jackson et al. [30] with
permission from the Royal Society of Chemistry)
Then, they enzymatically polymerized the DNA template by rolling circle
amplification creating long (on the order of 0.1 to 100 µm in length), repetitive patterns
of CTC-binding aptamers extending into solution. [74] While the avidin layer is arguably
unnecessary in this design, the utilization of rolling circle amplification to construct or
rather extend, a pre-immobilized aptamer was a unique strategy that can be applied to
essentially any microfluidic geometry.
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1.3.1.2
Geometrical Configurations
Selection

for Biological Property CTC

Various geometrical configurations have been adapted using microfluidics with
positive selection of CTCs to induce particle displacement in laminar flow, which is
characteristic in micro-dimensions due to low Reynolds numbers. [141] The main
objective is to increase the encounter rates between CTCs and the solid phase onto
which the

target ligands

are

attached. In one

microfluidic rendition, 78,000

functionalized microposts covering an area of 970 mm 2 whose size, spacing and
arrangement were optimized to yield non-linear flow streams and low shear forces. A 50
µm vertical periodic shift was applied every 3rd micropost row to change the trajectory of
the CTC to enhance the collision probability between CTCs and the posts. An
equilateral micropost array arrangement was the best configuration that resulted in the
highest hydrodynamic recovery (65%) for CTCs irrespective of their EpCAM expression
level. This device was used in clinical studies for lung, breast, prostate, pancreatic and
colon cancer. [31]
This CTC chip later adopted a staggered herringbone (Hb) mixer format (see Figure
1.7).[72] The Hb CTC chip consisted of 8 herringbone channels with a channel height of
50 µm and groove height of 45 µm. Chaotic flow was induced by the variation of the
shape of the grooves as a function of the axial position of the channels. The Hb chip
was found to be more efficient than its predecessor (CTC chip) in terms of throughput
(from 1 mL/h to 4.8 mL/h), which resulted in a decreased processing time. Recovery
also improved by 26.3% and an increase in purity levels from 9 ±0.1% to 14 ±0.1% was
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also observed. [32] The Hb CTC chip has since then been used for various clinical
studies. [32]

Figure 1.7 (A) The HB-Chip consists of a microfluidic array of channels with a single
inlet and exit. Inset illustrates the uniform blood flow through the device. (B) Cartoon
illustrating the cell-surface interactions in the HB-Chip, and (C) a traditional flat-walled
microfluidic device. (D) Micrograph of spiked cancer cells captured on the HB-Chip,
representative of capture cell viability (LIVE/DEAD). (Scale bar: 40 μm). (E) Micrograph
of spiked cells captured on the herringbone chip and subsequently cultured on the
device for 21 d. (F) On-chip FISH of captured LNCaP cells with nuclei stained with
DAPI, CEPX (green) and AR gene locus (red). (G) Micrograph of a fluorescently labeled
PC3 cell captured on the HB-Chip (top) and subsequent micrograph taken of the same
cell stained with H and E. (Scale bar: 10 μm). (Reproduced from Stott et al. [32] with
permission from the Proceedings of the National Academy of Sciences of the United States of
America (PNAS))

Kirby and coworkers adopted a similar approach to Toner groups first CTC chip
where they developed a micropost array in a device consisting of 5000 circular of
hexagonal or circular posts (100µm tall and 80µm in diameter) centered in an 8 mm by
25 mm channel (see Figure 1.8). In the geometrical enhanced immunocapture device
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(GEDI) the posts were arranged in way to create size dependent trajectories while
creating maximum streamline distortions. The arrangement ensured the reduced
capture of contaminating leukocytes by achieving a purity of 68% for LNCaP prostate
cells spiked in blood and 62% for PCTCs from patient samples.
The High Throughput Microsampling Unit (HTMSU) developed by Adams and
coworkers adopted sinusoidal parallel channels. In this format travelling CTCs were
propelled to the outer edges of the selection channel walls using curved channels due
to cross stream velocities and centrifugal forces acting on the wall. A total of 51
channels were deployed to increase the throughput and using a 2 mm/s volumetric
linear velocity, selected to optimize CTC recovery, ~37 min was required to process 1
mL of whole blood. Recoveries of 97% were reported for MCF7 cells spiked into rabbit
blood.
The same group modified the HTMSU to adopt a z-configuration of sinusoidal
microchannels to provide a higher number of channels (320) for higher throughput
processing (7.5 mL of whole blood processed in <20 min).[34] Using this design (see
Figure 1.9), the group demonstrated that high purity CTC fractions was achievable for
devices made from COC (98%) with recoveries >90% for MCF-7 CTC surrogates was
shown. In addition, findings based on computational simulations on the fluid dynamics
revealed that higher shear forces 13.3 dyn/cm2 were obtainable for blood in the
sinusoidal channels than posts (0.4 dyn/cm2) or herringbone structured channels, which
was adequate to release loosely bound leukocytes.[30] The CTC selection device could
be coupled with an impedance sensor for the label-less counting of single CTCs
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following release from the capture surface and finally, the released CTCs shuttled to a
staining and imaging device where the CTCs could be enumerated and phenotyped.
(see Figure 1.9).

Figure 1.8 (A) GEDI microfluidic device design and (B) Image of silicon device with
silicon gasket. (C) Top view of microfluidic obstacle array with array geometric
parameters. ∆ = obstacle offset. = obstacle spacing in the direction of bulk flow. =
obstacle spacing in the direction orthogonal to bulk flow. 2r = obstacle diameter.
Streamlines (gray) denote fluid flow. Path lines (various colors) denote trajectories of
cells of different diameters. Obstacle array spacing and orientation parameters are
also defined. (D) The rate of cell-wall collisions for cells traveling through the array is
a strong function of the offset parameter of the array; the GEDI design methodology
implies use of an offset parameter that leads to size-dependent collision rates. The
results predicted for the flow through the geometry at left are shown at right by the
solid line; the four specific cell sizes lead to results denoted by the four colored dots
on this graph. Other geometric arrangements lead to different results, shown at right
in the dotted and dashed lines. (E) Devices with the same surface area to volume
ratio give vastly different results: straight arrays lead to collisions that decrease as
the blood travels through the device; GEDI arrays lead to collisions that increase with
travel through the device. (Reproduced from Kirby et al. [29] with permission from the
author)
Using this system, whole blood from locally resectable and metastatic pancreatic
ductal adenoma carcinoma (PDAC) patients were analyzed. Using the CellSearch
technology, metastatic PDAC patients typically yield 0-1 CTC per 7.5 mL of whole
blood.[11, 142] Using this device and system, the authors demonstrated selection of
EpCAM positive CTCs from PDAC patients in high purity (>86%) and with excellent
yields (mean = 53 CTCs per mL for metastatic PDAC patients). In addition, they
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demonstrated the ability to detect CTCs in PDAC patients with locally resectable
disease (mean = 11 CTCs per mL). [34]

Figure 1.9 (A) Schematic operation of the HT-CTC module with 50 parallel,
sinusoidal microchannels and inlet/outlet channels arranged in the z-configuration. The
large arrow indicates sample flow direction through the selection channels. (B) SEM of
the selection bed showing high aspect ratio sinusoidal microchannels and the output
channel (top). (C) SEM of one of the high aspect ratio sinusoidal channels. (D) Fluid
dynamics simulation results showing the distribution of flow velocities and shear stress
in microfluidic selection channels. (E) Box plot from CTCs isolated from 7 metastatic
PDAC patients, 5 healthy donors, and 5 local resectable PDAC patients. Reproduced
from Kamande et al. [34] with permission

In all these cases, the geometry adapted for the CTC enrichment device plays a
critical role in shaping the fluid dynamics within the device. The linear velocity and the
shear forces experienced by the target cells of interest affect the recovery as well as the
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purity. Recovery is maximized when shear rate is low in order to reduce the shear
forces acting on the captured cells thus maintaining their viability as demonstrated by
Nagrath and coworkers. [31] However this is at the expense of purity because low shear
forces may not remove nonspecifically bound contaminating cells. A summary of the
clinical performance metrics and comparisons to CellSearchTM technology, of the above
mentioned devices in this section has been listed in Table 1.2.
1.3.1.3

Nature of the Solid Phase Surface

Various materials and surface textures have been applied by groups to enhance
recovery of CTCs based on their external morphological characteristics. One approach
is to mimic the nano-scale topography of the extra-cellular matrix (ECM) onto which
epithelial tumor cells are firmly held. [143, 144] The ECM proteins located on the
surface of the basement membrane contribute to the nanotextured surface which aid in
cell anchorage and proliferation. [145-147] Results indicate significantly improved CTC
recoveries from nanotextured surfaces in comparison to smooth surfaces. This occurs
through the morphological differences seen on tumor cells, which possess filopodia and
microvilli containing selection antigens.
A nanotextured surface with silicon nanopillars (SiNP) coated with antibodies
targeting EpCAM on CTCs has been reported. [69, 132, 148-151] The goal was to
enhance local topographical interactions along with specific bioaffinity targets to
increase the recovery for CTCs with filopodia and microvilli extensions. In an example
using Si nanopillars, [69] the dimensions of the nanopillars were 100-200 nm in
diameter and 25 µm in height enclosed in a serpentine microchannel with dimensions of
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800 mm in length by 1 mm width. Fishbone structures were later incorporated into the
serpentine channel in order to induce chaotic mixing to enhance recovery. [132] Results
indicated a recovery of 4-14% on a flat Si substrate and 45-65% recovery for MCF-7
cells using the nanostructured Si substrate. [69] Although an increased recovery was
demonstrated by the incorporation of nanostructures, the ability to release the captured
CTCs was only about 10% with a poor viability using the nanopillars format. Later, the
authors utilized a thermoresponsive polymer, (poly (N-isopropyl acrylamide), PIPAAM,
covalently grafted onto the SiNW substrate (P-SiNW). The P-SiNW was functionalized
with anti-EpCAM for CTC capture. At 37˚C, the biotinylated anti-EpCAM Abs on the PSiNW were exposed on the nano-substrate surface for CTC contact. However, when
the temperatures was reduced to 4˚C, conformational changes on the polymer
backbone led to the internalization of anti-EpCAM Abs within the polymer backbone
resulting in release of the CTCs. Results indicated recoveries of ~70% and a release
efficiency of 90% with a viability of 90%. [148]
As an alternative to vertically aligned silicon nanopillars, horizontally oriented
inorganic TiO2 nanofibers were demonstrated for CTC selection, which also consisted of
anti-EpCAM antibodies grafted onto the nanofibers. [151] Several advantages of using
this material were noted: i) The horizontal orientation was more representative of the
nanostructures embedded in the ECM matrix leading to improved cell-to-substrate
affinity; ii) more precise control over the packing density of the TiO 2 nanofibers (TiNF)
using electrospining (see Figure 1.10); and iii) flexibility in the choice of material that
could be electrospun onto any given substrate, such as glass or silicon (not only limited
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to TiO2). The authors demonstrated that the horizontal fibers were more sensitive and
specific to EpCAM expressing cells. The CTC recovery was also found to be highly
dependent on electrospining time; greater than 60 min electrospining time resulted in
maximum recoveries. [151]
A second generation device was designed to facilitate single CTC molecular
analysis by the incorporation laser microdisection (LMD) to the platform, thus
eliminating the concern of contaminating leukocytes affecting the analysis. The
substrate consisted of a transparent LMD slide onto which poly(lactic-co-glycolic acid),
PLGA, nanofibers were electrospun. These fibers were functionalized with a melanomaspecific antibody (CD146) for the isolation of circulating melanoma cells (CMCs). The
LMD microscope was used to cut out and harvest a positively identified CMC for further
molecular analyses. Results indicated 87% recovery for the M229 cell line seeded into a
cell culture medium at a flow rate of 0.5 ml hr-1. Molecular analysis from single CMCs
isolated using the device from 2 patient samples successfully found BRAF V600E
mutations using Sanger sequencing with results consistent with the patient’s tumor
biopsy. [149]
Nano-textured PDMS substrates for CTC isolation was also demonstrated to
yield higher recoveries in comparison to glass and smooth PDMS substrates. [152] In
this study, a 3D nanotextured PDMS substrate was prepared by casting PDMS over a
nano-textured surface, such as NaOH-treated poly (D, L-lactide-co-glycolide), PLGA
polymer. Aptamers against EGFR were immobilized onto the nano-textured PDMS
substrate and human glioblastoma (hGBM) cells were used as a model for CTC
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isolation.

Findings from this study found an increase in probe density on the nano-

textured PDMS surface compared to a planar glass or PDMS substrates without the
nano-texturing. However a decrease in specificity was observed when a mixture of
fibroblasts and hGBM cells were sampled. [152]

Figure 1.10 Schematic of the horizontally packed TiNFs for improved CTC capture
through combining cell-capture-agent (i.e., Anti-EpCAM) and cancer cell-preferred
nano-scale topography ( Reproduced from Zhang et al. [151] with permission)

Recently, nanoporous posts instead of solid posts were found to increase the
recovery of CTCs by increasing the interception efficiency (the fraction of particles in
flow intercepted by a collector) and the association strength between the particles and
affinity-agent decorated surface. The use of highly porous vertically aligned carbon
nanotubes (VACNT) allowed fluid streamlines to pass through the posts bringing cells
into direct contact with the posts, thus resolving the no-slip boundary condition observed
at the liquid-to-solid post interphase. Secondly, the highly porous surface reduced
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hydrodynamic resistance observed for solid posts. As a result, higher recoveries for
PC3 cells (0.8%) within the first row of nanoporous posts was observed compared to
solid posts (0.2%). [153]
In a similar manner, Hughes and coworkers used halloysite nanotubes (300 nm
diameter) along with a bimolecular surface of E-selectin to promote CTC rolling for
EpCAM specific CTC capture in a microfluidic device. [127] The halloysite tube led to
increased roughness that extended into the flow channel thereby increasing contact
with CTCs. Increased purity of CTC fractions were observed due to less leukocyte
spreading

on

the

nanotube-coated

surface

compared

to

a

smooth surface.

Consequently, a recovery of 50% was obtained with purities of 18-80% for clinical
samples of breast, prostate, lung and ovarian cancers.
1.3.1.4

Negative Enrichment

Negative enrichment of CTCs utilizes leukocyte-specific markers, such CD45, for
the depletion of these cell types from whole blood leaving an unbiased population of
CTCs following erythrocyte removal. Further, the EMT hypothesis suggests that downregulation of epithelial markers, such as EpCAM, is more apparent in circulation where
CTCs take on mesenchymal characteristics; as such, not all CTCs express EpCAM.
[24] Therefore, the reliance on EpCAM solely for the capture of CTCs in most
technologies may exclude sub-populations of CTCs with different phenotypes lacking
epithelial markers. [154-156] A common strategy used by various reports incorporates
RBC lysis or density gradient centrifugation[157] followed by CD45 leukocyte depletion
via magnetic separation, which is accomplished by introducing functionalized magnetic
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particles into the sample. [158] [159] The enriched sample is subsequently analyzed
using confocal imaging, [160] flow cytometry [51] or molecular analyses, such as the
use of RT-PCR for EGFR expression. [156, 160, 161]
Few reports on microdevices have documented the use of CTC negative
enrichment. Hyun and coworkers reported on a herringbone device termed the
geometrically activated surface interaction device (GASI). [162] This device consisted of
a PDMS-glass hybrid substrate with channels coated with CD45 antibodies for
leukocyte capture with the CTCs collected in the effluent. The device was found to
generate a capture efficiency <88% for leukocytes at a cell population of 10 6-107
cells/ml. GASI is an enhanced version of the original device with altered channel
dimensions such as increased apex dimensions, which resulted in 98.94% leukocyte
capture efficiency. Demonstrations on using GASI for CTC isolation from clinical
samples was reported for breast, lung and gastric cancers.
Chen et al. reported a disk-based microfluidic platform capable of isolating CTCs
via negative immunomagnetic separation. [163] Here, non-magnetically labeled MCF7
cells were used as model CTCs while magnetically labeled Jurkat cells or MNCs
(mononucleated cells) from blood were used as non-target cells. The device included a
multistage magnet configuration and double trapping region to enhance depletion
efficiency of non-target cells (~99%) while enhancing the collection of MCF7s (recovery
~60%).
One of the drawbacks to negative selection is the comparatively low purity of
isolated CTCs (0.94%-3.64%). [162] Huang et al. recently reported a study that
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improved the purity of CTCs by integrating optical-induced dielectrophoretic (ODEP)
force, which is based on cell manipulation for a laminar flow microfluidic system. CTCs
were further separated from leukocytes into two flow streams based on cell size and
electrical properties after conventional negative enrichment. The device consisted of a
multilayer layered structure consisting of PDMS, indium tin oxide coated glass, adhesive
tape with microfabricated channels and a lower ITO glass substrate coated with
photoconductive material for ODEP manipulations. Purities of 74-82% and 64-66% were
obtained for PC3 and OECM-1 cells, respectively. [150]
Advantages of negative enrichment are that they do not rely on the speci fic
phenotype of tumor cells for CTC enrichment. Thus, other rare cells can be enriched as
well such as, circulating endothelial cells (CECs), cancer stem cells (CSCs), circulating
progenitor cells (CPCs), and nucleated red blood cells (nRBC). Moreover, CTCs remain
intact without any alteration and are available for downstream processing. However, the
challenges are the relatively poor purities attained as well as the low CTC yields. Preprocessing steps such as erythrocyte lysis and centrifugation may also contribute to low
CTC yields.
Materials that have been utilized in the above mentioned devices are similar to
devices used for positive enrichment, such as PDMS, whose material properties are
well suited for bio-affinity selection of CD45 expressing cells. A magnetic disk was
utilized for the separation of magnetically-labeled leukocytes from unlabeled CTCs and
finally, the ODEP integrated to a PDMS microfluidic platform consisted of ITO glass with
photoconductive material selected to facilitate ODEP cell manipulations.
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1.3.1.5
Miscellaneous Microfluidic Devices for Positive or Negative
Selection of CTCs
Issadore and coworkers developed a µHall (micro-Hall) device for the detection
of immunomagnetically functionalized CTCs from ovarian cancer patients. The µHall
detector consisted of an array of 8 micro hall sensors that were able to sense the
characteristic magnetic moments of cells in flow that had been immunolabeled with
magnetic nanoparticles (MNPs). The signals generated depended upon the quantity of
MNPs bound to the cells, which in turn were directly proportional to their targeted tumor
marker expression level such as EpCAM, Her2/Neu, EGFR and Mucin1 (MUC1). Thus,
CTCs with a high expression of these markers could be distinguished from leukocytes
with low expressing tumor markers. The array was enclosed in PDMS with a chevron
structured channel to facilitate hydrodynamic focusing of the cells over the hall sensors.
A comparative study of 20 ovarian patient samples between the µHall detector and
CellSearchTM indicated a high diagnostic accuracy rate of 96% for the µHall detector
compared to 15% for CellSearch. The µHall device was fabricated from relatively low
cost hall sensors adapted from the semiconductor industry and herringbone channels
on the PDMS material. [164]
CTC-iChip (inertial focusing Chip) is an integrated microfluidic platform that was
recently developed by Ozkumur and coworkers that could be configured for either
positive (pos CTC-iChip) or negative enrichment (negCTC-iChip). [165] It was designed to
integrate 3 sorting techniques in a single device. Briefly, the first section was the
deterministic lateral displacement of nucleated cells from red blood cells (RBCs). The
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second section consisted of the alignment of nucleated cells within a single microfluidic
channel using inertial focusing and finally, the third section was based on the
displacement of magnetically labeled cells in a collection channel. The device could
process large volumes of blood at a reasonable rate (8 mL/h).

pos

CTC-iChip recovery

rates for high EpCAM expressing SKBR3 cells was 98% while low EpCAM expressing
MDA-MB231 was 78% with a sample purity of 0.2 to 43%. For

neg

CTC-iChip, the

average depletion rate of white blood cells (WBCs) was 32,000 WBCs/mL with a
recovery of 97% for mesenchymal expressing MCF10A-LBX1 cells. Also the

pos

CTC-

iChip was found to be more sensitive for CTC capture than CellSearchTM for patients
that had low disease burden.
1.3.2

Microfluidics for CTC Enrichment Based on Physical Properties

Physical-based assays are able to discriminate CTCs from hematopoietic cells
on the basis of size, density, electric charges, or deformability. CTC diameters range
from 10 µm to 30 µm while hematopoietic cells are typically below 8 µm in diameter.
Reports on size-based separation devices have employed a number of strategies, such
as microfabricated filter pores, traps and slots for the entrapment of CTCs from whole
blood. [49, 50, 52, 68, 100, 166-168] A number of reviews have adequately discussed
physical CTC enrichment devices. [38, 43, 169, 170] Table 1.2 lists some of these
devices and shows their performance metrics for sample processing as well as
compares their clinical metrics with the current FDA approve CellSearchTM technology.
These devices achieve higher throughputs than biological enrichment microdevices
and as a result can process large volumes of blood at shorter times. However, this is at
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the expense of purity values which are considerably much lower than biological
enrichment microdevices (see Table 1.2).
2.1.3.1 Dielectrophoretic Microdevices for CTC Enrichment
There have been a number of reports on the enrichment of CTCs using
dielectrophoretic separation. Dielectrophoresis is based on the inherent differences in
the dielectric properties of CTCs from normal hematopoietic cells, which is dictated by
their physical and electrical properties such as morphology, bilipid membrane
characteristics, internal structure, cytosolic constitution, and nucleus size. [171, 172]
Dielectrophoretic separations is based upon two dissimilar neutral particle populations
subjected to non-uniform electric fields, which induce differences in translational motion
and/or reorientation of the particles due to their dielectric properties. [173, 174]
Within certain frequency ranges, cells tend to move in the direction of increasing
electric field (towards the electrode); this is termed positive DEP while the converse is
negative DEP. The DEP crossover frequency is the frequency at which the DEP force
makes the transition from negative to a positive force and is dependent of the cell and
medium conductivity and permittivity. [175],[176],[172] CTCs are attracted by positive
DEP forces while blood cells remain levitated by negative DEP forces resulting in the
separation of these two cell populations in a hydrodynamic flow. It has been
documented that the mean crossover frequencies for breast, lung and ovarian cancer
cells are low, 30-40 kHz compared to 90-140 kHz for the majority of peripheral blood
cells. This difference forms the basis of CTC separation from the bulk of the blood cell
components when a frequency range of 45-84 kHz is applied where CTC experience
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positive DEP force while peripheral blood cells remain in the bulk fluid resulting in
separation. The DEP force is given by;
F = 2πr3
where

Re [K] ∇ E2

(2)

is the absolute permittivity of the suspending medium, ∇ E is the local electric

field (rms) intensity, Re [K] is the real part of the dipolar Clausius-Mossotti factor and
determines the sign of the force (positive or negative) being defined as:
K=
where

and

(3)

are the complex permittivity of the particle and medium, respectively.

The complex permittivity for a dielectric material can be described by its permittivity
and conductivity

where

is the angle frequency of the applied electric field E. [177]

DEP force is strongly dependent on the volume of the particle and the gradient of the
electric field. [178] Devices for CTC separation have been documented using different
formats, such as electrode affinity columns, [172, 179-182] DEP-field flow fractionation
devices, [176, 183-185] 3D asymmetric devices with continuous variation in electric
responses [186, 187] and DEP devices with planar electrode configurations. [188, 189]
We shall briefly highlight a few examples. Gupta and coworkers recently reported a
device that is now commercially available, called the ApoStream TM device, which is
based on DEP-FFF (field flow fractionation). DEP-FFF uses the effect of viscous flow of
liquid near a surface and the application of a force field that will place different particles
at different heights from the surface. Particles will travel at different speeds according to
their distance above the surface and thus, when they are introduced to the force field at
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the same time and point, they will exit the device at different times according to their
heights above the surface and their reaction to the imposed field. [190] DEP-FFF uses a
continuous flow mode rather than a batch processing configuration resulting in high
throughput processing. The device consisted of a flow chamber with the floor containing
a polyimide film sheet with electroplated copper and gold electrodes while acrylic sheets
formed the ceiling of the chamber and a gasket formed the side walls. Here, high
EpCAM expressing ovarian cancer model cells SKOV3 as well as low EpCAM
expressing model breast cancer cells, MDAMB-231 spiked into PBMCs were
continuously introduced at a low flow rate. Upon application of an AC electric field to the
flow chamber, the CTCs were separated from the PBMC fraction. CTC recoveries as
high as 75% and reduction efficiencies of the PBMCs of ~99% were obtained. Viability
of CTCs obtained was as high as 98%. [191]
DEP devices have been used in combination with other techniques in order to attain
higher purities of CTC fractions. Moon and coworkers combined multi-orifice flow
fractionation along with DEP for the isolation of MCF7 model breast cancer cells from
RBCs and WBCs.

MOFF involves microparticles that are moved laterally by

hydrodynamic inertial forces driven by a multiorifice structure.
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Figure 1.11 APO Cell device (A) Schematic of the top view of the flow chamber
showing sample injection and sample collection port locations. (B) Still image
from video demonstrating the flow and collection of fluorescently labeled SKOV3
cancer cells through the collection port in the ApoStream flow chamber. Cancer
cells are collected into the collection port when the DEP field is activated. (C)
Still image from video demonstrating the flow of fluorescently labeled PBMCs
through ApoStream flow chamber. The first half of the video (10 s) demonstrates
that most PBMCs fall into the collection port when the DEP field is not active.
(Reproduced from Gupta et al. [191] with permission)
Extent of lateral movement varies according to particle size. Although this method
has a throughput of 300 µL/min, the reduction efficiencies of both RBCs and WBCs
were 88% and 61%, respectively. Addition of a DEP module with electrodes consisting
of gold and chromium sputtered onto glass and sealed with PDMS resulted in a 162-fold
increase in the separation efficiency of MCF7 as well as 99% and 92% reduction in
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RBC and WBCs fractions, respectively. In this report both high processing speeds and
high purities were attained through the integration of these two techniques. [53]
Materials used for DEP CTC enrichment devices are mainly selected to be
compatible with biological-based separations. Joule heating is one of the major factors
affecting DEP separations. In order to lower thermal heating in DEP devices, the
application of 3D silicon electrodes instead of planar electrodes has been shown to
maintain suitable temperatures for cell manipulations even as the voltage increases.
[192] For optical DEP cell manipulations, Indium Titanium Oxide (ITO) over glass has
been used as an alternative to gold or platinum electrodes due its transparency. [150]
Recently a nanodetector referred to as the Gilupi device was designed for the in
vivo detection and collection of CTCs. It has been made commercially available by
GILUPI GmbH medical technology company. The device consists of an anti-EpCAM
biofunctionalized structured medical seldinger guidewire wire (FSMW) that can be
inserted into the vein of a patient’s arm by the use of a 20 gauge needle (see Figure
1.12). The needle is a stainless steel wire coated with a gold layer and an anti-EpCAM
functionalized hydrogel. It is inserted into the arm for a total of 30 min and over that time
period, 1500 mL of blood is sampled allowing the potential for the capture of large
numbers of CTCs. This device has been used in patients with breast, lung and prostate
cancer and has successfully identified CTCs in 80% of these patients. Material
considerations were mainly devoted to minimizing in vivo cytotoxity. FSMW was
compared to copper wire and Teflon as alternatives by looking at the viability of normal
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human dermal fibroblasts (NHDF) after contact. It was found that FSMW gave the
highest cell viability while copper wire gave the lowest. [193]

Figure 1.12 Outline of the Gilupi nanodetector (A) Section of the guidewire which
remains inside the puncture cannula (B) 20 mm long gold coated tip of the stainless
steel guidewire which is in direct contact with the blood circulation and biofunctionalized
with EpCAM antibodies to target CTC. (Reproduced from Saucedo-Zeni et al. [193] with
permission.)

The application of functional assays can be used as a means for the detection of
viable CTCs. Epispot (epithelial immunospot) assay is based on the secretion of specific
marker proteins. Nitrocellulose membranes are coated with an antibody against a
specific protein marker. Cells are seeded and cultured for 48 h during which time
secretion of proteins are directly captured on the plate. Cells are then washed off and
fluorescently labeled secondary antibodies are then added. Immunospots are then
detected via video camera imaging, which signifies the presence of viable cells. CK19
and MUC1 have been used for breast cancer CTC detection while prostate specific
antigen (PSA) was used for prostatic CTC detection for clinical trials. Findings indicated
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90% of breast cancer patients secreted MUC1 marker, 54% secreted CK19 while 83.3%
of prostate cancer patients secreted PSA.[45]
Similarly, the collagen adhesion matrix (CAM) technology has the ability to enrich
CTCs based on their avidity to invade the CAM. [196] This assay targets more
aggressive and invasive phenotypes of CTCs, which are capable of ingesting CAM.
Mononucleated cell fractions from patient blood were placed in fluorescently labeled
CAM coated 16-well chamber slides distributed by Vitatex Inc. and cultured with cancer
cell culture (CCC) media. Studies on breast cancer patients revealed that enriched
CTCs using this assay had distinct populations and were capable of propagation.
Results indicated a CTC recovery rate of 54%, assay purity range of 0.5 - 35% and a
100 assay positivity rate. [197]
AdnaTest is a molecular-based assay that selects CTCs via immunomagnetic
enrichment after which gene expression profiling is performed using a multiplex RTPCR to evaluate tumor associated transcripts such as HER2, MUC-1n and GA773-2 for
breast cancer specifically. This method boasts higher sensitivity compared to
CellSearchTM with about 2 CTCs per 1 ml of blood.[26] CTCs were detected in 69% of
breast cancer patients and their expression profiles shown to be heterogeneous. [198]
1.4 Beyond Enumeration of CTCs
1.4.1

Phenotypic Characterization of CTCs

CellSearchTM, which is the only FDA approved technology for the isolation of
CTCs from epithelial cancers such as breast, colorectal and prostate uses 4 markers to
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phenotype CTCs: 1) EpCAM, which is usually used as the selection target; 2)
cytoplasmic cytokeratins (8, 18, 19); 3) nuclear component confirmed by DAPI or
Hoechst staining; and 4) CD45 as a negative indicator (indicative of leukocyte). Events
are scored as CTCs if they stain positive with DAPI and cytokeratins, but negative for
CD45. In addition, CTCs tend to have a larger nucleus to cytoplasmic ratio than
leukocytes. Optical and fluorescence imaging is usually used to identify the phenotype
of CTCs. [199] As a result CTCs enriched from blood using microfluidic devices typically
follow the same labeling protocol for establishing CTC phenotypes. [30-32, 34, 57]
However, studies on the EMT hypothesis suggests that CTCs are heterogeneous
with mesenchymal as well as epithelial characteristics. [200] [201] Moreover, recent
reports on CTC enrichment using the Herringbone device among others, identifi ed cells
that stained positive for both epithelial (CK 8, 18, 19) and CD45 markers. [32] [34]
These cells could also be considered as artifacts in the device or nonviable cells that
may nonspecifically absorb the staining markers.
Studies also indicate a down regulation of EpCAM expression for metastatic
cases thus technologies that use EpCAM as a selection target may miss CTCs with
absent or low expressing epithelial antigens. Recent CTC enrichment devices are using
different strategies such as negative enrichment [71, 163, 202] or the use of both
epithelial and mesenchymal antibodies to select both CTC types. [33] As a result,
increased CTC recoveries have been observed.[33] However, the use of multiple
selection markers decreases the specificity of cells captured and thus the sample purity
is in turn adversely affected.
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The process of CTC phenotype identification also requires the use of fixatives
and permeabilization agents that can render the cells unusable for downstream
analysis, such as propagation or genomic profiling. Due to the lack of consensus in CTC
phenotyping, additional identification criteria such as CTC molecular analysis for gene
expression or mutation analysis should be used as well.
1.4.2

Genotype Characterization of CTCs selected by Microfluidics

Cancers typically result from the disruption of cell signaling pathways that lead to
the alteration of genes. This in turn leads to the formation of cells with uncontrolled
growth patterns compared to normal cells. [41, 203, 204] Gene expression profiling is a
genomic technique used to investigate genes encoded in the genome of cells. These
genes are transcribed into mRNA, which dictates protein synthesis in a cell. Gene
expression is a major determinant of the behavior of both normal and malignant cells.
Studies have shown that gene expression profiling can been used to predict clinical
outcomes of breast, prostate and colorectal cancer patients. [205-210] It has also been
used to predict the therapeutic response for drugs against cancer, such as docetaxel in
breast cancer. [211] CTCs are also good candidates for tumor biology studies. Their
molecular characterization may give insight to aberrant pathways, such as TGF-β
signaling, Wnt signaling, and EMT markers associated with tumor development and
progression. In addition they may be used to investigate drug targeting markers and
cancer stem cell markers. Various techniques can be used for gene expression profiling
such as reverse transcriptase polymerase chain reaction (RT-PCR), cDNA microarrays
and in-situ hybridization.
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Due to the higher purity many times obtained through the use CTC microfluidic
devices compared to CellSearchTM, molecular characterization studies are feasible. The
capacity to isolate concentrated, viable CTCs makes the microfluidic devices for CTC
enrichment ideal tools for molecular access to rare CTC subpopulations such as
metastatic precursor cells or cancer stem cells. To highlight a few examples, the PSA
gene marker KLK3 was found expressed in CTCs isolated from metastatic prostate
cancer patients as well as the TTF-1 (thyroid transcription factor-1) from pulmonary
adenocarcinoma patients using a posted CTC microfluidic chip. [31] Protein expression
was first determined by immunostaining and then cells were lysed on chip to extract
genomic material. RT-PCR was used to interrogate the KLK3 and the PCR product was
detected using slab gel electrophoresis. This was achievable due to the purity level of ~
50% obtained from the CTC microchip assay. [31]
Using a Herringbone microfluidic chip, various molecular tests on CTCs have
been carried. For example, FISH analysis on spiked cells for prostate cancer as well as
CTCs isolated from prostate patient samples were analyzed; the androgen receptor
gene (AR) as well as TMPRSSR-Exon1 and –ERG in Exon 5 fusion transcripts were
evaluated. [32]
More recently, Min and coworkers developed a quantifiable dual colorimetric
RNA-in situ hybridization assay to analyze epithelial transcripts Keratins (KRT 5, 7, 8,
18 and 19) and EpCAM, and mesenchymal transcripts, FNI fibronectin, CDH2 (cadherin
2) and SERPINE1 (Serpin peptidase inhibitor) in CTCs isolated from metastatic breast
cancer patients. Important findings based on the EMT hypothesis were found using
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RNA-ISH on CTCs; i) CTCs expressed more EMT markers than tumor cells within the
tissue of the primary tumor; and ii) a prominent association of the presence of
mesenchymal markers were found in CTC clusters rather than in single migratory cells
suggesting mesenchymal transformation of epithelial cells mediated by TGF-β release
from platelets. [33]
In another study, isolated CTCs from genetically modified mouse models as well
as pancreatic cancer patient samples were analyzed for the WNT gene. [57] This gene
is associated with an increased metastatic propensity in vivo through the suppression of
anoikis and also enhances anchorage independent sphere formation in tumor cells. The
Wnt gene is also a potential drug target for metastasis, because the suppression of
TAK1 kinase suppresses the WNT effect. A RNA single-molecule sequence analysis
assay was developed for digitized gene expression profiling (DGE) as a result of the
minute amount of CTCs captured and low purity levels (0.1-6%) generated by the
selection device.
1.4.3
Drug Targeting and Response Monitoring from Microfluidically
Selected CTCs

In many cases, obtaining tumor tissue may involve invasive surgery and/or fine
needle aspirations to secure material for various drug targeted studies. This has further
led to the significance of CTCs as an important biomarker due to the ease of
accessibility. [44, 46] [37, 38] Patient treatment response monitoring could be simplified
if CTC changes were used as a response marker during the course of therapy. Specific
genotypes expressed in tumor tissues are associated with more aggressive forms of
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disease and worse prognosis, such as HER2 gene expression in breast cancer patients.
[212-214] Drug targeting studies as well as response to treatment have been employed
in clinical studies involving CTC enrichment microfluidics.
The posted CTC chips were the first microfluidic devices used for monitoring
drug efficacy for patients by observing changes in CTC numbers and correlating them to
clinical and radiographical changes. Gefitnib, an EGFR inhibitor was administered to 9
patients with non-small cell lung cancer were serially monitored over the course of their
therapy. A significant correlation (Pearson’s correlation = 0.68) was observed between
the change in quantity of CTCs captured and the response to treatment measured by
CT scans. [215]
The GEDI device was also used to monitor CTC numbers during drug studies
specifically

for

the

assessment

of microtubulin bundling

upon application of

Paclitaxel.[216] The GEDI devices with CTCs captured from prostate patient samples
were placed in culture dishes and treated with Paclitaxel for 24 h. In all samples,
microtubule bundling was clearly evident by the distorted shape orientation of
microtubules

as

observed

with increased

fluorescence

intensity indicating the

effectiveness of the drug. [29]
In another the report, a lectin aided filter-based CTC microfluidic device facilitated in
vitro studies of Cytarabine, a leukemia drug that inhibits DNA and RNA polymerases on
a K562 model leukemia cell line. Viability of filtered K562 cells greatly decreased with
increase concentration of Cytarabine. [52]
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1.4.4

Culture of Viable CTCs Isolated from CTC Enrichment Microdevices

CTCs carry pertinent oncogenic information because they are shed from primary
and metastatic tumors. It therefore follows that they could be used as surrogates for
tumor tissue for tumor biology studies. Propagation of CTCs is one of the main interests
for tumor biologists and a number of studies have demonstrated the ability to culture
CTCs directly from patient blood. One such study utilized the CAM assay, which
separates invasive CTC sub-populations by their ability to ingest collagenous matrices.
CTCs enriched are cultured with cancer cell culture (CCC) media consisting of 1:1
mixture of Dulbecco’s modified Eagles medium and RPMI 1640 medium supplemented
with serum and glutamine and streptomycin for 12 h (see Figure 1.13). CTCs cultured
using this method have been subjected to both cellular and molecular analysis such as
gene expression profiling which revealed that subpopulations retained both epithelial
and EMT stem cell ( CD44 and TWIST1) genes. [218, 219]
Bo and coworkers used biocompatible parylene slot filter device to capture PC3 cells
spiked into whole blood. Selected PC3 cells were cultured on or off the device. For off
device culture, the PC3 cells were selectively removed from the slot filter device using a
glass micropipette with a tip diameter of 20 µm suctioned by a P-87 micropipette and
placed into culture media for 3 to 6 d. In both cases more than 90% of the PC3 cells
were found to be viable.[166] For liquid-based non-adherent CTCs, Raji cells, which are
immortalized B chronic lymphocytes, were captured on magnetic bead columns
(Ephesia device). The cells were cultured in vitro with CO2 independent growth media
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Figure 1.13 Viability and proliferation of circulating cells isolated by CAM from
blood of breast cancer patients. (A) A mixture of live green fluorescent cells and dead
red fluorescent cells were seen in the cell fraction of pre-CAM enrichment. Bar = 40 µm.
(B) Viability of circulating cells prior to and post to CAM enrichment. Percentages of live
cells in pre- and post-CAM fractions were measured as percentage of green cells in
both green and red cells. (c, d) CAM-enriched cells were cultured on the CAM scaffold
for 1–33 days. Live cells were photographed under phase contrast microscopy (PCM)
and fluorescence microscopy (CAM, to reveal CAM uptake/labeling of tumor cells).
Tumor cells grew as time increased. On day 1 (C), tumor cells were seen to associate
with CAM uptakes and as round cells (large white arrows) larger than hematologic cells
(small yellow arrowheads). On day 10 (D), tumor cells were seen as round cells (white
arrows) larger than hematologic cells (red arrows). By day 33 (E), tumor cells grew in
clusters with large epithelioid cells (open arrows) but hematologic cells decreased their
number and not seen in the field. Reproduced from Lu et al. [217] with permission
infused through the device while maintaining temperature between 36˚C and 37˚C via a
microthermocouple embedded into the device with mitosis observed after 12 h of
culture. [122]
Unfortunately, very few reports involving microfluidic devices have shown the
ability to culture actual CTCs isolated from clinical samples. There are controversies
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with regards to the use of cell lines as representative of tumor cells because they are
already immortalized and adapted to growth in culture and as a result, are expandable
without limitation. Some of the challenges involved with the culture of primary cells
compared to established cell lines are: 1) Primary cells have a limited life span in culture
and are not accustomed to culture media created for established cell lines; 2) primary
cells are slow in proliferation; and 3) CTCs isolated from patient blood samples
constitute heterogeneous populations and may contain contaminating cells that may not
adapt well in existing growth media used for cell lines.
Kirby and coworkers were able to demonstrate the culture of CTCs isolated from
patient blood samples using the GEDI device for the purposes of drug target
engagement. This was achievable due to their reported purity of 68% and high viability
of the CTCs captured. Briefly, the GEDI microfluidic device containing CTCs enriched
from prostate cancer clinical samples was placed in a culture dish with RPMI-1640
media containing 2% serum and supplemented with either 0.1% DMSO control or
paclitaxel at concentrations of 100 nM or 1 mM and incubated at 37 oC for 24 h.
Although the authors were able to demonstrate culture of CTCs from clinical samples
for purposes of drug target engagement, CTCs grown in culture were fixed after a short
time frame of 24 h; these conditions may not be a suitable for continuous long term
propagation of CTCs derived from patient samples. [29]
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Table 1.2 Clinical performance metrics of CTC enrichment devices for various cancers
Cancer Type

Device

Sample preprocessing
required
no
†
yes
no
no

Volumetric
velocity
(mL/h)
1-2
1
1-2
4.8

Processing
Time for
7.5ml (h)
3.8-7.5
10.6
3.8-7.5
1.6

No. of CTCs/7.5 ml
CTCs /7.5 ml by
Veridex
705 (n = 7)
12 (n = 2)
645 (n=19)
2895 (n=15)

Assay
Positivity
(%)
NR
NR
100
93

Purity
(%)
53
NR
49
14

[31]
[51]
[31]
[220]

10.6
7.5
0.07
0.06-0.13
3.8-7.5
0.07
0.2
0.06-0.13

51 (n=24), 5
405( n=30), 2
96( n=28), 18
37.5 (U),22.5 (D) ( n=1)
593 (n=10)
25 (n=11), 12
1 - 21 (n=24)
218 (U),60 (D) (n=3)

81
100
100
100
100
100
79
100

NR
68
NR
<0.01
60
NR
NR
<0.01

[51]
[29]
[221]
[49]
[31]
[221]
[53]
[49]

Refs

Localized
Prostrate

CTC Chip
SiNP
CTC Chip
HB Chip

Advanced
Prostrate

SiNP
GEDI
PFD
µSieve
CTC Chip
PFD
p-MOFF
µSieve

yes†
no
no
yes‡
no
no
†
yes
‡
yes

1
1
108
<120
1-2
108
36
<120

CTC Chip
HB Chip
HT-CTC
CTC Chip
PFD
µSieve
CTC Chip

no
no
no
no
no
‡
yes
no

1-2
4.8
1.65
1-2
108
<120
1-2

3.8-7.5
1.6
4.5
3.8-7.5
0.07
0.06-0.13
3.8-7.5

1470 (n=15)
135 (n= 15)
390 (n=7)
908 (n=10)
10 (n=12), 0.3
60 (U),128 (D) (n=3)
1163 (n=55)

100
73
100
100
81
100
100

53
0.1-6
86
67
NR
<0.01
52

[31]
[220]
[34]
[31]
[221]
[49]
[31]

VLBD
PFD
µ-Hall
µSieve

no
no
no
‡
yes

2
108
0.1-1
<120

3.8
0.07
7.5-75
0.06-0.13

187 (n=5)
10 (n=6), 0.3±0.5
57 (n=20),1
22.5 (U), 45(D) (n=1)

100
50
100
100

83
NR
100
<0.01

[168]
[221]
[64]
[49]

Breast

Pancreatic

Colorectal

Lung
Bladder
Ovarian
Cervical

60

NR (Not Reported)
†
Blood sample was subjected to RBC lysis and centrifugation
‡
Blood sample diluted with PBS, U (Undiluted blood sample) and D (Diluted blood
sample)
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CHAPTER 2. MODULAR MICROSYSTEM FOR THE ISOLATION, ENUMERATION
AND PHENOTYPING OF CIRCULATING TUMOR CELLS: MANAGING PATIENTS
WITH PANCREATIC CANCER
2.1 Introduction
The presence of circulating tumor cells (CTCs) in cancer patients was documented
as early as1869. [1] They are shed from many solid tumors and have been implicated
as key participants in the metastatic process. As such, CTCs have attracted
considerable attention as an exciting new class of biomarkers that can provide valuable
clinical information for staging of patients, early diagnosis of relapse, guiding therapy,
monitoring response to particular therapies and detection of disease recurrence. [2-21]
Another exciting attribute of CTCs is that they can easily be obtained through a simple
blood draw (~7.5 mL), potentially obviating the need for securing biopsies, which can be
anatomically difficult to obtain or problematic if monitoring response to therapy as this
would require many biopsy samples taken over an extended period of time.
The main challenge associated with the analysis of CTCs is their low frequency;
1-100 CTCs per 109 erythrocytes. Thus, highly sensitive enrichment techniques are
required to enable effective CTC clinical analysis. Three important metrics are
considered when evaluating CTC enrichment techniques; (i) throughput, defined as the
maximum volume processing rate; (ii) recovery, an indicator of the number of target
cells selected from the input sample with respect to the seed level of the target in that
same sample; and (iii) purity defined as the ratio of CTCs selected to the total number of
cells enriched.
* Reproduced with permission from the Analytical Chemistry.
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CellSearchTM (Veridex) is the only FDA approved technology for CTC enrichment
and has been approved for breast, prostate and colorectal cancers. It utilizes
functionalized immunomagnetic beads that target tumor specific antigens associated
with CTCs, which in most cases is the epithelial cell adhesion molecule, EpCAM. This
system has been validated through many clinical reports, however, it suffers from low
purity (0.01–0.1%) and poor clinical sensitivity; recent data has shown that 7/9 normaltype breast cancer cell lines could not be recovered using the CellSearch system. [22,
23] In addition significant sample preprocessing is required and the assay cost is
prohibitively high. Thus, new technologies that can provide higher CTC sensitivity and
specificity as well as automate the entire processing pipeline from CTC selection to
enumeration are needed.
CellSearch typically recovers fewer CTCs from clinical samples than newer
platforms, such as those based on microfluidics, [24] which can directly process whole
blood and search for CTCs with high recovery. [25-31] Microfluidic devices are attractive
platforms for the analysis of CTCs for several reasons: (i) they can be configured to
select CTCs based on several different modalities including biological cell properties,
such as expression of antigens specific to the CTC type or physical cell properties, such
as size. [32] (ii) Microfluidic chips operate in a closed architecture, minimizing the
potential of sample contamination artifacts that may provide false positive results,
especially in clinical laboratory settings. (iii) Microfluidic devices can be produced in a
high production mode and at low-cost. For example, devices can be produced in
thermoplastics

using

micro-replication, the

same
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technology used

to

produce

consumables such as CD and DVDs. [29, 33, 34] (iv) CTC selection devices can be
integrated to other processing steps to fully automate sample processing negating the
need for operator intervention and thus, minimizing false negative results.
Challenges with microfluidics include the high surface-to-volume ratio associated
with these devices requiring special attention to engineer surfaces that reduce nonspecific adsorption artifacts, especially when dealing with clinical samples such as
whole blood. Also, microfluidics are many times incompatible with high throughput
processing; for typical volume flow rates of 300 nL/min (50 x 50 µm2 microchannel
cross-section, 0.2 cm s-1 linear velocity), 3,333 min (55.5 h) would be required to
exhaustively process 1 mL of sample.
A common physical cell property used to enrich CTCs is based on differences in
the size of a CTC compared to that of erythrocytes and leukocytes. Generally, these
devices demonstrate very high throughputs (1 mL/min) but low purity. [35-40] For
example, Hosokawa et al. reported a microcavity array device with circular pores
possessing dimensions of 8.4 µm – 9.1 µm that could use flow rates of 0.2 – 1 mL/min
with recoveries of 85%. [41] The device also demonstrated substantial amounts of
leukocyte infiltration within the enriched samples; 1,000 – 3,000 per mL of processed
blood. In addition, to secure high recoveries using size selection, the cells must be fixed
prior to filtration, negating the ability to culture selected cells.
Microfluidic devices using affinity-based assays (i.e., positive selection or
biological cell property enrichment) typically demonstrate higher purities compared to
their size-based counterparts, but at the expense of throughput. [29, 30, 33, 34, 42] CTC
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affinity beds configured in microfluidic platforms have employed a variety of geometrical
configurations (arrays of microposts, high aspect ratio microchannels) and fluid
dynamics to optimize recoveries. [29, 30, 33, 34] Low throughputs result from the
necessity of using low linear velocities imposed by the limitation set by the maximum
shear forces that selected cells can withstand without being stripped from the selection
surface. In addition, certain flow velocities must be employed to promote highly efficient
antigen/antibody interactions. [29, 30] For example, a CTC chip utilizing a staggered
arrangement of microposts produced a recovery of 65% at low shear (0.4 dynes/cm 2)
with a throughput of 1 mL/h. [30] Other geometries have employed herringbone
channels to induce chaotic mixing leading to recoveries on the order of 91% and purities
from 9% to 14%. [43] Recently, a nanotextured herringbone device consisting of silicon
nanopillars poised on a fluidic channel was reported. [44] A flow rate of 1 mL/h was
used for CTC selection from clinical samples. Adams and coworkers utilized sinusoidal
high aspect ratio microchannels to reduce pressure drops and increased throughput to
1.6 mL/h. A recovery of MCF 7 cells spiked into blood was reported to be 97%.
Irrespective of the CTC selection modality employed, the enumeration process,
which consists of staining the selected cells with DAPI, anti-CD45 antibodies and a
cytokeratin cocktail, has been difficult and tedious to undertake requiring imaging of
large areas and, in some cases, several imaging planes. For example, using a positive
selection CTC microfluidic device developed by our group, [29] 6 h of imaging time was
required using a confocal microscope to enumerate the cells based on staining results,
cell morphology and the nuclear-cytoplasmic ratio. As another example, Stott et al.
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reported a total scan time of 8 h for a CTC microfluidic chip utilizing positive selection.
[43] Another challenge that has been observed for CTC assays is that some epithelial
cancers do not show high sensitivity to the CTC assay, for example pancreatic cancer.
Pancreatic ductal adenocarcinoma, or PDAC, is one of the deadliest forms of pancreatic
cancer and the fourth-leading cause of cancer-related deaths worldwide. According to
the National Cancer Institute, it is one of the most prognostically unfavorable human
cancers with the rate of incidence nearly equal to the rate of mortality. [45-48] Newly
diagnosed patients have a median survival of 6 months and a 5-year survival rate of
only 3 – 5%. Unfortunately, minimal advances have been made to improve patient
outcome in PDAC over the past 20 years primarily because of failures at the diagnostic
level. CTCs for this disease could be attractive biomarkers to manage this type of
cancer. Unfortunately, several CTC technologies provide low clinical yields for this
disease. For example, the CellSearch system demonstrated clinical CTC yields for
metastatic PDAC patients in the range of 0-1 per 7.5 mL of blood using EpCAM-positive
selection. [49, 50] With sized-based selection, the median yields are slightly higher (~9
CTCs per 7.5 mL) but at the expense of purity. [51, 52] Recently, a micro-pillar-based
CTC fluidic device has generated fairly high yields of CTCs for PDAC patients when
using anti-EpCAM antibodies as the selection marker. [30]
Herein we present a novel platform for the selection and subsequent analysis of
CTCs directly from blood samples using a modular microfluidic system to achieve high
throughput required for clinical sample processing, high recovery, high purity and full
process automation with a short assay turnaround time. The three main components of
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the modular system included: (i) A high throughput (HT) CTC selection module used for
the affinity enrichment of CTCs with high recoveries and purities; (ii) an impedance
sensor module for label-free enumeration; and (iii) a staining and imaging module for
placing the CTCs in a small viewing area to reduce imaging time. The HT-CTC selection
module consisted of a parallel network of high aspect ratio curvilinear channels (30 µm
wide and 150 µm deep) arranged in a z-configuration. The z-configuration occupied a
smaller footprint compared to our previously reported CTC selection device and allowed
for uniform addressing of a large number of parallel microchannels. This module could
be scaled from 50 to 320 microchannels depending on the blood volume processing
needs while keeping the processing time below 45 min irrespective of the input volume.
As a prescreening tool, we included an impedance sensor module that utilized two
orthogonally placed Pt electrodes to enumerate CTCs released from the selection
module. The third module, referred to as the staining and imaging module, was used for
collection, staining, and visualization of the selected cells for phenotype identification. It
consisted of a 2D array of 800 triangular-shaped microfabricated pores with dimensions
of 8 µm by 6 µm. This module eliminated the arduous task of scanning large area
selection beds by indexing CTCs within a small area and a single imaging plane. The
clinical utility of this modular microsystem was tested using blood samples from PDX
(patient derived xenograft) mouse models and from patients with local resectable and
metastatic PDAC.
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2.2 Experimental
2.2.1

Materials

Pt wires (75 µm diameter) were purchased from Sigma-Aldrich (St. Louis, MO). COC
(Topas 6013S-04) plates (1/8” thick) and films (250 µm thick) were acquired from Topas
Advanced Polymers, Florence KY. 1/8" thick PMMA hot embossing stock was acquired
from SABIC Polymershapes (Raleigh, NC). 250 µm thick PMMA films used as the
imaging module cover plates were purchased from Goodfellow Corporation (Oakdale,
PA). PEEK tubing and connectors were purchased from IDEX Health & Science (Oak
Harbor, WA). Chemicals used for PMMA and COC surface cleaning and modification
included

reagent

grade

isopropyl

alcohol,

1-ethyl-3-[3-dimethylaminopropyl]

carbodiimide hydrochloride (EDC), N-hydroxysuccinimide (NHS), fetal bovine serum,
and 2-(4-morpholino)-ethane sulfonic acid (MES) all of which were acquired from
Sigma-Aldrich. Monoclonal anti-EpCAM antibody was obtained from R&D Systems
(Minneapolis, MN). Tris-glycine buffer was obtained from Bio-Rad Laboratories
(Hercules, CA). PBS buffer and trypsin from porcine were purchased from SigmaAldrich. For CTC immunostaining, the nuclear stain DAPI was obtained from Thermo
Pierce Technologies (Rockford, IL). Anti-CD45-FITC antibody (HI30 clone) and anticytokeratin antibodies

(8/19 conjugated to Texas Red) were purchased from

eBiosciences (San Diego, CA). Bovine serum albumin (BSA) in PBS buffer (pH 7.4) was
secured from Sigma-Aldrich. MEM-non essential amino acids were obtained from
GIBCO (Grand Island, NY GEAA).
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2.2.2

Fabrication of Microfluidic Modules

The CTC processing system (see Figure 2.1) consisted of three separate, task-specific
polymer modules: (1) HT-CTC selection module; (2) impedance sensing module; and
(3) the staining and imaging module. Hot embossing and laser ablation were used as
the primary tools for fabrication of the polymer fluidic modules as described
previously.53 Hot embossing mold masters were prepared in brass using high
precision-micromilling (KERN 44, KERN Micro- und Feinwerktechnik GmbH & Co.KG;
Murnau, Germany) and standard carbide bits (Performance Micro Tool, Janesville,
WI).53 Hot embossing of polymer modules was performed using a HEX03 embossing
machine (Jenoptik Optical Systems GmbH, Jena, Germany). The embossing conditions
consisted of a temperature of 155°C and 30 kN force for 120 s for cyclic olefin
copolymer,

COC,

substrates

and

160°C

poly(methylmethacrylate), PMMA, substrates.

and

20

kN force

for 240

s

for

Laser milling was done using an ArF

excimer laser (Rapid X 250, Resonetics Inc., Nashua, NH) with a laser fluence at the
workpiece of ~15 J/cm2 and a repetition rate of 50 Hz.
2.2.3

HT-CTC Selection Module

The HT-CTC module (see Figure 2.2) was made from the thermoplastic, cyclic olefin
copolymer, COC, due to its ability to be embossed with high aspect ratio
microstructures, its optical clarity, its propensity to be UV functionalized with high
efficiency irrespective of channel aspect ratio, and the minimal amounts of non-specific
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adsorption of leukocytes it demonstrated providing high purity levels of enriched CTCs
from whole blood. 54
The HT-CTC module consisted of an array of high-aspect ratio sinusoidal
microchannels with a nominal width of 30 µm and depth of 150 µm serving as the CTC
selection bed. Selection beds were addressed using a single inlet and outlet
microchannel arranged in a unique z-configuration. The selection bed employed 50 to
320 sinusoidal microchannels with the maximum number of channels set by the
maximum length of the chip, which was chosen to be 75 mm to match the length of a
standard microscope slide, and the smallest channel-to-channel spacing that was
machineable.
After hot embossing, the HT-CTC module and cover plate were flood exposed to
broad band UV light at ~22 mW/cm2 (measured at 254 nm) for 15 min using a homebuilt system employing a low pressure Hg grid lamp (GLF-42, Jelight Company Inc.,
Irvine, CA). UV exposure produced carboxylic acid surface scaffolds that were used for
the covalent attachment of monoclonal antibodies for CTC selection (anti-EpCAM
antibodies).55, 56 After UV exposure, the substrate was enclosed with a cover plate by
Thermal fusion bonding at a temperature of 132°C and a bonding pressure of ~1
N/cm2. Bonding conditions were carefully selected to achieve high bond strength, but
preserve structural integrity of the high-aspect ratio microchannels.
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Figure 2.1 Modular microfluidic system for CTC analysis. (A) Schematic representation of
the operation of the system and the three modules comprising the system including the
HT-CTC module, the impedance sensing module and the staining and imaging module.
Arrows indicate flow of sample (1 and 1’), wash buffer (2 and 2’), CTC release buffer (3
and 3’), and fixation and staining reagents (4 and 4’). For detailed operational procedures
please refer to the Experimental Section. (B) Picture of the assembled system. Roman
numerals correspond to modules described in (A). (C) Micrographs and data plots
showing the various outputs of the three different task-specific modules including: (I) HTCTC selection module, which used anti-EpCAM-coated sinusoidal microchannels for the
positive selection of CTCs; (II) electrical signatures of CTCs obtained using the
impedance sensor module; and (III) images of CTCs stained with DAPI and collected at
the staining and imaging module.
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After assembly, the surface of the microfluidic channels was modified using EDC NHS

chemistry.

This

consisted

dimethylaminopropyl]carbodiimide

of

50

hydrochloride),

mg/mL
5

EDC
mg/mL

(1-Ethyl-3-[3NHS

(N-

hydroxysuccinimide) in 100 mM MES (pH 6), followed by incubation with a solution of
anti-EpCAM monoclonal antibodies (0.5 mg/mL; 150 mM PBS buffer, pH 7.4) overnight
at 4°C. The optimum concentration of the antibody was chosen based on studies to
optimize CTC recovery (see Figure 2.5).

Figure 2.2 (A) Schematic operation of the HT-CTC module with 50 parallel,
sinusoidal microchannels and inlet/outlet channels arranged in the z-configuration. The
large arrow indicates sample flow direction through the selection channels. (B) SEM of
the selection bed showing high-aspect ratio sinusoidal microchannels and the output
channel (top). (C) SEM of one of the high-aspect ratio sinusoidal channels. (D) SEM
image of a portion of the high-precision micromilled brass molding tool showing the
sample inlet port with continuously changing width and height for minimizing unswept
volumes during sample (i.e., blood) introduction. (E) Assembled HT-CTC modules with
different numbers of microfluidic sinusoidal channels designed for efficient processing of
various sample volumes
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2.2.4

Evaluation of Flow Uniformity in HT-CTC Selection Bed

Video microscopy was used to study the uniformity of the linear flow velocities
through the HT-CTC selection bed with inlet and outlet all arranged in z-configuration.
The HT-CTC chip with 320, 20 mm long sinusoidal microchannels was used for these
experiments. The experimental setup for these measurements consisted of a syringe
pump connected to the HT-CTC chip through a manual HPLC sample injector equipped
with a 20 µL volume sample loop. During measurements, buffer solution was
continuously pumped through the HT-CTC chip at volumetric a flow rate of 176 µL/min,
which produced an average linear flow velocity in the sinusoidal microchannels of 2
mm/s. Aliquots of 20 µL of red food dye were injected into the clear buffer solution and
the time required for the dye plug to travel from the inlet channel to the outlet channel
was then recorded. Because monitoring of the filling time for individual channels was
not feasible due to the overall size of the chip and the limited optical resolution of our
video recording system, the chip was divided into 16 observation windows with roughly
20 selection microchannels per window and an average filling time was recorded for
each window. The recorded times were divided by the channel length (20 mm) to obtain
the average linear velocity as presented in Figure 2.4C.
2.2.5

Impedance Module

The impedance sensing module, which was made in poly(methylmethacrylate),
PMMA, and consisted of two perpendicular microchannels. A microchannel with
dimensions of 50 µm width x 75 µm depth served as a conduit for cells flowing through
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this module. The second microchannel (75 x 75 µm2) was used as guides to place two
Pt wires, which were used as electrodes for making the single-cell impedance
measurements. Impedance measurements were conducted using previously described
circuitry. [29] Data were collected and analyzed using a NI-USB-6009 (National
Instruments) data acquisition board and software written in LabView (National
Instruments). Data were collected at 2 kHz, which allowed for sample processing
through the sensor at a maximum flow rate of 20 µL/min (80 mm/s) without generating
signal aliasing. The raw output data was subjected to a 1,000 point adjacent averaging
algorithm to establish the baseline for the measurement without generating signal bias.
Baseline was then subtracted from the data in order to correct for signal drift.
2.2.6

Staining and Imaging Module

The design of the staining and imaging module is presented in Figure 2.3. It
consisted of two independent microchannel networks, one consisting of an array of
smaller microchannels laser machined into the module cover plate and a second set of
fluidic

channels

embossed into the substrate, which consisted of interleaving

input/output channels of larger cross section. The smaller channels on the cover plate
were positioned perpendicular to the interleaved input/output channels contained within
the substrate. The input/output channels (50 µm depth; varying width) were hot
embossed into PMMA using a high precision micromilled mold master. Laser ablation
was used to fabricate the array of smaller microchannels into a thin PMMA film serving
as the module cover plate. Both parts were thermal fusion bonded at 106°C and a
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pressure of ~3 N/cm2 with the patterned surfaces facing each other. The staining and
imaging module possessed 800 pores arranged in a 2D matrix and spaced by 100 µm

Figure 2.3 Staining and imaging module. (A) Assembly process; (a) – cover plate with
an array of 8 x 6 µm2 channels, which form pores for retaining cells between the
interleaving inlet and outlet channels (b). (B) Schematic of an assembled module and its
operation; Red – input channels; Blue – output channels; Yellow – interconnecting
channels. (C) Image of the staining and imaging module filled with fluorescein. The
lower fluorescence intensity in the interconnecting channels is due to the smaller crosssectional area of these channels compared to the input/output channels. (D)
Fluorescence image of CTCs retained by pores. The cells were stained with DAPI for
visualization. (E) High magnification fluorescence image of Hs578T cells retained at the
pore structures of the staining and imaging module. These cells were stained with
PKH67 lipid membrane green fluorescent dye for visualization.
Addressing of the microfluidic networks and connection between modules was
accomplished using glass capillaries (Polymicro Technologies, Phoenix, AZ) affixed to
inlet and outlet ports of each module via epoxy (Permapoxy, Permatex, Hartford, CT).
93

Capillaries were connected to each other using low dead volume interconnects secured
from Polymicro.
2.2.7

Cell Culture

MCF-7 (breast), Hs578T (breast) and SW620 (colorectal) cancer cell lines were
purchased from American Type Culture Collection (ATCC, Manassas, VA) and cultured
according to recommended conditions. Briefly, all cell lines were incubated at 37˚C
under a 5% CO2 atmosphere. Eagles minimum essential medium (MCF-7 and Hs578T)
and Dulbecco’s minimum essential medium (SW620s) containing 1.5 mM L-glutamine
supplemented with 10% FBS (GIBCO, Grand Island, NY) was used. A 0.01mg/mL
solution of bovine insulin (GIBCO, Grand Island, NY) was added to the complete growth
media for the MCF-7 cells. The Hs578T cell line required 1X non-essential amino acids
to complete the final growth medium. The cell lines were grown as adherent monolayers
in T75 culture flasks (Corning) to 80-95% confluence with media changes every 2-3d.
Cells were washed in a flask with Dulbecco’s phosphate buﬀered saline, DPBS
(GIBCO, Grand Island, NY), dissociated by using TrypLE™ Express (1X) (GIBCO,
Grand Island, NY) at 37˚C for 5-7 min and subsequently seeded into culture flasks at a
low concentration.
2.2.8

Patient Samples

Patients with pancreatic cancer were recruited according to a protocol approved by
the University of North Carolina’s IRB. Blood specimens from healthy volunteers were
collected under a separate IRB-approved protocol. A total of 8 patients with known
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metastatic PDAC and 6 patients with non-metastatic PDAC were used as positive
controls. Five non-cancer patients also served as negative controls. All specimens were
collected into BD Vacutainer® (Becton-Dickinson, Franklin Lakes, NJ) tubes containing
the anticoagulant EDTA and were processed within 5 h of the blood draw.
2.2.9

Patient-derived Xenograft (PDX) Models

Tumors from de-identified PDAC patients were grafted onto the flanks of
immunocompromised mice under approval by the Institutional Animal Care and Use
Committee. Terminal bleeds were obtained via cardiac puncture. Blood samples from
the PDX models were then analyzed using the microfluidic system.
2.2.10

Staining Procedure

The staining protocol was as follows: 0.25% BSA in PBS buffer (pH 7.4) was infused
through the staining and imaging module at a flow rate of 20 µL/min. Next, 100µL of
0.0025mg/mL anti-human CD45-FITC was infused at a flow rate 10 µL/min and allowed
to incubate at 4˚C followed by a 5 min wash with 0.02%TX-100/PBS at 20 µL/min. For
fixation and permeabilization, 2-4% paraformaldehyde in PBS buffer was infused at a
flow rate of 15 µL/min followed by 0.1%TX-100 in PBS buffer at the same flow rate.
Next, 100 µL of 0.01mg/mL anti-cytokeratins 8/19 labeled with Texas Red was infused
at 10 µL/min and incubated at 4˚C followed by a 10 min wash consisting of 0.25%BSA
in PBS at 20 µL/min. For nuclear staining, 0.001mg/mL DAPI in PBS was infused at a
flow rate of 15 µL/min followed by a wash with 0.25% BSA in PBS.
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2.2.11

HT-CTC Module Operation

Prior to analysis of all samples, the HT-CTC selection module was thoroughly
washed with PBS buffer at a flow rate of 40 µL/min for at least 5 min in order to remove
unbound antibody from the microchannel walls. Blood specimens collected into BD
Vacutainer® tubes were placed on a nutator for at least 10 min to allow for homogenous
distribution of blood components. Following homogenization, 3 mL of patient blood or
approximately 1 mL of PDX blood was transferred into a disposable Luer Lok TM syringe
(BD Biosciences, Franklin Lakes, NJ) using a BD vacutainer female luer transfer
adapter. Immediately after transfer, blood samples were processed through the HT-CTC
selection module. A PHD2000 syringe pump (Harvard Apparatus, Holliston, MA) was
used to hydrodynamically drive the blood through the HT-CTC selection module at the
appropriate volume flow rate to attain an optimal average linear velocity of sample
through the sinusoidal microchannels (2 mm/s) to maximize recovery.[29] During the
course of blood sample introduction, the syringe was rotated by 180° along its
longitudinal axis and lightly tapped in order to prevent sedimentation of the blood
components inside the syringe to assure exhaustive and representative sample
introduction. Finally, the HT-CTC selection bed was flushed with 2.5 mL of PBS at a
linear velocity of 4 mm/s to remove any nonspecifically bound cells.
During blood infusion into the HT-CTC module and the subsequent washing step,
the output capillary to this module was disconnected from the impedance sensing
module and inserted into a microfuge tube for waste collection. When the release buffer,
which contained trypsin, was introduced into the HT-CTC module, the output capillary
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was reconnected to the impedance sensing module. The output port of the impedance
sensing module was connected to the input port of the imaging and staining module
(see Figure 2.1).
2.2.12

Operation of the Integrated System and Data Collection and Analysis

All three modules were connected in series using glass capillaries (see Figure 2.1).
Following HT-CTC module washing, 200 µL of the CTC release buffer consisting of
0.25% w/v trypsin in 25 mM TRIS/192 mM glycine buffer (pH 7.4) was infused through
the HT-CTC selection module to allow for the release of CTCs from the antibodycontaining selection channels and into the downstream processing modules. As the
CTCs traversed through the impedance sensor, an electrical signal was recorded using
in-house designed and built electronics as described previously. [29] The raw output
data was subjected to a 1,000 point adjacent averaging algorithm to establish the
baseline for the measurement without generating signal bias. Baseline was then
subtracted from the data in order to correct for signal drift. Impedance responses
generated from CTCs were counted when the signal-to-noise ratio exceeded 3:1. Cells
counted were directed into the staining and imaging module for staining with
fluorescently labeled markers including cytokeratins 8/19, the nuclear stain (DAPI), and
a negative control consisting of FITC labeled anti-CD45 antibodies.
The staining protocol was as follows: 0.25% BSA in PBS buffer (pH 7.4) was infused
through the staining and imaging module at a flow rate of 20 µL/min. Next, 100 µL of
0.0025 mg/ml anti-human CD45-FITC was infused at a flow rate 10 µL/min and allowed
to incubate at 4˚C followed by a 5 min wash with 0.25% BSA/PBS at 20 µL/min. For
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fixation and permeabilization, 2-4% paraformaldehyde in PBS buffer was infused at a
flow rate of 15 µL/min followed by 0.1%TX-100 in PBS buffer at the same flow rate.
Next, 100 µL of 0.01 mg/ml anti-cytokeratins 8/19 labeled with Texas Red was infused
at 10 µL/min and incubated at 4˚C followed by a 10 min wash consisting of 0.25% BSA
in PBS at 20 µL/min. For nuclear staining, 0.001 mg/ml DAPI in PBS was infused at a
flow rate of 15 µL/min followed by a wash with 0.25% BSA in PBS.
The stained cells were imaged using an inverted Olympus 1X71 microscope (Center
Valley, PA) using 10x, 20x, 40x, and 60x dry objectives equipped with a high resolution
(1344 x 1024) CCD camera (Hamamatsu ORCA-03G) and a mercury arc lamp as an
illumination source. Images were collected using 40× (0.6 NA) and 60× (0.7 NA) dry
lens objectives and analyzed using Metamorph software (Olympus). Exposure times for
the DAPI, FITC/CD45, and Texas Red/CK channels were 50, 600, and 600 ms,
respectively.
Statistical analysis was performed using the Kruskal-Wallis Test (p = 0.05) for three
sample groups of healthy, non-metastatic and metastatic PDAC patients. For pairwise
test analysis, Wilcoxon Rank-Sum (p = 0.05) was applied..
2.3 Results and Discussion
2.3.1

HT-CTC Module

The HT-CTC module utilized COC as the substrate material. COC demonstrates
higher UV transmissivity compared to PMMA, therefore generating a higher surface
density of carboxylic acid groups on channel walls. These surface-confined carboxyl
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groups serve as functional scaffolds for the attachment of CTC recognition elements.
[53, 54] Higher UV transmission also resulted in a more uniform modification of the
high-aspect ratio microchannel walls when made from COC. COC also demonstrated
higher CTC purities due to lower non-specific adsorption of hematopoietic cells to its
surface compared to PMMA. [54]
Considering the requirements for the microfluidic channel geometry and linear
velocity of the sample through the selection channels to maximize recovery, [29] it was
clear that higher throughput could be achieved by either increasing the number of
parallel microchannels or increasing the depth of the microchannels without changing
the width. For results reported herein, we used larger number of parallel channels as a
method for increasing throughput. For example, the previously reported device used 51
parallel channels (cross-section 30 µm x 150 µm) and could process 1 mL of whole
blood in 37 min. Thus, it would take nearly 4.7 h for this device to process 7.5 mL. By
increasing the number of channels to 320, 7.5 mL input volumes could be processed in
<45 min using an average linear velocity of 2 mm/s.
To uniformly address all parallel channels within the selection bed employing
large numbers of parallel sinusoidal channels, we adopted a unique z-configuration
(Figure 2.2). In this configuration, fluid enters the selection bed through a single inlet
channel with a larger cross-sectional area and exits through a single outlet channel also
possessing a larger cross-section compared to the sinusoidally-shaped selection
channels

(see

Supporting

Information).

Both

inlet

and

outlet

channels

were

perpendicular to an array of high aspect ratio channels comprising the selection bed
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(Figure 2.2A).

The z-configuration provides the smallest possible footprint for

addressing the isolation bed and allows for easy scaling of the CTC isolation bed size.
For example, in a recently proposed fluidic design for neutrophil isolation

[55],

bifurcation was used for addressing parallel channels of the isolation bed, which nearly
doubled the footprint of the proposed device in order to allocate space for the fluid
distribution network. Furthermore, compared to previously reported design, [29] the high
linear fluid velocities in the inlet and outlet channels of z-configuration allow for more
efficient removal of persistent air bubbles that are inevitably introduced into device
architectures during operation and may interfere with the fluid flow.
Uniformity of the fluid flow in z-configuration is highly dependent on the flow
resistance ratio between the inlet/outlet channels and the flow resistance in the parallel
channels. In general, wider (lower fluidic resistance) inlet channels and longer and/or
narrower (higher fluidic resistance) parallel channels show higher flow uniformity
throughout the array. Inhomogeneity of the flow rate is exacerbated by the number of
parallel channels in the array. As seen in Figure 2.4A, a parabolic fill profile was
observed over the entire selection bed during filling. Qualitatively, if each channel of the
array was filling under a constant linear velocity, the filling profile of the array should
show a linear gradient.
To evaluate flow uniformity in the CTC selection beds with various numbers of
sinusoidal channels and for various lengths of the selection bed, we performed
numerical simulations to establish average linear velocities of fluid in individual
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Figure 2.4 (A) Various stages of filling a 320-channel HT-CTC module (20 mm length)
with a dye solution. (B) Numerical simulation results showing the distribution of flow
velocities for different configurations of the CTC selection beds arranged in a zconfiguration. (C) Average linear velocity of fluid in 16 groups of 20 adjacent
sinusoidal high aspect ratio microchannels based on the results depicted in Figure
2.4A (filled bars) and theoretical values obtained via numerical simulation (empty
bars). (D) Distribution of cells selected in 20 mm long microchannels
sinusoidal microchannels. Due to the numerical limits of simulating large geometries
using computational fluid dynamics (CFD), we employed a method described by Zhang
and coworkers. [56] This method splits the selection bed into an interconnected system
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of individually defined parallel channels and the addressing inlet/outlet channels. Each
channel segment was treated as a fluidic resistor, and the flow dynamics through the
entire system was described by pressure and mass balance equations. [56]
Figure 2.4B presents solutions for microfluidic selection beds with 50, 250 and
320 channels possessing dimensions of 0.03 x 0.15 x 30 mm 3 along with the results for
320 channels with varying lengths of 30, 20 and 8.4 mm. As can be seen from this data,
for the 320 channel device with 8.4 mm selection channel lengths, the maximum and
minimum flow velocities fall outside the range of 1 mm/s – 4 mm/s, a range that was
determined to provide CTC recoveries >80%. [29] However, when using 320 channels
and incorporating a length of 30 mm, the average flow velocity remains within an
acceptable range for maximum CTC recovery. The simulated results were also
confirmed experimentally (Figure 2.4C). The results indicated good agreement with the
simulation results; the slowest flow rates were observed in the middle and fastest at the
outer channels with an RSD of 16%. We also evaluated the distribution of selected
MCF-7 cells inside a HT-CTC bed modified with anti-EpCAM antibodies. MCF-7 cells
(~500) labeled with a PKH 67 fluorescent membrane dye were spiked into normal blood
and processed using the selection bed comprised of 320 channels and the numbers of
MCF-7 cells per channel were counted using a fluorescence microscope. Figure 2.4D
shows the selected cell distribution within individual channels. A uniform distribution of
cells across the entire series of microchannels occurred with most of the channels
capturing 1 or 2 cells and only a few capturing 3 - 4 cells or no cells at all. The overall
average CTC recovery for these experiments was 83.1% ±5.2% (n = 4). Selection beds
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with at least 30 mm channel lengths were necessary to achieve recoveries >90% (see
section on the effect of bed length on recovery).
2.3.2

Optimization of anti-EpCAM Antibody Concentration

In order to increase the probability of interaction between antigens on the CTC
surface and selection channel wall bound antibodies, it is critical that there be a
maximum coverage of the antibody on the channel walls. On the other hand, the
amount of antibody used for the reaction should be kept to a minimum in order to keep
the cost of the assay low. The amount of antibody required to produce a monolayer
coverage of the walls within the selection bed can be estimated using the following
assumptions. Theoretically, a monolayer of an IgG-type antibody has been reported to
be on the order of 1.1 pmolcm-2. [57] For comparison, the surface density of carboxylic
acid moieties produced on a polymer surface using UV activation has been reported to
be on the order of1 nmolcm-2, indicating significant excess of carboxylic acid moieties
compared to the surface density of antibodies for a monolayer coverage. [58] In studies
previously published by our group describing CTC isolation using polymer microfluidic
devices, a relatively high concentration of anti-EpCAM antibody was used (1 mg/mL).
[29, 33] For microchannels with cross-sectional dimensions of 30 µm wide x 150 µm
deep, a solution of antibody at 1mg/mL concentration injected into the microchannels
provides an amount of antibody corresponding to nearly 10x excess to the theoretical
amount required to achieve complete monolayer coverage. One has to also note that
the maximum surface coverage is not a single parameter for determining optimal
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performance of the CTC recovery process as the activity of surface bound antibodies is
important as well. The activity of the antibody is dependent on its conformation on the
surface and possible steric effects caused by crowding.

Figure 2.5 Recoveries of MCF-7 cells using selection beds modified with EpCAM
antibody at different antibody concentrations. Results were normalized to recovery
obtained for antibody concentration of 1 mg/mL.

In order to establish the optimum concentration of anti-EpCAM antibody required
during the covalent attachment process to optimize recovery, we evaluated the
recoveries of MCF-7 cells obtained using selection beds prepared with different
concentrations of antibodies. Figure 2.5 presents a summary of these experiments
using beds modified with 1 mg/mL, 0.5 mg/mL, 0.25 mg/mL, and 0.1 mg/mL of antiEpCAM antibody. As can be seen from this data, there seems to be no difference in
recovery when the antibody concentration is reduced 2-fold to 0.5 mg/mL. However,
further reductions in the amount of antibody leads to significant drop in the recovery of
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the MCF-7 cells. Therefore, the concentration of 0.5 mg/mL was used throughout this
work.
2.3.3

Effect of CTC Selection Bed Length on Recovery

We were also interested in evaluating whether the length of the selection channels
was critical in regards to CTC recovery. The use of shorter selection channels can
reduce pressure drops within the selection channels and require less use of antibody.
To evaluate selection bed length on recovery, the location of MCF-7 cells recovered
using 8, 20, and 26 mm long beds (320 channels) were recorded and assigned to one
of three equidistant zones along the microchannel length (see Figure 2.6). The overall
average recovery for beds with 8 mm long channels was 67%, the 20 mm long channels
was 83% and the 26 mm length channels was 93%. Inspection of the location of the
selected CTCs along the 20 mm length channel bed indicated that 69% of the cells
captured were found in a 0-10 mm region of the channel (the 0 coordinate is the input
end of the channel), 23% were 10-15 mm region from the inlet and 8% were within the
15-20 mm zone with comparable numbers seen for the other two channel lengths. It is
important to note that although the majority of the selected cells were captured within
the first half-length of the selection channels, there was still a relatively large number of
cells captured in the second half of the channels indicating that shorter selection beds
do not provide optimal CTC recoveries. Indeed, evaluation of 8 mm long channels
comprising the selection bed produced an overall recovery of 67%. For comparison, the
original CTC selection beds employed by Adams, et al. [29] used 26 mm long sinusoidal
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microchannels and demonstrated recoveries >90% (see Figure 2.6). Therefore, all of
the results reported herein used selection beds with channels ~30 mm in length.

Figure 2.6 Capture efficiencies of MCF-7 cells using isolation beds with varying
channel length. Zone 1 first 50% of channel length, zone 2 – 50-75% of channel
length, zone – 75 – 100% of the channel length
2.3.4

Impedance Sensor Module

The impedance sensor adopted a geometry similar to that reported previously by our
group. [29, 33, 59],[29] Using this sensor, we were interested in determining the ability
to discriminate between leukocytes and CTCs based on size differences, which is the
cell characteristic measured at the operating frequency (40 kHz). At this frequency, the
amplitudes of signals produced by single cells are dominated by cell size. [59] This
module was fabricated in PMMA and consisted of a pair of Pt electrodes placed
orthogonally to a 50 µm channel through which released CTCs traversed. Figure 2.7A
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provides results for SW620 cells spiked into buffer and traversing through the pair of Pt
wires. Also shown are leukocytes that were isolated from a buffy coat of blood secured
from a healthy donor and measured using the impedance sensor. There was only a
slight overlap

in the

signal amplitudes

between the two cell types with a

misclassification frequency of ~15%. Similar results were observed when the cell sizes
for the same populations were measured using an optical imaging technique (Figure
2.7B). A 100% concurrence between the impedance sensor response and passing cells
were observed when using a microscope to watch the passage of single cells through
the pair of electrodes (data not shown). However, because there was some size overlap
between CTCs and leukocytes, we could not clearly distinguish between these two cell
types based solely on the magnitude of the impedance response. In spite of this
limitation, the high purity of our selected CTC fractions from whole blood (>80%, see
below) indicates that the leukocyte infiltration is low anyway. Nevertheless, the
impedance sensor in its current format can measure signatures from single cells that
are unlabeled and thus, can serve as a prescreening tool for assessing the need to
immunocytochemically stain for CTCs. If no impedance signals are generated, the
sample can be considered negative for CTCs and thus, forgo the need for staining
reducing assay cost and operator time.
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Figure 2.7 Single-cell electrical impedance sensing. (A) Histograms for impedance
response for leukocytes (blue bars) and SW620 cancer cells (red bars). (B) SW620
(red bars) and leukocyte (blue bars) cell sizes measured optically
2.3.5

Staining and Imaging Module

PMMA was selected as the substrate of choice for the staining and imaging module
due to the high quality machining it generated using laser ablation as well as its
favorable optical properties. [60] The design and operation of the novel 2D imaging
module are shown in Figure 2.3. It consisted of two independent networks of channels;
an interleaving input/output channel network interconnected using an array of smaller
channels positioned orthogonally to the input/output channels. The interconnecting/feed
channel interface generated a pore structure, whose dimensions were determined by
the size of the interconnecting channel (8 µm base and 6 µm height). During operation,
CTCs released from the primary selection bed were transported through the impedance
sensor to the staining and imaging module where they were retained due to their larger
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size as compared to the size of the pore. After collection at each pore, CTCs could be
fixed, permeabilized, and immunostained directly within the staining and imaging
module followed by fluorescence imaging.
The unique geometry of the staining and imaging module offered important
benefits: (i) A small footprint (0.16 cm2) as compared to the primary selection bed (4
cm2 for the 50-channel z-configuration selection module), which significantly reduced
the time required for imaging; (ii) cells are brought to a single focal plane further
reducing imaging time; and (iii) the highly ordered configuration of the pores allowed for
indexing cell position, which also reduced imaging time.
To validate the performance of the staining and imaging module, we determined
the collection efficiency of fixed and unfixed cells at a flow rate that was used to move
the released CTCs from the selection channels to the staining and imaging module. We
used Hs578ST cells seeded into PBS as a model for these studies. The collection
efficiency was defined as the ratio of cells collected at the pores to the number of cells
enumerated by the impedance sensor (see Figure 2.9). We determined that for fixed
cells, the collection efficiency of the staining and imaging module was 96 ±6% (n=5)
while for unfixed cells, the collection efficiency was 85 ±11% (n=5). The difference in the
collection efficiency is indicative of the higher deformability of unfixed cells compared to
those that are fixed (see Figure 2.8). [61]
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We also found that the cells resident within a pore adhered to the pore structure
even when the solution flow was terminated. Therefore, the cells could be trapped at the
pore without requiring boundary conditions to contain the cells. Because of this
adhesion, we could remove the staining and imaging module from the system and place
it on a conventional microscope stage without losing cells from their respective pore
location.

Figure 2.8 Fluorescent images of CTCs collected in the staining and imaging module.
(A-D) Images of a CTC from a PDAC patient after being released from the selection
bed, impedance counted, and collected at a pore on the staining and imaging module
followed by fixation and staining with DAPI, anti-cytokeratin antibodies (8/19) labeled
with Texas Red, and FITC-labeled leukocyte antibody marker for CD45. (E)
Fluorescent image of a CTC with the cytoplasm partially deformed and pulled into the
pore and the interconnecting channel. Dashed lines indicate the edges of the input
channel and the interconnecting channel. Scale bar is 10 µm in all cases.
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2.3.6

Correlation of Impedance Responses with Imaging Data

We next evaluated the collection efficiency of the staining and imaging module for
patient samples(n = 4, PDAC). Impedance responses from each sample were analyzed
and correlated to the number of CTCs collected using the staining and imaging module
that were scored as CTCs (DAPI(+), CD45(-) and CK(+)). A Pearson correlation of 0.93
(n=4) was obtained between the impedance responses and the CTCs collected at the
staining and imaging module. As seen from the impedance trace for one patient (Figure
2.9A), 14 peaks were assigned as cell events. Variations of the peak amplitude
responses for the impedance trace were most likely due to differences in CTC size
and/or transduction of leukocytes (see Figure 2.7). The CTCs collected on the staining
and imaging module were found to be 8 for this same sample and were definitively
identified as CTCs by their staining pattern. For all PDAC samples analyzed, the
collection efficiency of CTCs by the staining and imaging module was 72 ±13% (see
Figure 2.9). While the staining and imaging module demonstrated higher collection
efficiencies for the Hs578T cell line compared to the clinical samples, this difference
could have arisen from impedance signals recorded for leukocytes as well as the CTCs,
which were not present in the cell line studies. Also, most of the CTCs are in an
apoptotic state and therefore, their cell membrane may not be rigid enough to withstand
the pressure exerted on the cell by the pore structure (see Figure 2.8). [62-64]
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Figure 2.9 (A) Impedance counts generated from CTCs selected from 2.0 mL of blood
from a patient with metastatic PDAC. The sample was processed through the HTCTC selection module at a linear flow velocity of 2.0 mm/s. CTCs were then released
from the selection bed using a CTC release buffer at a volumetric flow rate of 10
µL/min. A total of 14 CTCs were enumerated using impedance sensing based on a
signal-to-noise threshold of 3 (dotted line). The red dotted line represents the
threshold level, which was used to differentiate ‘true’ events from noise. Data
presented here were smoothed using algorithms described in the Experimental
Section. After impedance counting, the cells were directed to the staining and imaging
module for phenotypic identification (DAPI, CD45 and cytokeratins). (B) Plot showing
the correlation between the impedance counts versus CTCs enumerated via i mmunostaining on the staining and imaging module for 4 different metastatic PDAC patient
samples. (●) Represents expected numbers of CTC events based on the impedance
signatures and (□) shows the experimental enumeration data from the staining and
imaging module (r = 0.93). (C) Interface between a capillary and plastic module
showing the capillary inserted into a guide channel to accommodate the 365 µm od
capillary and stepping to a channel size of 150 µm, which matches the id of the
interconnect capillary.

The high correlation between the impedance responses and those ascertained
through immunostaining using the staining and imaging module also indicated that
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minimal cell loss was induced by the capillary interconnections between modules. Any
potential loss of cells by these interconnects could be induced by shearing effects at
module/capillary junctions or the unswept volumes created by these same junctions.
However, the relatively large size of the CTCs and the small capillary diameters used as
the interconnects (id = 150 µm) as well as the carefully designed capillary-to-module
interface minimized unswept volumes. The interface between the capillary and module
was accomplished by using multiple levels of microstructures. A guide channel for the
capillary matching the capillary od (365 µm) was used as the capillary holder and the
fluidic channel dimensions matched that of the capillary id (150 µm). Figure 2.9C shows
this interface.
2.3.7

Preclinical Studies Using PDX Models

We processed blood samples from PDX models (n = 7) that were engrafted with
biopsy tissue from metastatic PDAC patients. In addition, we analyzed blood from
healthy mice (n = 3) to serve as negative controls. Cells were classified as CTCs only if
they met the following criteria; (i) intact cells with nuclei; (ii) immunocytochemically
positive for cytokeratins 8/19 and negative for leukocyte marker CD45; and (ii)
morphological characteristics such as having a nucleus to cytoplasm ratio of 2:1 with a
large visible nucleus (Figure 2.10C i. a-d). CTCs generated from PDX models were
isolated within a range of 13 to 112 CTCs/mL (median = 24/mL, mean = 44 ±36/mL),
while healthy mice (n = 3) generated a mean of 0.83 /mL (p = 0.022). A summary of this
data can be seen in the box plot shown in Figure 2.10A.
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2.3.8

Clinical Studies in Metastatic and Local Resectable PDAC Patients

For metastatic PDAC patient blood samples, we isolated an average of 53 ±29
CTCs/mL, median = 51/mL with a range of 9 to 95 CTCs/mL. To establish assay
reproducibility, we also processed three aliquots from the same patient sample through
three different HT-CTC modules. An RSD value of 14% (n = 3) was obtained. CTCs
were selected in all patients with metastatic PDAC. For the healthy blood donors, in
most cases no CTCs were observed (p = 0.004). Metastatic patients had a statistically
significant higher CTC count compared to healthy patients (p = 0.008).
We also analyzed blood from 5 patients who had been determined to have local
resectable PDAC by CT scans. We found an average of 12 CTCs/mL for this group of
patients. Based on the Kruskal-Wallis test (p = 0.002), there was a significant difference
in the CTCs/mL between metastatic, local resectable, and healthy patients. Pairwise
Wilcoxon Rank-Sum tests suggested that there was a significant difference between
metastatic and healthy patients (p = 0.005). Between local resectable PDAC and
healthy patients there was also a statistically significant difference in terms of CTC
numbers (p = 0.011). Comparison between metastatic and local resectable patients also
indicated a significant CTC number difference (p = 0.023). These results remained
significant when accounting for multiple testing using the Hochberg method (p-values of
0.016, 0.022, and 0.023).This data is summarized in the box plot shown in Figure
2.10B. The presence of CTCs from locally resectable patients may be indicative of
micrometastatis, which is undetectable by conventional diagnostic methods. CT scans,
which are commonly used for tumor imaging, are less informative with regard to the
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micrometastatic nature of the tumor because they cannot detect tumors smaller than 1
cm and thus, may not be effective for assessing the micrometastatic nature of PDAC as
our assay has demonstrated. [45] Continuous monitoring of CTC counts from this group
of patients may be important in predicting the reoccurrence of the disease after surgical
resection.
The purity of the assay when processing clinical blood samples was determined
as well. The purity was calculated using the ratio of the number of CTCs selected to the
total number of cells selected and was found to be 86 ±12% for all samples analyzed.
For many CTC selection platforms, purity is calculated as the ratio of CTCs (DAPI(+),
CK(+) and CD45(-)) divided by the total number of selected DAPI(+) cells.
Unfortunately, the purity number when calculated in this fashion can be biased if the
leukocyte numbers are relatively constant, but the CTC number per patient varies (can
vary over 3-orders of magnitude). We show in Table 2.1 the numbers of those cells
selected and classified as CTCs and cells classified as leukocytes or double stained
cells (CK(+) and CD45(+)) for several patients (n=4) with different states of disease as
well as healthy donors.

115

Figure 2.10 Staining and enumeration of CTCs via immunophenotyping. (A) Box plot
representing results from the phenotypic enumeration of CTCs isolated from 7 PDX and
3 healthy mice. (B) Box plot from CTCs isolated from 7 metastatic PDAC patients, 5
healthy controls and 5 local resectable PDAC patients. (C) Fluorescence images of
various selected cells from a metastatic PDAC patient: (i) CTC; (ii) two white blood cells;
and (iii) cluster of CTCs. (b, f, j) CTC marker for Cytokeratin 8/19 (red) with b, j positive
for this marker and f negative for this marker; and (c, g, k) leukocyte antigen marker
CD45 (green) with c, k negative for this marker and g positive for this marker.
Micrographs (i-l) are of an aggregate of 6 CTCs captured in the HT-CTC module. This
aggregate showed positive for cytokeratins 8/19 (j) and negative for leukocyte marker
CD45 (k). In all of these panels the nuclei were stained with DAPI (blue). Bars are 10
µm.
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For these studies, the cells were not released from the selection module using
trypsin, but were enumerated directly within the selection module following staining
within the same module. Without release using trypsin, potential damage to antigenic
membrane targets could be avoided, which could misrepresent specific cell population
numbers, including the leukocyte population. The purity for the PDX models was found
to be 89 ±16%. The high purity levels observed in our studies compared to others were
mainly due to the relatively high shear forces applied to the selected cells during the
post selection wash, which used a linear velocity of 4 mms -1. While the CTCs selected
on the channel walls remained unaffected by the high shear forces due to the high K d
value (3.3 x 108 M-1) between the EpCAM antigen and EpCAM antibody and the multipoint contact, [29] the non-specifically adsorbed leukocytes are more easily removed
from the surface due to their apparent lower adhesion force to the surface.
As can be seen from this data, the number of leukocytes selected ranged from
approximately 1 – 9 per mL of blood processed with the lowest infiltration rate of
leukocytes found for the local resectable PDAC patients and highest numbers
associated with the metastatic PDAC patients. Also, the CTC number varied
tremendously as would be expected and as shown in Figure 2.10 of the main text for
these three cases. From this data, the purity level as calculated using the method
described previously was 86% for the metastatic PDAC patients
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Table 2.1 Average number of CTCs, leukocytes and double-stained cells selected
using the HT CTC selection module depicted in Figure 2.2 for two different PDAC
pathologies and healthy donors. For this data, the selected cells were stained within the
selection module and not released from the surface using trypsin. The cells were
stained with DAPI (nucleus), cytokeratins and CD45. Each row of the data set
corresponds to a different patient analyzed, which was performed in triplicate (blood
sample, split into three equal volumes and run on three different HT-CTC modules). The
number shown represents the mean for each patient.
Pathology

CTCs/mL

Healthy Donors

Means
Local

Resectable

PDAC
Means
Metastatic PDAC

Means

0
2
0
.0
0
0.5 (±1)
10.5
8
19.0
.7
10.5
12 (±4)
34.0
68.3
94.7
73.8
68 (±25)

Leukocytes/m L
7
2
.0
2
.0
2
.0
3 (±2)
.5
1
0
.0
2
0
.0
0.8 (±0.9)
.5
12.0
9
10.7
.7
2
9 (±4)
.3

Double Stained Cells/mL
0
2
0
.0
0
0.5 (±1)
1
0
.0
0
0
0.3 (±0.5)
3
2
.5
1
.3
1
.7
2
.0
(±1)

Also seen in this data for the healthy donors, one case we detected CTCs, which
could be classified as a false positive result. However, follow up on this individual may
be warranted because the CTC number may be indicative of a non-diagnosed
micrometastatic or metastatic condition for not just PDAC, but any solid tumor that can
produce CTCs. In addition, our data clearly shows that all cases that were diagnosed as
metastatic or micrometastatic (local resectable), CTCs were found indicating that the
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false negative rate is 0 in this limited data set. However, a larger cohort of samples still
needs to be analyzed to reach a concise clinical decision as to the false positive and
false negative rate of CTC detection using our assay. This is currently ongoing in our
laboratory. In addition, a rigorous comparison to the standard CTC analysis platform,
CellSearch, must be undertaken and this work is also currently being undertaken in our
laboratory and will be reported in subsequent manuscripts.
We also noticed microclusters of CTCs in some of the PDAC blood samples (71%)
that were processed (Figure. 7C i-l). These clusters were predominantly found near the
entrance to the sinusoidal microchannels of the HT-CTC selection module. Recent
reports on CTC isolation have cited the presence of similar clusters or microemboli. [43]
It is speculated that these clusters form in circulation or break off from the primary tumor
as a cohort of cells. As a cluster, CTCs can escape the immune surveillance system
more readily than individual CTCs and can be indicative of an increased metastatic
potential of the cancer. [6, 65]
We also noted the presence of cells that stained positive for all three markers (DAPI,
cytokeratins, and CD45). The frequency of the "triple positive" cells was on the order of
1.6 ±2.0 cells/mL, which was lower than the CTC and/or leukocyte occurrence. This is
contrary to other reports, which indicated a much higher frequency of such cells. [43]
Although at this point we do not understand the origin of these cells, they could be a
sub-population of CTCs acquiring mesenchymal markers or leukocytes with an
abnormally increased cytokeratin expression. In current studies these cells were not
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classified as CTCs, however, they were included in purity calculations as contaminating
cells
2.4 Conclusion
In this study we adopted a modular approach with 3 task-specific modules for
processing CTCs in an automated fashion. The first module consisted of a HT-CTC
selection module designed with a z-configuration to obtain uniform flow properties
throughout an array of microchannels and was scalable to process volumes of 7.5 mL in
less than 45 min. The selected cells could be released from the antibody-decorated
selection surface and shuttled through an impedance sensor module. The inclusion of
the impedance sensor module was useful as a prescreening tool to allow the user to
make decisions based on the impedance response as to whether staining and imaging
of selected CTC fractions was necessary, which can result in a significant reduction in
assay cost and time.
We also described a unique staining and imaging module consisting of a high
density array of pore structures made at the intersection of large input channels and
smaller interconnecting channels. This module demonstrated a significant reduction in
the analysis time for CTC imaging; 6 h processing time for analyzing cells in the
selection module to 10 min when using the staining and imaging module. Although the
collection efficiencies were slightly lower for CTCs generated from clinical samples
compared to cell lines, this can be rectified by re-engineering the pore structures
comprising this device to possess smaller dimensions and at the same time increasing
the number of pores.
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Using this system, we have achieved some interesting clinical data for PDAC as
well, both local resectable and metastatic PDAC. We have detected CTCs in all patients
diagnosed with PDAC (see SI Table 2.1) and with high purity resulting from the high
shear forces exerted on the cells following selection in the HT-CTC module. This high
purity level should provide the ability to secure high quality molecular proﬁles of the
CTCs that can be used to guide therapy by stratifying patients with PDAC and other
solid tumors.
Using our integrated and modular system, CTC assay time was significantly
reduced compared to the approach requiring manual processing. For the manual case,
the assay time was found to be ~8 h (CTC selection, staining and imaging) with the
majority of time relegated to imaging the relatively large selection bed. For the
microsystem presented in this manuscript, the assay time was reduced to 1.5 h (45 min
CTC selection time even for 7.5 mL of blood, 15 min release time, 20 min fixation,
permeabilization and staining time and 10 min imaging time).
The modular approach presented herein provides multiple advantages toward
constructing integrated, sample-to-answer systems. These include: (i) flexibility in the
selection of materials used for construction of task-specific modules to optimize
performance for each processing step; (ii) ease of reconfiguration of fluidic cartridges
without re-engineering the entire system in order to accommodate alternative and/or
improved processing steps; (iii) ability to use separate production schemes optimized
for each module in order to reduce the overall assay cost; and (iv) high production
yields of integrated systems. The main challenge when using modular approach lies
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with the proper interconnection technologies which will minimize the potential CTC loss
during processing due to existence of unswept volumes that may trap the CTCs. Our
current efforts are directed toward integrating the modular assay using interconnects
recently described by our group which will provide zero-dead volume fluidic path. [66]
* All technical and clinical data were mainly contributed by authors J.Kamande
and M. Hupert. Collaborator and author J.J Yeh mainly obtained the blood samples
under an approved IRB #11-1924 (see appendix and permissions sections).
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CHAPTER 3. MOLECULAR PROFILING OF ENRICHED LOW-ABUNDANCE
CIRCULATING TUMOR CELLS (CTCS) USING A HIGH-THROUGHPUT
MICROFLUIDIC SYSTEM.
3.1 Introduction
Propagated malignancy is the main cause of cancer-related deaths. Despite the
harmful and destructive growth at the site of origin, primary tumors are only responsible
for only 10% of cancer-related deaths while 90% are due to metastases occurring at the
time of diagnosis or as a recurrence of a previously diagnosed cancer [1-3]. It has been
speculated that cancerous tissues shed cells into the bloodstream, which are
responsible for the metastasis of cancer. This process is not well understood however,
mouse models of tumor spread have implicated the process of an epithelial to
mesenchymal transition (EMT) by which adherent epithelial cells acquire migratory cell
fates. These models, however, differ significantly from human cancer metastases and
therefore the study of this process in mouse models is limited [4]. A better
understanding of human metastases can be obtained only from the study of Circulating
Tumor Cells (CTCs). In carcinomas, CTCs are epithelial in origin; they overexpress
EpCAM surface antigens, which is only expressed on malignant tumors derived from
epithelia and is usually targeted in peripheral blood using monoclonal antibodies
specific for EpCAM. CTCs appear at very low frequencies of about 1 CTC in 1×10 9
hematological cells.
---------------------------------* Reproduced with permission from the Analytical Chemistry. Work presented in this
chapter is centered on the molecular profiling of colorectal CTCs and authors JK, UD,
and NK were the major contributors to this section.
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Elucidating the quantity of CTCs in peripheral blood can serve as an indicator for the
clinical management of several cancer-related diseases by providing information on the
success/failure of therapeutic intervention and disease stage forecasting. Isolation and
enumeration of exfoliated CTCs in peripheral blood or bone marrow for a variety of
cancer-related diseases has already been reported such as breast, colorectal, prostrate,
renal, bladder and non-small cancers. [5-9] Studies have shown that the presence of >5
CTCs in 7.5 mL of blood from metastatic breast cancer patients has been associated
with poor prognosis and overall survival. [3, 9, 10]
Multiple approaches have been used to detect CTCs, ranging from size-based
separations to the use of immunomagnetic beads containing antibodies directed against
EpCAM [11, 12]. Although the establishment of CTC levels in peripheral blood has been
associated with poor prognosis, there are reports suggesting that this information may
not correlate with the degree of metastases, but their molecular profiles should be more
informative [13-16]. Tumors contain genetically heterogeneous cell subpopulations with
different propensities to spawn metastatic disease and therefore, if the CTC population
responsible for metastasis could be identified through unique genetic profiles,
oncologists could match proper therapy to the individual patient. Molecular profiling of
CTCs can provide additional clinical information that cannot be garnered simply by
enumerating the selected cells. For example, mutations in certain gene fragments that
are associated with metastasis, such as the KRAS mutations in colorectal cancer, can
provide opportunities for personalized treatment of a patient. It has already been shown
that metastatic CRC patients with mutated KRAS do not benefit from anti-EGFR mAb
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therapy, whereas patients with wild-type KRAS genotypes do benefit from ceturimab
and panitumumab-based treatments. [17-19] In addition, it has been noted that nontumor epithelial cells can also be present in the blood and express antigens that would
select these cells as well.
Human colorectal carcinomas harbor 19 different KRAS mutations the majority of
which are clustered in two codons. Approximately 90% of the activating mutations in the
KRAS gene are scored in codon 12 (wild type: GGT) and 13 (wild type: GGC) in exon 1
while only 5% are located in codon 61 (wild type: CAA) in exon 2. PCR/LDR assay is a
sensitive and specific method to identify and score the presence of KRAS mutations.
This assay was developed by Barany et al. and is presented schematically in Scheme
3.1 [28-31].

Scheme 3.1 Overview of the molecular profiling strategy adopted for CTCs
resident in peripheral blood
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The attractive nature of this assay strategy for the mass-limited samples anticipated
for CTC analyses is that two stages of amplification are used; exponential amplification
associated with the polymerase chain reaction, PCR, and also a linear amplification
using the ligase detection reaction LDR. In addition the assay can be configured in a
highly multiplexed fashion to search for many mutations in a single processing step.
In this Chapter, we will primarily focus on KRAS mutational analysis of CRC CTCs
that were enriched via a previously reported microfluidic system. [20] The system
included; (i) Selection, release and subsequent enumeration of CTCs via a previously
reported high-throughput microsampling unit(HTMSU) (see Figure 3.1); and (ii) an
electrokinetic

micromanipulation unit for enrichment of low-abundant CTCs for

subsequent molecular profiling of rare point mutations in gDNA of the CTCs. CTCs were
enriched into a reservoir (2 µL) for subsequent molecular interrogation for detection of
point mutations in gDNA. SW620 cells from colorectal circulating cancer cell line were
used as a model. The selected cells were enumerated using on-chip conductivity
transducer, thereby, the enumerated cells were directed to a manipulation section for
pre-enrichment into a cell collection cassette. The enriched CTCs were collected and
gDNA was extracted for genotyping. Because most KRAS mutations are localized to
codon 12 and to a lesser extent codons 13 and 61, the PCR/LDR/CE assay was
performed on KRAS oncogenes (codons 12) to detect the presence/absence of point
mutations possessing clinical relevance for the diagnosis/prognosis of colorectal
cancers.
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3.2 Experimental
3.2.1

Materials and Reagents

PMMA substrates and cover plates (0.5 mm thickness) were purchased from Good
Fellow (Berwyn, PA). Platinum wires were purchased from Alfa Aesar (Boston, MA).
Polyimidecoated fused silica capillaries were purchased from Polymicro Technologies
(Phoenix, AZ). Chemicals used for the PMMA surface cleaning and modification
included

reagent

grade

isopropyl

alcohol,

1-ethyl-3-[3-dimethylaminopropyl]

carbodimide hydrochloride (EDC), N-hydroxysuccinimide (NHS), fetal bovine serum and
2-(4-morpholino)-ethane sulfonic acid (MES) and these were purchased from SigmaAldrich (St. Louis, MO). Monoclonal anti-EpCAM antibody was obtained from R&D
Systems (Minneapolis, MN). The SW620 (colorectal cancer cell line), growth media,
HEPES buffer, Phosphate Buffered Saline (PBS) and trypsin were purchased from
American Type Culture Collection (Manassas, VA). Citrated rabbit blood was purchased
from Colorado Serum Company (Denver, CO). TRIS-glycine buffer was obtained from
Bio-Rad Laboratories (Hercules, CA). All solutions were prepared in nuclease-free
water, Invitrogen (Carlsbad, CA). Nuclease-free microfuge tubes were purchased from
Ambion (Foster City, CA) and were used for preparation and storage of all samples and
reagents. A fluorescein derivative, PKH67, was purchased from Sigma-Aldrich.
Oligonucleotide probes and primers were obtained from two different sources,
Integrated DNA technologies (Coralville, IA).
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3.2.2

Cell Culture and Imaging

SW620 cells were cultured to 80% confluence in Dulbecco’s Modified Eagle’s
Medium supplemented with high glucose containing 1.5 g/L sodium bicarbonate
(NaHCO3), 15 mM HEPES buffer, and 10% fetal bovine serum. A cell stripper solution
was prepared in 150 mM PBS and used to harvest the SW620 cells from the culturing
plate. SW620 cells were stained with PKH67 for microscopic visualization experiments
using fluorescence. A modified protocol for cell staining was implemented whereby the
dye concentration was increased twofold resulting in more evenly distributed fluorescent
labels over the cell’s periphery. Cell counts were determined by counting three aliquots
of cells in succession using a hemacytometer. The cell count accuracy was within 10%.
In cases where the cells required optical visualization to assist in the operational
optimization of the HTMSU or the electro-manipulation unit, the PMMA devices were
fixed onto a programmable motorized stage of an Axiovert 200M (Carl Zeiss,
Thornwood, NY) microscope and video images were collected during each experiment
at 30 frames/s using a monochrome CCD (JAI CV252, San Jose, CA). A Xe arc lamp
was used to excite the fluorescent dyes incorporated into the cells’ membrane.
3.2.3

Fabrication of Microsampling Unit

The microfluidic chips were hot embossed into PMMA substrates via microreplication from a metal mold master. A detailed description of the HTMSU fabrication
protocol was given in Adams et al. [21] The HTMSU consisted of a series of 51 highaspect ratio curvilinear channels that in concert formed the cell capture bed. Each
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channel was 150 µm (depth) × 30 µm (width) and shared common inlet/outlet ports
(Figure 3.1A). Curvilinear shaped capture channels were used to improve the cell
capture efficiency as described previously. [21] The cell-free marginal zone apparent in
straight channels was not observed in curvilinear channels and the cell radial
distribution was unaffected by changes in cell translational velocity. Cells migrate to the
outside of the curved channels due to centrifugal forces acting on the cells and the
cross-stream velocity component due to the reversal of the direction of curvature. The
result is an increase in the antibody/antigen encounter rate as the cells moved through
the capture beds at the relatively high-linear velocities used here. The channel width of
the cell capture bed (30 µm) was comparable with the average target cell diameter,
which was used to increase the probability of cell–antigen interactions with the solutionborne target cells. The large channel depth (150 µm) was selected to reduce the
pressure drop in high-volume flow rates and also, to increase sample processing
throughput.
Before final assembly, 1 mm holes were drilled into the electro-manipulation unit
reservoirs, input port and electrodes. Then, the chips were washed with ~0.5% Alconox
solution, rinsed and ultrasonicated with DI water followed by rinsing with 2-propanol,
and again ultrasonication for 15 min in DI water. The channels were examined under a
microscope to ensure they were not filled with debris. The embossed devices were
assembled by heat annealing a coverplate made from the same material to the
substrate. The coverplate and substrate were clamped together and placed in a
convection oven for ~20 min at 101 ˚C for UV-modified HTMSU and 105 ˚C for UV134

unmodified HTMSU. After successful heat annealing, the 125 µm diameter Pt wire
wrapped Cu electrodes were placed into the drilled holes in electro-manipulation unit.
The other end of the Pt wire was inserted into the holes drilled in opposite ends of the
microchannel.
Appropriately cleaned PMMA HTMSUs devices and cover plates were exposed
through a mask to UV radiation resulting in the formation of carboxylate moieties only in
the exposed areas of the PMMA. The exposed areas were restricted to only the cell
capture bed region of the device. UV irradiation was performed through an aluminum
mask for 10 min at 15 mWcm-2 to facilitate the formation of the carboxylated scaffold.
Pt electrodes (d = 76 µm) served as the contact conductivity sensor in the detection
zone of the HTMSU and were placed into guide channels that were positioned
orthogonal to the fluidic output channel following thermal assembly. Then, Pt wires
positioned in HTMSU and the cover plate were aligned and clamped together between
two borosilicate plates. Insertion of the electrodes was monitored using a microscope to
carefully control the inter-electrode gap (~50 µm). The cell constant of the Pt
conductivity sensor, K, was ~0.01 µm-1, which allowed for the specific detection of
SW620 cells based on their average size (diameter=25 µm).
3.2.4

Antibody Immobilization

Antibody immobilization was carried out in a two-step process. The UV-modified
thermally assembled HTMSU device was loaded with a solution containing 4mg/mL
EDC, 6 mg/mL NHS in 150 mM MES (pH~6) for 1h at room temperature to obtain the
succinimidyl ester intermediate. After this incubation, the EDC/NHS solution was
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removed by flushing nuclease-free water through the device. Then, an aliquot of 1.0
mg/mL of the monoclonal anti-EpCAM antibody solution contained in 50 mM PBS
(pH~7.4) was introduced into the HTMSU and allowed to react for 4 h. The device was
then rinsed with a solution of PBS (pH~7.4) to remove any non-specifically bound antiEpCAM antibodies.
3.2.5

SW620 Cell Capture, Release and Enumeration Using the HTMSU

To connect the HTMSU to the pump, a luer lock syringe (Hamilton, Reno, NV) was
placed on the pump equipped with a luer-to-capillary adapter (Inovaquartz, Phoenix,
AZ). This was then attached to the capillary that was sealed to the input port of the
HTMSU. A pre-capture rinse was performed with 0.2 mL of 150 mM PBS at 50 mm/s
linear velocity to maintain isotonic conditions. Then, the appropriate volume of a cell
suspension was introduced at the 27.5 µL/min volumetric flow rate, which is optimized
by Adams et al. to produce the desired linear velocity of 2 mm/s in each microchannel
comprising the capture bed. Next, a post-capture rinse was performed with 0.2 mL of
150 mM PBS at 50 mm/s to remove any non-specifically adsorbed cells.
Following a post cell capture rinse, a 0.25% trypsin solution in 0.2 mM TRIS/ 19.2
mM glycine buffer (pH ~8.3) was infused into the HTMSU. The captured cells could be
observed under a microscope until they were enzymatically removed with Stoke’s forces
acting on the wall.
The released cells from the capture surface were traversed at 1 µL/min (mm/s) linear
flow rate through a set of Pt electrodes. We used a specially designed circuit as
described earlier to measure the changes in solution conductivity due to single cell
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passing the detector as a function of time to create the desired conductivity trace from
which cell numbers were determined. (see scheme 3.2 summary of the CTC selection
assay).

Scheme 3.2 CTC selection assay on PMMA based HTMSU device. First panel
illustrates the exposure of PMMA to UV radiation to generate a monolayer of
carboxylic acid moieties that facilitate antibody attachment. The second panel
shows the selection of CTCs from blood after covalent attachment of anti- EpCAM
to the PMMA substrate. Third panel illustrates the elution of unbound cells (RBCs
and WBCs) from the captured CTCs and the release of CTCs for downstream
processing.
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3.2.6

DNA Extraction

Genomic DNA (gDNA) was extracted from captured cells using Lyse-and-Go PCR
reagent

(Pierce

Biotechnology,

IL,

USA).

Following

the

manufacturer’s

recommendations, 5 µL of Lyse-and-Go PCR reagent was added to a known number of
cells and thermocycled using the following temperatures: 65 ˚C for 30 s; 8 ˚C for 30 s;
65 ˚C for 90 s; 97 ˚C for 180 s; 8 ˚C for 60 s; 65 ˚C for 180 s; 97 ˚C for 60s; 65 ˚C for 60
s. Prior to the addition of the PCR cocktail, the samples were put to hold at 80 ˚C
3.2.7

PCRs, LDRs and CE

PCR ampliﬁcations were carried out to generate 290 bp amplicons of SW620 using
the gene-speciﬁc primer sequences: exon 1 forward –5’ TTA AAA GGT ACT GGT GGA
GTA TTT GAT A 3’, (Tm = 55.4 0C) and exon 1 reverse – 5’ AAA ATG GTC AGA GAA
ACC TTT ATC TGT 3’(Tm = 56.3 ˚C). In here, 45 µL of a PCR cocktail containing 10
mM TRIS–HCl buffer (pH~8.3), 50 mM KCl, 1.5 mM MgCl2, 200 µM dNTPs, and 0.4 µM
of each forward and reverse primers (sequences shown above) was added to the cell
lysate previously held at 80 ˚C in the thermo cycler. After a 2-min initial denaturation,
1.5 U of AmpliTaq DNA polymerase (Applied Biosystems, Foster City, CA, USA) was
added under hot-start conditions and ampliﬁcation was achieved by thermally cycling for
30 cycles at 95 ˚C for 30 s, 60 ˚C for 2 min, and a final extension at 72 ˚C for 3 min.
To test the fidelity and yield of the PCR, slab gel electrophoresis was run on an
aliquot of each reaction. From each aliquot either 2 µL PCR product for standard cell
solutions or 3 µL PCR product for microchip processed solutions was mixed with 1 µL
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loading dye and 3 µL of 1X TBE buffer for standard cell solution or 2 µL of 1X TBE
buffer for microchip processed solution, then the mixture was loaded into an individual
well of a Ethidium bromide prestained 3% agarose gel (Bio-Rad Laboratories, Hercules,
CA). The slab gel electrophoresis was typically run at 5 V/cm for 30 min. The developed
slab gel images were captured using Gel Logic 200 Visualizer (Carestream Molecular
imaging, New Haven, CT)
Bench-top LDRs were executed in a total volume of 20 µL in 0.2 mL polypropylene
microtubes using a commercial thermal cycling machine (Eppendorf Thermal Cycler
(Brinkmann Instrument, Westbury, NY, USA). The reaction cocktail typically employed
in this work consisted of 10 mM TRIS–HCl (pH~8.3), 25 mM KCl, 10 mM MgCl2, 0.5 mM
NAD+ (nicotinic adenine dinucleotide, a cofactor for ligase enzyme), and 0.01% Triton
X-100,

2

µL

of

100

nM

of

AAACTTGTGGTAGTTGGAGCTGT 3’ (Tm=71.3

the

discriminating

primer:

5’

0

C) and fluorescently labeled freshly

phosphorylated common primer: 5’ Phos/TGGCGTAGGCAAGAGTGCCT/Cy5.5Sp 3’
(Tm = 63.5 0C) and 2 µL of the PCR product as template. 40 U of Taq DNA ligase (New
England Biolabs) was added to the cocktail under hotstart conditions and the reactions
were thermally cycled 20 times for 30 s at 94 0C and 2 min at 65 0C. The LDR products
were stored at 4 0C until needed for capillary gel electrophoresis (CGE).
The LDR products were separated using a CEQ 8000 Genetic Analysis System
(Beckman Coulter, Fullerton, CA, USA). Data acquisition was performed using the
Beckman P/ACE software.
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3.3 Results and Discussion
3.3.1

PCRs/LDRs/CE

A method that can detect single point mutations in DNA is the ligase detection
reaction (LDR) coupled to a PCR.[22-30] A schematic of the PCR/LDR is depicted in
Scheme 3.1. Following PCR amplification of the appropriate gene fragments, which
contain sections of the gene with point mutation(s), the amplicon is mixed with two LDR
primers: common and discriminating that flank the point mutation of interest. The
discriminating primer contains a base at its 3’-end that coincides with the single base
mutation site. If bases are mismatched, ligation of the two primers does not occur. A
perfect match, however, results in a ligation of the two primers and product length that is
the sum of nucleotides from two primers.
In our experiment, captured and enumerated cells (see Figure 3.1) were lysed and
PCR/LDR assay has been performed using their purified genetic material. Specifically,
point mutations in codon 12 in the KRAS gene (12.2V) have been targeted that occurs
in cell line SW620. Most of KRAS mutations are localized in codon 12, but they are also
present in 13 and 61 [31-38] and they are found in nearly 35–50% of all patients with
colorectal cancer. [39-41] Once acquired, KRAS mutations are conserved throughout
the course of disease progression.
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Figure 3.1 Diagrams of the microfluidic system made via micro-replication into
PMMA from a metal mold master. and agarose gel electrophoresis of the PCR products.
(A) Cell selection HTMSU. The capture bed consisted of curvilinear channels that were
30 mm wide and 150 mm deep (51 channels). (B) Brightfield images represents time
lapse micrographs of a captured SW620 cell(a) under 0.25%w/w trypsin processing
which took 20 min for release(b). Flow rate for cell capture was 27µl/min. linear flow
velocity of 2mm/s (C) Impedance readout of approximately 26 SW620 cells released
from the capture bed at linear velocity of 2mm/s. PCR was set for 32 cycles. Each cycle:
94 °C (30 s), 60 °C (30 s),72 °C (40 s). Gel stained with EtBr products separated at 4.8
V/cm. (D) Gel Electropherogram for PCR performed on standard SW620 samples (a)
no gDNA template, Negative control; (b) DNA from 10 SW620 cells; (c) DNA from 20
SW620 cells; (d) DNA from 50 SW620 cells; (e) DNA from 100 SW620 cells; (f) DNA
from 500 SW620 cells; (g) DNA from 1,000 SW620 cells; (h) DNA from 5,000 SW620
cells; (i) gDNA template from SW620, Positive control; Lanes a-i contains 3 µL of DNA
amplicons. (E) Gel Electropherogram for PCR performed on SW620 cells obtained from
HTMSU selection followed by electrokinetic enrichment a) gDNA template from SW620,
Positive control; (b) PCR product from 10 SW620 cells selected from whole blood using
HTMSU (c) PCR product from whole blood with no SW620 cells (d) no gDNA template,
Negative control. Lanes a-d contains 3 µL of DNA amplicons.
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Before cells from the chip were tested using PCR/LDR, an assay was tested on
varying number of SW620 cells;10, 20, 50, 100, 500, 1,000, and 5,000 cells to acquire
information on limit of detection of the assay. As shown in the gel image in Figure 3.1D,
cells ranging from 5,000 to as low as 10 were successfully amplified to yield 300 bp
PCR product. To demonstrate the capability of the integrated microenrichement system
in the pre-concentration of the selected CTCs for subsequent molecular profiling, an
average volume (~1 mL) of whole blood containing low abundant CTCs was processed.
As a result, 10 SW620 cells were selected and enriched from 1 mL of whole blood and
subjected to PCR yielding the results shown in the Figure 3.1E lane b. The presence of
mutations within the amplified DNA sequence (~ 300 bp) was discerned by a follow-up
allele-speciﬁc ligation. The LDR common primer possessed a Cy5.5 ﬂuorescent label
and a 5’ phosphorylation modification to facilitate covalent coupling with the unmodified
discriminating primer in the event of successful ligation. Point mutations were confirmed
by the formation of a 43 nt LDR product, which indicated that the ligation event had
occurred between a 23 nt and 20 nt long discriminating and common primers. The
capillary gel electrophoresis results of LDR product separation generated from PCR
products of different number of cells are shown in Figures 3.2A-H. Clearly, LDR results
showed a detectable signal generated from CTCs samples (43 nt peak labeled (b)) in
Figure 3.2A -H from as low as 10 CTCs
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Figure 3.2 The LDR mixtures contained a discriminating and common primers for
KRAS c12.2V, could selectively detect mutations in G12V. Two µL of amplicons from
PCR with SW620 (mutant) were used for analyzing point mutation in the KRAS gene.
LDR was set for 20 cycles. Initial denaturation 95 °C for 2 min. Each cycle consisted
of: 95 °C (30s), 65 °C (2 min), and 4 °C as final hold. LDR was performed at capillary
temperature of 60°C, denaturation temperature of 90 °C (3 min), Injection at 2.0 kV
(30 s) and separation at 6.0 kV (20 min). Peak a represents the primer and peak b is
the LDR product. CGE analysis was acquired for the following samples; A) 0 B) 10 C)
20 D) 50 E) 100 F) 500 and G) 5,000 SW620 CTCs. The insets shown in (A) and (B)
represent a magnified view of the LDR product peaks. H) CGE trace for LDR analysis
of 50 HT29 CTCs. DNA size markers of 20 and 80 nt were co-electrophoresed with
the LDR products.
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Whole blood without CTCs and whole blood containing 10 CTCs was processed via
HTMSU and electro-manipulation system, the results of which are shown in Figure 3.3A
and 3.3B respectively. As expected, our results showed no mutation in the whole blood
that contained no CTCs (Figure 3.3A) while the results of whole blood containing 10
SW620 cells were positive (Figure 3.3B). These results indicated that the HTMSU and
electro-manipulation system were very efficient platforms, which can be adopted for cell
capture, release and enumeration for subsequent highly speciﬁc mutation proﬁling of
low abundant CTCs.

Figure 3.3 Two µl of amplicons from PCR were used for analyzing point mutation in
the KRAS gene for blood samples spiked with and without 10 SW620s. The LDR
products were analyzed using capillary electrophoresis. The capillary electrophoresis
responses for sample after processing blood with no SW620 are shown in A, and B
shows the electropherogram for 10 spiked SW620s in blood. Peak ‘a’ represents the
primer and peak ‘b’ is the LDR product for SW620.
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3.4 Conclusion
We have successfully demonstrated the ability to carry out KRAS mutational
analysis from as low as 10 CTCs in blood using an integrated system via a high
throughput microsampling unit (HTMSU) for selection and enumeration followed by the
electrokinetic manipulation unit for pre-concentrating the cells into as low volumes of 2
µL. Though only a single point mutation was analyzed as a proof of concept for CTC
genotyping using the microfluidic system, we envision our technique being multiplexed
through the use of a primary PCR of the gene of interest. This could be followed by
multiplex LDR with different primer pairs that flank multiple mutation sites being
interrogated. Finally, moving the PCR/LDR step to a microﬂuidic chip could reduce
processing time, eliminate the potential of contamination when implemented in a
centralized laboratory, and provide full process automation. Work is currently underway
in our laboratory to realize such a system. Ultimately, evaluation of this assay for
uncovering the presence/absence of prognostic mutations in the genome of CTCs
isolated from blood samples secured from patients with metastatic CRC is the next step
in evaluating the utility of our assay for assisting in the management of CRC -related
diseases.
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CHAPTER 4. ISOLATION AND CHARACTERIZATION OF CIRCULATING MULTIPLE
MYELOMA CELLS (CMMCS) USING A POLYMER MICROFLUIDIC DEVICE
4.1 Introduction
Multiple

myeloma

(MM) is

an incurable hematological neoplasm, which

constitutes 1% of all cancers diagnosed. [1, 2] This condition is associated with the
abnormal expansion of terminally differentiated B clonal plasma cells in the bone
marrow. DNA breaks as a result of additional variable diversity joining (VDJ) gene
rearrangements, hypersomatic genetic changes and isotype class switching that occur
in the Ig heavy chain variable region in post germinal centers give rise to malignant
clonal plasma cells. [3, 4] These pathological cells produce a toxic monoclonalparaprotein in the serum, which in turn affects the kidneys leading to renal failure.
Anemia is also associated with MM as a result of suppression of other vital bloodforming cells in the bone marrow by the plasma cells.[5]
The prognosis for this condition is dim with a 5 year survival rate of 40%. High
dose chemotherapy followed by autologous transplantation is the only current treatment
option for this condition. The International myeloma working group (IMWG), has defined
three stages of progression for MM: (i) MGUS (monoclonal gammopathy of
undetermined significance), considered as the premalignant stage of MM. It is
characterized by the presence of low monoclonal protein in the serum of less than
30g/L, less than 10% of clonal plasma cells in the bone marrow and no symptoms of
end organ damage such as hypercalcemia, renal insufficiency and bone lesions
(CRAB). (ii) SMM (smoldering multiple myeloma) is a more advanced stage of MGUS
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with a higher risk progression to symptomatic myeloma (10% per year) than MGUS (1%
per year). It is characterized by the presence of equal or more than 30g/L of monoclonal
protein in the serum and/or a proportion of more than 10% of clonal plasma cells in the
bone marrow but no symptoms of end organ stage damage (CRAB). (iii) Final advanced
stage is the symptomatic myeloma stage referred to as active MM and is characterized
by greater than 10% of clonal plasma cells in the bone marrow, presence of monoclonal
protein in the serum (≥30g/L) and urine and evidence of end organ stage damage
(CRAB). [2, 6]
The presence of circulating multiple myeloma cells (CMMCs) in peripheral blood
have been considered clinically significant because: (i) Studies have shown that the
frequency of occurrence of CMMCs can be used as a measure of disease activity; [7]
(ii) CMMCs can serve as an independent prognostic factor for survival in MGUS, SMM
and active MM; [8] and (iii) CMMC presence in blood may hinder autologous
transplantation protocols that rely on circulating stem cells in the peripheral blood. [1, 7,
9] It therefore follows that CMMCs have the potential to be viewed as critical biomarkers
for MM disease staging, designing therapy, and monitoring patients with minimal
residual disease. Furthermore, CMMCs could be used as surrogates for tissue biology
studies.
However, CMMCs are rarely found in the peripheral blood and when present,
constitute approximately 0.1% of the total blood composition. [1] Conventional
techniques

for

CMMC

detection have

been primarily based

on slide-based

immunofluorescence, [10-12] multiparametric flow cytometry (MFC), [9, 13, 14] and/or
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molecular methods for Ig gene rearrangements. [15] Slide-based immunofluorescence
techniques are routinely used for the clinical assessment of blood smears, however they
suffer from poor sensitivity and thus, unsuitable for very low level of CMMC detection,
especially in the asymptomatic MGUS stage. Though flow cytometry has been shown to
be more sensitive (1 CMMC per 10,000 peripheral blood cells,

PBCs) than

morphological based methods, flow cytometry requires a large sample volume and
many complex sample processing steps such as red blood cell lysis and cell staining
procedures that may lead to CMMC loss. Molecular methods, on the other hand, have
been documented to be more sensitive (1 CMMC : 100,000 PBCs). [15]
Microfluidic devices have been shown to provide better sensitivity for the
detection and enumeration of low abundant samples, such as circulating tumor cells
(CTCs) in blood whose frequency of occurrence are on the order of 1:10 9 PBCs. [16-24]
Advantages of using microfluidics for the enrichment of rare cells are;(i) they have the
ability to select CTCs with low expression of the target antigen; (ii) there is less damage
to fragile cells due to low shear stress; and (iii) minimal sample preparation is required
prior to analysis. The detection of CMMCs in peripheral blood can be paralleled to the
detection of epithelial CTCs in peripheral blood when considering the analysis modality
based upon a positive selection process in which antibodies are used to capture cells
expressing unique antigens targeted by the selection antibody. CTCs and CMMCs are
both low abundant and have prognostic significance; the only difference is that CTCs
are epithelial-based cells while CMMCs are from a hematopoietic origin.
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A number of studies for the microfluidic enrichment of CTCs have been
documented and have demonstrated superior performance criteria in terms of
throughput, purity, and recovery compared to slide-based immunofluorescence, flow
cytometry, and molecular techniques for the detection of these rare cells. [18, 22, 25]
Microfluidics could offer several advantages for CMMC analysis such as: (i) Requiring
smaller input volumes than flow cytometry as well as minimal reagents for staining
producing a reduced assay cost; (ii) selected cells may be made available for post
analysis, such as gene profiling and propagation; and (iii) in-situ immunofluorescence
as well as in-situ FISH assays are feasible, which is significant for prognostic studies
involving MM.
In a pilot study involving 20 MM patients with different disease classifications of
SMM and active MM, we demonstrate the diagnostic utility of a polymer-based
microfluidic device (coined here as a CMMC selection device) for the high sensitivity
analysis of CMMCs directly from peripheral blood. We have previously demonstrated
the isolation and enumeration of pancreatic CTCs using a similar device, which
provided high purity (~86%) of the selected cell fraction and high sensitivity (51
CTCs/mL) for clinical samples and utilized anti-EpCAM antibodies for the selection of
the CTCs bearing EpCAM antigens. [24] In this work, we demonstrate the ability to
select CMMCs via affinity selection using anti-human CD138 as the selection antibody.
In addition, we perform in-situ immunophenotyping by using fluorescently-labeled
CD56+/CD38+/CD45- markers for the positive identification of CMMCs with respect to
other infiltrating

leukocytes. For selected

samples, we
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also

demonstrate the

identification of monoclonal CMMCs by cytoplasmic immunoglobulin (cIg) light-chain
staining for the κ and λ light chains. The data presented in this work also describes the
ability to correlate the number of CMMCs selected with disease classification (SMM and
MM). Finally, we assess the ability to determine the KRAS mutational status of gDNA
isolated from CMMCs selected from patient samples using a highly sensitive
PCR/LDR/CE assay. To the best of our knowledge, this is the first report on the use of
a microfluidic device for the analysis of CMMCs directly from clinical patient samples.
4.2 Experimental
4.2.1

Fabrication of the CMMC Selection Device

Hot embossing and laser ablation were used as the primary tools for fabrication
of the CMMC selection device as described previously.[26] Mold masters used for hot
embossing were prepared in brass using high precision-micromilling (KERN 44, KERN
Micro- und Feinwerktechnik GmbH & Co.KG; Murnau, Germany) and standard carbide
bits

(Performance

Micro Tool, Janesville, WI).[26] Hot embossing of polymer

microfluidic devices was performed using a HEX03 hot embossing machine (Jenoptik
Optical Systems GmbH, Jena, Germany). The embossing conditions consisted of a
temperature of 155°C and 30 kN force for 120 s for the cyclic olefin copolymer, COC,
substrates and 160°C and 20 kN force for 240 s for poly(methylmethacrylate), PMMA,
substrates. Laser milling was accomplished using an ArF excimer laser (Rapid X 250,
Resonetics Inc., Nashua, NH) with a laser fluence at the workpiece of ~15 J/cm 2 and a
repetition rate of 50 Hz.
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The CMMC selection device (see Figure 4.2) was made from the thermoplastic,
cyclic olefin copolymer, COC, due to its ability to be embossed with high aspect rati o
microstructures, its optical clarity, its propensity to be UV functionalized with high
efficiency irrespective of channel aspect ratio, and the minimal amounts of non-specific
adsorption of contaminating cells as reported elsewhere. [27] The CMMC selection
device consisted of an array of high-aspect ratio sinusoidal microchannels with a
nominal width of 30 µm and depth of 150 µm serving as the selection bed. Selection
beds consisted of 50 sinusoidal microchannels, which were addressed using a single
inlet and outlet microchannel arranged in a unique z-configuration.
After hot embossing, the CMMC selection device and cover plate, both of which
were made from the same material, were flood exposed to broad band UV light at ~22
mW/cm2 (measured at 254 nm) for 15 min using a home-built system employing a low
pressure Hg grid lamp (GLF-42, Jelight Company Inc., Irvine, CA). UV exposure
produced carboxylic acid surface scaffolds that were used for the covalent attachment
of monoclonal antibodies for CMMC selection (anti-CD138 antibodies).[28, 29] After UV
exposure, the substrate was enclosed with the cover plate by thermal fusion bonding at
a temperature of 132°C and a bonding pressure of ~1 N/cm 2. Bonding conditions were
carefully selected to achieve high bond strength to accommodate the high pressures
generated from pumping high viscosity fluids (i.e., whole blood) at relatively high volume
flow rates (~27 µL/min), but preserve structural integrity of the high-aspect ratio
microchannels (aspect ratio = 5:1).
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After assembly, the surface of the microfluidic channels was modified using EDCNHS

chemistry.

This

consisted

dimethylaminopropyl]carbodiimide

of

50

hydrochloride),

mg/mL
5

EDC
mg/mL

(1-Ethyl-3-[3NHS

(N-

hydroxysuccinimide) in 100 mM MES (pH 6) followed by incubation with a solution of
anti-CD138 monoclonal antibodies (0.5 mg/mL; 150 mM PBS buffer, pH 7.4) overnight
at 4°C. The optimum concentration of the antibody was chosen based on studies to
optimize CTC recovery as reported elsewhere. [24]
In the case of impedance sensing of single cells, a separate device, which was
made in PMMA, consisting of two perpendicular microchannels was fabricated via hot
embossing from a mold master. A microchannel with dimensions of 50 µm width x 75
µm depth served as a conduit for cells flowing through this module. The second
microchannel (75 x 75 µm2) was used as guides to place two Pt wires, which were used
as electrodes for making the single-cell impedance measurements. Impedance
measurements were conducted using previously described circuitry.[30] Data were
collected and analyzed using a NI-USB-6009 (National Instruments) data acquisition
board and software written in LabView (National Instruments). Data were collected at 2
kHz, which allowed for sample processing through the sensor at a maximum flow rate of
20 µL/min (80 mm/s) without generating signal aliasing.
Addressing the microfluidic network and connection between the CMMC
selection device and the impedance sensor device was accomplished using glass
capillaries (Polymicro Technologies, Phoenix, AZ) affixed to inlet and outlet ports
configured on each module; the capillaries were sealed to the devices using epoxy
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(Permapoxy, Permatex, Hartford, CT). Capillaries were connected to each other using
low dead volume interconnects secured from Polymicro.
4.2.2

Materials

Pt wires (75 µm diameter) were purchased from Sigma-Aldrich (St. Louis, MO).
COC (Topas 6013S-04) plates (1/8” thick) and films (250 µm thick) were acquired from
Topas Advanced Polymers, Florence KY. 1/8" thick PMMA hot embossing stock was
acquired from SABIC Polymershapes (Raleigh, NC). 250 µm thick PMMA films were
used as cover plates for the impedance devices and were purchased from Goodfellow
Corporation (Oakdale, PA). PEEK tubing and connectors were purchased from IDEX
Health & Science (Oak Harbor, WA). Chemicals used for PMMA and COC surface
cleaning and modification included reagent grade isopropyl alcohol, 1-ethyl-3-[3dimethylaminopropyl] carbodiimide hydrochloride (EDC), N-hydroxysuccinimide (NHS),
fetal bovine serum, and 2-(4-morpholino)-ethane sulfonic acid (MES) all of which were
acquired from Sigma-Aldrich. Monoclonal anti-CD138 antibody was obtained from R&D
Systems (Minneapolis, MN). Tris-glycine buffer was obtained from Bio-Rad Laboratories
(Hercules, CA). PBS buffer and trypsin from porcine were purchased from SigmaAldrich. For CMMC immunostaining, the nuclear stain DAPI was obtained from Thermo
Pierce Technologies (Rockford, IL). For immunofluorescence analysis, antibodies, such
as anti-CD138 pacific blue, anti-CD45-FITC (HI30 clone), anti-CD56-PE, anti-CD38APC, anti-Ig kappa light chain-FITC, and anti- Ig lambda light chain-APC, were
purchased from eBiosciences (San Diego, CA). Propidium Iodide for viability analysis in
flow cytometry studies was obtained from Thermo Pierce Technologies (Rockford, IL).
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Bovine serum albumin (BSA) in PBS buffer (pH 7.4) was secured from Sigma-Aldrich.
MEM-non essential amino acids were obtained from GIBCO (Grand Island, NY GEAA).
QIAamp DNA Mini Kit (Valencia, CA) for genomic DNA isolation and purification,
custom made oligonucleotide probes and primers for both PCR and LDR reactions were
obtained from Integrated DNA Technologies (IDT, Coralville, IA). Taq 2X master mix
and Taq DNA ligase were purchased from New England Biolabs (NEB; Ipswich, MA).
4.2.3

Cell Culture

The RPMI-8226 (multiple myeloma) cancer cell line was purchased from
American Type Culture Collection (ATCC, Manassas, VA) and cultured according to
recommended conditions. Briefly, the cell line was incubated at 37˚C under a 5% CO2
atmosphere. RPMI 1640 with 2.5 mM L-glutamine supplemented with 10% FBS
(GIBCO, Grand Island, NY) was used. For subculturing conditions, RPMI-8226 cells
were grown as non-adherent cell suspensions in T25 culture flasks (Corning) by
maintaining a cell density between 5 x 10 5 and 2 x 106 viable cells/mL with fresh media
changes every 2-3 d either via dilution or replacement of new medium.
4.2.4

Flow Cytometry: RPMI-8226 Surface Antigen Characterization

All flow studies were performed at the UNC Flow Cytometry Core Center. A
Beckman Coulter (Dako) Cyan ADP instrument equipped with 11 parameter analysis
capability – forward and side scatter and 9 colors of fluorescence using 405 nm, 488 nm
and 635 nm excitations – was used. The software, which provided instrument control
and data acquisition for the Cyan, was Summit. For sample preparation, approximately
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106 RPMI-8226 cells obtained from total culture media were centrifuged and
resuspended in cold 0.5% BSA/PBS buffer in a 1.5 mL microcentrifuge tube. One-µg of
Fc blocker (Human IgG) was added to the cell suspension and left to incubate on ice for
15 min. Ten-µl of fluorescently-labeled antibody or Isotype control was added to the cell
suspension and left to incubate for 45 min at 4˚C under dark conditions. Upon
completion of immobilization of the surface antibody, cells were washed 3 times by
centrifuging and replacing the buffer with cold 0.5% BSA/PBS. Right before flow
cytometry analysis, propidium iodide (PI) was added for viability testing.
4.2.5

Clinical Samples

Patients with different clinical stage classifications of multiple myeloma (MGUS,
SMM or active MM) were recruited according to a protocol approved by the University of
North Carolina’s IRB. Blood specimens from healthy volunteers were collected under a
separate IRB-approved protocol. A total of 20 patients with unknown disease
classifications were analyzed for CMMCs while a total of 6 healthy donor blood samples
served as negative controls. All specimens were collected into BD Vacutainer® (BectonDickinson, Franklin Lakes, NJ) tubes containing the anticoagulant EDTA and were
processed within 5 h of the blood draw.
4.2.6

CMMC Selection Device Operation

Prior to blood sample infusion, the CMMCs selection module was thoroughly
washed with 0.5%BSA/PBS buffer at a flow rate of 40 µL/min for at least 5 min in order
to remove unbound antibody from the microchannel walls. Blood specimens collected
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into BD Vacutainer® tubes were placed on a nutator for at least 10 min to allow for
homogenous distribution of blood components. Following homogenization, 0.5 mL to 2
mL of patient blood was transferred into a disposable Luer Lok TM syringe (BD
Biosciences, Franklin Lakes, NJ) using a BD vacutainer female luer transfer adapter.
Immediately after transfer, blood samples were processed through the CMMC selection
device. A PHD2000 syringe pump (Harvard Apparatus, Holliston, MA) was used to
hydrodynamically drive the blood through the CMMC selection device at the appropriate
volume flow rate to attain an average linear velocity of sample through the sinusoidal
microchannels (1.1 mm/s) that would maximize recovery of the CMMCs. During the
course of blood sample introduction, the syringe was rotated by 180° along its
longitudinal axis and lightly tapped in order to prevent sedimentation of the blood
components inside the syringe to assure exhaustive and representative sample
introduction. Finally, the CMMC selection device was flushed with 2.5 mL of 0.5%
BSA/PBS at a linear velocity of 4 mm/s to remove any nonspecifically bound cells. At
this point, the device was either submitted for on-chip immunofluorescence staining for
phenotype identification or prepared for trypsin release of captured cells for impedance
sensing of the selected CMMCs.
4.2.7
On-chip Immunostaining of Phenotypic Cell Surface Antigens and
Light Chain Cytoplasmic Immunoglobulins (λ light chains and κ light
chains)
Selected cells were analyzed for surface antigens via immunostaining by; (i)
Treating with Fc blocker (IgG); (ii) incubation with anti-human CD45-FITC Abs, antihuman CD38-APC, and anti-human CD56-PE for 30 min; (iii) cell fixation with 2% PFA;
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(iv) permeabilization with 0.1% Triton-X100; and incubation with nuclear staining dye,
DAPI. For clonal population staining, selected cells were; (i) Fixed with 2% PFA; (ii)
permeabilized with 0.1% Triton-X-100; and (iii) incubated with anti-human-Ig kappa light
chain-FITC, and anti-human Ig lambda light chain-APC. The stained cells were imaged
using an inverted Olympus 1X71 microscope (Center Valley, PA) using 10x, 20x, 40x,
and 60x dry objectives equipped with a high resolution (1344 x 1024) CCD camera
(Hamamatsu ORCA-03G) and a mercury arc lamp as an illumination source. Images
were collected and analyzed using Metamorph imaging software (Olympus).
4.2.8

Impedance Sensing

Following CMMC selection device rinsing, 200 µL of the CMMC release buffer
consisting of 0.25% w/v trypsin in 25 mM TRIS/192 mM glycine buffer (pH 7.4) was
infused through the CMMC selection device to allow for the release of CMMCs from the
antibody-containing selection channels and the subsequent collection of the released
CMMCs into a microcentrifuge tube. As the CMMCs traversed through the impedance
sensor, an electrical signal was recorded using in-house designed and built electronics
as described previously. [30] The raw output data was subjected to a 1,000 point
adjacent averaging algorithm to establish the baseline for the measurement without
generating signal bias. Baseline was then subtracted from the data in order to correct
for signal drift. Impedance responses generated from CTCs were counted when the
signal-to-noise ratio exceeded 3:1. Note that during blood infusion into the CMMC
selection bed and the subsequent washing step, the output capillary of the CMMC
selection device was disconnected from the impedance sensing device with the output
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going into a microfuge tube for waste collection. When the release buffer was
introduced into the CMMC selection bed, the output capillary was then reconnected to
the impedance sensing device. The output port of the impedance sensing device was
also inserted into a 1.5 mL microcentrifuge tube where all released cells were collected
for subsequent molecular analysis.
4.2.9

KRAS Mutational Analysis of CMMCs

Genomic DNA (gDNA) was extracted and purified from HT-29 and RPMI-8226
cell lines and released CMMCs using a QIAamp DNA Mini Kit (Valencia, CA). For on
chip gDNA extraction, the lysing buffers provided in the kit were infused through the
device and eluent was further processed and purified following the recommendations of
the manufacturer.
PCR ampliﬁcations were carried out to generate 290 bp amplicons of gDNA from
HT-29, RPMI-8226 and CMMCs from clinical samples using gene-speciﬁc primer
sequences (see Table 4.1 for KRAS primer sequence). The PCR cocktail consisted of a
50 µL reaction consisting of 10 mM Tris-HCl, 50 mM KCl, 1.5 mM MgCl2, 0.2 mM
dNTPs, 5% Glycerol, 0.08% IGEPAL® CA-630, 0.05% Tween® 20, 25 units/mL Taq
DNA Polymerase, (pH 8.6) and cellular gDNA. Amplification was achieved by thermally
cycling for 35 cycles at 94˚C for 30 s, 59˚C for 2 min and a final extension at 72˚C for 3
min. PCR was carried out using an Eppendorf Thermal Cycler (Brinkmann Instrument
Inc., Westbury, NY).
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Table 4.1 KRAS PCR primer sequences
Sequence

Bases

Tm(˚C)

KRAS PCR
primers
KRAS- Forward

TTAAAAGGTACTGGTGGAGTA TTTGA TA

28

54.0

KRAS- Reverse

AAAATGGTCAGAGAAACCTTTA TCTGT

27

54.8

Slab gel electrophoresis was performed on an aliquot of the PCR products using
a 3% agarose gel (Bio-Rad Laboratories, Hercules, CA) prestained with ethidium
bromide. Amplicons were indexed against a DNA sizing ladder (50 – 1,000 bp,
Molecular Probes, Eugene, OR). Separation was performed at 4.8 V/cm in 164 1x TBE
(Tris/Boric Acid/EDTA, Bio-Rad Laboratories). After separation, the gels were imaged
using a Logic Gel imaging system (Eastman Kodak). For KRAS mutational analysis,
the PCR amplicons were either submitted for Sanger sequencing by Genewhiz
Technologies(Research Triangle ParK N.C) or used for subsequent LDR analysis. For
Sanger sequencing, DNA analyzer ABI 3730xl was used for capillary electrophoresis
and fluorescent dye termination detection
Bench-top LDRs were performed in a total volume of 20 µL in 0.2 mL
polypropylene microtubes using a commercial thermal cycling machine (Eppendorf
Thermal Cycler (Brinkmann Instrument, Westbury, NY, USA). The reaction cocktail
typically employed in this work consisted of 10 mM TRIS–HCl (pH~8.3), 25 mM KCl, 10
mM MgCl2, 0.5 mM NAD+ (nicotinic adenine dinucleotide, a cofactor for ligase enzyme),
and 0.01% Triton X-100, 2 µL of 50 nM of the discriminating primers and fluorescently
labeled freshly phosphorylated common primers (see Table 4.2 for the LDR common
and discriminating primer sequences) and 2 µL of the PCR product as template. Forty
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U of Taq DNA ligase (New England Biolabs) was added to the cocktail under hot-start
conditions and the reactions were thermally cycled 20 times for 30 s at 94˚C and 2 min
at 60˚C. The LDR products were stored at 4˚C until needed for capillary gel
electrophoresis (CGE). The LDR products were separated using a CEQ 8000 Genetic
Analysis System (Beckman Coulter, Fullerton, CA, USA). Data acquisition was
performed using the Beckman P/ACE software.

Table 4.2 KRAS LDR primer sequences
LDR primer

5’-Sequence-3’

Common_12.1
Common_12.2

GTGGCGTAGGCAAGAGTGCCAA-Cy5
TGGCGTAGGCAA GAGTGCCT-Cy5

Bases

Tm

22
20

62.2
61.5

Common_13.3
Common_13.4
KRAS 12.1 WT
KRAS 12.1 A
KRAS 12.1 C

GCGTAGGCAAGAGTGCCTTGA-Cy5
CGTAGGCAAGAGTGCCTTGA C-Cy5
TTTTTTTTTTTTTTTTTA TA TAAACTTGTGGTAGTTG
TTTTA TA TAAACTTGTGGTAGTTGGAGCTA
GAGCTG
TTTTTTA TA TAAACTTGTGGTAGTTGGA GCTC

21
21
43
30
32

59.9
58.1
58.4
54.5
55.8

KRAS
KRAS
KRAS
KRAS
KRAS

12.1
12.2
12.2
12.2
12.2

T
WT
A
C
T

TTTTTTTTA TA TAAA CTTGTGGTA GTTGGAGCTT
TTTTTTTTTTTTTTTTTTTTAAACTTGTGGTAGTTGG
TTAAACTTGTGGTA GTTGGAGCTGA
AGCTGG
TTTTAAACTTGTGGTAGTTGGAGCTGC
TTTTTTAAACTTGTGGTAGTTGGA GCTGT

34
43
25
27
29

56.1
60.0
56.3
57.8
57.3

KRAS
KRAS
KRAS
KRAS

13.1
13.1
13.2
13.2

WT
A
WT
A

TTTTTTTTTTTTTTTTTTTTGTGGTA GTTGGAGCTGG
CTTGTGGTA GTTGGAGCTGGTA
TG
TTTTTTTTTTTTTTTTTTTTGTGGTA GTTGGAGCTGG
TGTGGTAGTTGGAGCTGGTGA
TGG

39
22
40
21

59.9
56.4
61.0
58.2
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4.3 Results and Discussion
4.3.1
Flow Cytometry Phenotype Characterization of RPMI-8226 as a Model
Cell Line for CMMC
Multiple myeloma cells have a characteristic antigen surface expression that
distinguishes them from normal B-plasma cells. Normal B plasma cells go through
somatic hypermutations (SHM) in the Ig gene that take place during the germinal center
stage of differentiation while malignant clonal plasma cells are formed at the post
germinal center stage of differentiation and do not go through SHM processes resulting
in a different in surface antigen expression from normal B-plasma cells. The criteria for
MM phenotype identification that has been well documented indicates that primary
myeloma cells strongly express CD38 and CD138 and in some cases, the expression of
CD56 is also observed. In addition, a weak to almost no expression of CD45 is
observed in most stages of MM. [31] A number of studies have utilized cells lines as
models for primary myeloma cells as they share some essential features, such as Ig
gene re-arrangement, cytoplasmic idiotype expression and surface antigen expression.
[31] In this study, we selected RPMI-8226 cells as a model for primary multiple
myeloma cells.
We first performed phenotypic characterization of these cells using flow cytometry in
order to evaluate the fraction of RPMI-8226 cells expressing key myeloma surface
antigens. Results indicated that out of a defined population of approximately 60,000
RPMI-8226 cells, 98% expressed CD38, 90% expressed CD138, 74% expressed CD56
while <0.01% showed minimal expression of CD45 (see Figure 4.1). This agrees well
with studies that utilized the same cell line.[31] Though a greater fraction of RPMI 8226
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expressed CD38 than CD138, we chose to use anti-CD138 as the selection agent for
CMMCs because CD138 is solely and strongly expressed on plasma cells as opposed
to CD38, which is expressed in both lymphoid and myeloid cells and thus may not
provide the necessary specificity. [31, 32]

Figure 4.1 Fluorescence dot plots showing typical CD antigen expression on RPMI-8226
cells. All plots were gated on CD45-. The resulting dot plots indicate: (A) 74% of these
cells express CD56+; (quadrant R6); (B) 90% of the cells express CD138 + (quadrant
R6); and (C) 98% of the cells express CD38 + (quadrant R6). Fluorochromes used for
each antibody was PE for CD56, APC for CD38, Pacific blue for CD138 and FITC for
CD45

4.3.2
RPMI-8226 Cell Translational Velocity Optimization for Capture on
the CMMC Selection Device
The CMMC selection device has been utilized in previous studies in our research
group for the specific selection of CTCs on the basis of antigen-antibody interactions
(i.e., positive selection). [23, 24, 30, 33] The selection bed consisted of 50 high
aspect ratio curvilinear channels with dimensions of 30 µm (width) and 150 µm
(depth) arranged in a z-configuration format (see figure 4.2 a & b). The channel
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width dimension was designed to be as close as possible to the CTC diameters,
which ranged from 10-25 µm, while a depth of 150 µm was selected to increase the
throughput of the device. [30] Similarly, plasma cells have been found to be oval
with diameters ranging from 9-20 µm; the average cell diameter for RPMI-8226 was
measured to be 13.7 ±2 µm via optical analysis. Based on the similar dimensions of
CTC and CMMCs, we sought to use the same device for the selective capture of
CMMCs.[34] Figure 4.2 d indicate DAPI stained CMMCs captured along the walls of
a curvilinear channel in the CMMC selection device.
In previous studies, tumor specific antibodies such as anti-EpCAM were
immobilized onto the walls of a selection bed via commonly used peptide chemistry
following activation of the selection bed surfaces with UV light to generate carboxylic
acid moieties. [18, 30, 35] Based on the same premise, CD138 was anchored onto
the channels walls of the CMMC selection device and used as the selection antibody
for CMMCs.
Optimal capture conditions for cells travelling through curvilinear channels were
based on the Chang and Hammer model, which describes the dependence of the
linear velocity of solution containing antigenic-bearing targets on the encounter rate
and probability of reaction between solution-borne cells and surface tethered cell
affinity agents. [36] We proceeded to investigate the optimal linear velocity in order
to obtain the maximum recovery for CMMCs using RPMI-8226 as a model for this
study.
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Figure 4.2 (A) Schematic of the CMMC selection device with an array of 50
parallel sinusoidal microchannels and inlet/outlet channels arranged in a zconfiguration. Flow of blood is indicated by the green arrow. (B) SEM of the
selection bed depicting high-aspect ratio (30 x 150 µm, w x d) sinusoidal
microchannels and the output channel. (C) Blood processing setup in a
biological safety hood showing blood filled syringes set on a Harvard
apparatus multi–syringe pump. The syringes are each connected to inlet
capillaries interfaced to the CMMC selection devices. (D) DAPI fluorescent
image of CMMCs captured on either side of a sinusoidal microchannel.

Based on our findings as presented in Figure 4.3A, the maximum cell capture
efficiency (71% ± 6%) was found to occur at a translational velocity of 1.1 mm/s
under the conditions employed. These flow rate dependent capture studies followed
the same trend as seen in previous studies for CTCs, which indicated that the cell
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capture efficiency maximized by balancing conditions to optimize the encounter rate,
which increases at higher flow rates, and the antigen/antibody reaction time, whose
probability is reduced at higher flow rates. [37, 38] From previous studies, the
optimal linear velocity for CTC recovery was found to be 2.0 mm/s. However, our
findings indicated that the optimal translational velocity was less than that for CTCs
(1.1 mm/s) indicating that the reaction rate is much slower for the anti-CD138/CD138
interaction compared to the anti-EpCAM/EpCAM association. A number of factors
determine the rate dependent probability of association; (i) the expression level of
the target molecule on the surface of the cell; (ii) adhesion strength between the
antibody and antigen; and (iii) the accessibility of the antibody to its recognition
element.[30, 38] CTCs are adherent cells and have a tendency to stick onto
surfaces, which could increase reaction time lowering the strict dependency on flow
rate. Also, the expression level of epithelial adhesion molecules in many cell types is
very high; approximately 500,000 for breast cancer cell lines and 1,000,000 for
colorectal cancer cell lines. [39, 40] However for CMMCs, which are primarily
hematopoietic cells, they tend to be non-adherent and thus, have less of a tendency
to stick onto surfaces. Though the exact expression level of CD138, which is the
selection antigen we are using herein, has not been documented for CMMC model
cells lines, we can assume that it is lower than CTC model cell lines as seen in
tissue culture of both cells types. RPMI 8226 cells expand as suspended cells in
growth media while MCF 7s (epithelial based CTCs) tend to attach and flatten onto
the surface of tissue culture plate with the growth media covering the cells.
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Lower reaction rates of the anti-CD138/CD138 pair in the case of CMMCs
compared to the anti-EpCAM/EpCAM pair can be attributed to the expression of the
antigen molecule CD138 also referred to as Syndecan-1 molecule. In MM, the
systems of adhesion are regulated by cytoplasmic and extracellular mechanisms.
Syndecan-1 molecules are the principal MM receptor systems of the extracellular
matrix. Major roles of these molecules are to control tumor cell survival, growth,
adhesion and bone cell differentiation in MM. Reports have indicated that the
expression of CD138 is significantly decreased in MM cells and this has been
associated with poor clinical outcomes. [41-45] Also the loss of Syndecan-1 is
associated with the loss of anchorage dependent growth. Therefore, MM cells adapt
a mesenchymal morphology and behavior. [43, 45] This low expression may result
in a lower reaction rate requiring lower linear velocities to maximize the recovery as
observed in the CMMC translational studies
In order to evaluate the capture sensitivity of the CMMC selection assay, we
seeded 20, 150, 250 and 500 RPMI-8226 cells per 500 µl of blood. The best-fit linear
function to the data plotted in Figure 4.3B had a slope of 0.6865 (r2 = 0.9994). This
demonstrated the ability of the assay to maintain capture recovery at different seed
levels within the tested range. In addition the ability to detect varying numbers of cells
makes this assay suitable for the detection of varying numbers of CMMCs from patient
with different disease classification from MGUS to SMM to fully active MM. [1, 7]
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Figure 4.3 (A) Graph showing cell capture efficiency versus cell translational velocity.
In these experiments an estimated 500 RPMI-8226 cells were seeded into RPMI-1640
total cell medium. The cells were prestained with a live nuclei cell dye and were
introduced in the CMMC selection device at linear velocities ranging from 0.4-2 mm/s.
Capture efficiency was determined by the ratio of RPMI-8226 cells captured on the
CMMC selection device to the total number of RPMI-8226 cells selected on chip and
collected in the effluent. Number of cells captured was determined by both brightfield
and fluorescence microscopy. (B) Calibration plot of RPMI-8226 cells seeded (20-500
cells/0.5 mL) of healthy donor blood and processed through the device at the
optimized linear velocity of 1.1 mm/s. Capture sensitivity for the CMMC selection
assay was given by the slope (m = 0.6865, r2 = 0.9994).

4.3.3
On-chip Phenotype and Clonal Identification of RPMI-8226 Cells and
CMMCs from Clinical Samples

Multiparametric flow cytometry (MFC) immunophenotyping has been used in
clinical research studies for the differential diagnosis of MGUS, SMM and active
MM.[46] There has been growing consensus on the use of a panel of antigens for the
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detection of both normal and aberrant plasma cells in the bone marrow or in the
peripheral blood. In particular, six-color analysis of CD138, CD38, CD45, CD56,
cytoplasmic Ig κ, and cytoplasmic Ig λ, has been employed in MFC for the detection of
both normal and aberrant clonal fractions of plasma cells. [1, 47] Each of these antigen
markers have a functional role and are classified as: (i) Co-receptors for plasma cell
signaling; (ii) molecules involved in cell-to-cell adhesion; (iii) molecules that facilitate
growth of plasma cells; and (iv) proteins involved in cell survival. [32] Both CD138 and
CD38 are used in combination and are found to be expressed in plasma cells. CD138 in
particular is a heparin sulfate proteoglycan that promotes cell surface adhesion to
collagen, fibronectin and thrombospondin. CD56 is found in some cases of active MM
and has been correlated with the aggressiveness of the disease and thus, a useful
marker for follow-up of minimal residual disease. [46, 47] For specific identification of
clonal populations within the plasma cell population, the addition of both cytoplasmic
immunoglobulin (Ig κ) and (Ig λ) light chain markers have been utilized. Normal plasma
cell populations will have approximately equal expressions of both light chain
cytoplasmic immunoglobulin markers, while pathological plasma cells will show higher
expressions with κ/λ ratios >0.5. [48]
Although flow cytometry has been shown to be more clinically sensitive than
morphological methods, flow cytometry does have some drawbacks for the analysis of
pathological plasma cells in peripheral blood. For instance, the depletion of plasma cells
in the blood resulting from RBC lysis procedures leads to sample loss, flow cytometry is
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not an enrichment technique and therefore the analysis is only limited to detection and
renders the plasma cells detected inaccessible for further downstream analyses such as

Figure 4.4 In-situ immunophenotyping and cytoplasmic staining of CMMCs. Panels
(A) and (B) represent RPMI-8226 cells and CMMCs selected in a polymer microchannel
via anti-human CD138/CD138, respectively. Positive CMMC surface markers are
presented by micrographs: (b,g) CD56-PE; (c,h) CD38-APC; while (d,i) are negative
control marker CD45-FITC for leukocyte identification. DAPI was used for nuclei
identification (a,f,l). Panel (C) represents cytoplasmic staining of RPMI-8226 cells, which
are the λ light chain expressing cells, using anti human Igκ-PE (m) and anti-human IgλAPC (n). (D) H&E image of a released plasma cell from the CMMC selection bed using
enzymatic release via trypsin. All bars represent 10 µm.

propagation and molecular profiling. Microfluidics has, on the other hand, been shown
to be more sensitive in the detection and enrichment of rare occurring cells compared to
flow cytometry. [18, 22, 24, 40] The advantages of using microfluidics compared to flow
cytometry include the fact that smaller samples are sufficient for the analysis, samples
are contained in an enclosed device therefore minimizes sample contamination, no
sample pre-processing steps are required, and finally, assay cost reduction due to the
use

of

lower

amounts

of

fluorescently
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tagged

antibodies

required

for

immunophenotyping of the plasma cells. Studies involving the enrichment of CTCs
using microfluidics have demonstrated on-chip immunophenotyping for the identification
and enumeration of CTCs captured on chip. [24, 49] Following the same concept, we
performed in-situ immunophenotyping of plasma cells selected by CD138 from either
cell suspensions of RPMI-8226 in media as well as plasma cells selected from clinical
samples. For surface staining, the following criteria was used to identify both normal
and aberrant plasma cells; CD38+/CD56+/DAPI+/CD45- and/or CD38+/DAPI+/CD45and/or CD56+/DAPI+/CD45- (see Figure 4.4 and 4.5). All other phenotypes were
considered to be contaminating cells. Our results indicated that successful on-chip
immunophenotyping was achieved in both RPMI-8226 model myeloma cell line (Figure
4.4A) and in CMMCs enriched from clinical samples (Figure 4.4B). Standard on-chip
fluorescence imaging conditions were optimized using the RPMI-8226 cell line as a
control as we already established the phenotype using flow cytometry as discussed in
Section 4.1.
For cytoplasmic light chain staining, the approach we adopted used fluorescentlylabeled anti-cytoplasmic Ig (k) and anti-human Ig (λ) to identify clonal populations of
CMMCs captured on-chip. In order to establish monotypic clonality using cytoplasmic
light chain staining conditions, we used RPMI-8226 as a standard because it has
already been established that RPMI-8226 is a lambda light chain expressing cell line
(See Figures 4.4C and 4.6A).[31]

Therefore, for one patient, we identified clonal

populations of Kappa expressing cells, which formed a greater majority of the total
number of cells captured on the CMMC selection chip (see Figure 4.6B).
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Figure 4.5 Alternative confirmatory phenotypes for CMMCs isolated from a
patient sample. Panel (A) represents 6 CD138 selected cells that were found to
be CD56+ (b) and CD38– (c). Panel (B) shows a mix of two phenotypes side-byside, 3 CD38+/CD56+ positive cells (g,h) next to 2 CD56+/CD38- cells (h). Both
panels show dim to no expression of CD45 (c,i). Nuclei were stained with DAPI
(a,f). Composite images are show in e & j for both panels.
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Figure 4.6 Panels A and B represent cytoplasmic staining of a clinical sample
with active MM (B) using anti-human Ig κ-PE (b,e) and anti-human Ig λ-APC (c,f)
and (C) cytoplasmic staining of RPMI-8226 cells as a control. Results indicated
strong Kappa expression for approximately 70% of the cells enumerated and
weak expression of about 10% of the total cells captured on the device for the
clinical sample. Imaging conditions: 5x objective, 1.2 s exposure time for PE
(Kappa) and 9 s exposure time for APC (Lambda). Bars represent 150μm.

4.3.4

CMMCs in SMM and Active MM Clinical Samples

A total of 20 MM patient samples were analyzed in a blind study in order to
determine the correlation of disease state and number of CMMCs selected. MM patients
diagnosed were diagnosed with either SMM (n = 6) or active MM ( n =14 ). For active
MM patients, we isolated an average of 347.8 ±300.4 CMMCs/mL, median = 213
CMMCs/mL with a range of 100 to 742 CMMCs/mL. CMMCs were selected in all
patients with active MM. For the controls, in most cases no CMMCs were observed. We
also analyzed blood from 6 patients who had been determined to have asymptomatic
SMM. We found an average of 13.2 ± 8.9 CMMCs/mL for this group of patients. Based
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on the Kruskal-Wallis test (p = 0.00005), there was a significant difference in the
CMMCs/mL between asymptomatic SMM, and symptomatic MM, and controls. Pairwise
Wilcoxon Rank-Sum tests suggested that there was a significant difference between
active MM and healthy patients (p = 0.0006). Between SMM and controls there was also
a statistically significant difference in terms of CMMC numbers (p = 0.04). Comparison
between asymptomatic SMM and symptomatic MM patients also indicated a significant
CMMC number difference (p = 0.0006). This data is summarized in the box plot shown
in Figure 4. 7.

Figure 4.7 Box plots presenting count of CMMCs selected in chip from MM patient
blood samples. Data are normalized to 1 mL. Lower and upper edges of box show
25th and 75th percentiles, respectively. Solid line in box represents median, and
solid diamond represents mean. Error bars show maximum and minimum values.
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4.3.5

KRAS Mutational Analysis of Isolated CMMCs (PCR/LDR/CE)

RAS mutations in codons 12, 13 and 61 have been found at high frequencies in a
number of cancers such as pancreatic, colorectal, lung and thyroid cancers.[50-58]
The RAS genes encode membrane-associated guanosine triphosphates (GTPases),
which are important signaling intermediates involved in the responses to a number
of growth factors.[50] It therefore followed that alterations in the RAS gene may
affect cell growth leading to cancer. RAS mutations have been shown to have
diagnostic significance in colorectal cancer, whereby patients with mutated KRAS do
not benefit from anti-EGFR therapy, whereas patients with wild-type KRAS
genotypes do benefit from this therapy. [56, 58, 59]
In multiple myeloma, while the pathogenesis of the disease is not clearly known,
reports have hypothesized that activating mutations of RAS oncogenes may
contribute to interleukin 6-independent growth of myeloma cells and the suppression
of apoptosis.[60] Both NRAS and KRAS mutations have been documented with a
frequency of occurrence of 39% in newly diagnosed patients. It has been reported
that NRAS mutations within codon 61 are more frequent than NRAS mutations found
in 12, 13, and KRAS mutations in most MM cases. [61] The same study also
indicated that KRAS mutations had prognostic significance with tumor burden and
survival rate while NRAS mutations did not. Other reports also indicated that multiple
mutations were found in some patients indicating heterogeneous populations of
pathological plasma cells. [57]
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In this study, we performed KRAS mutational analysis from purified genomic
DNA extracted from both RPMI-8226 cells captured on the selection device and from
CMMCs captured on chip from 4 clinical samples. In order to evaluate the sensitivity
of our CMMC selection assay for subsequent KRAS mutational analysis, we seeded
RPMI-8226 cells ranging from 20 to 750 cells into 0.5 mL of total cell medium and
subsequently enriched them using the CMMC selection device. These cells were
then released from the selection bed via trypsin, enumerated using an impedance
sensor and the eluent was purified for its gDNA content with the purified material
subjected to PCR. In addition, CMMCs selected from 4 clinical samples using the
CMMC selection device were also released and subjected to PCR. gDNA extracted
from HT-29 cells as well as RPMI-8226 cells were used as positive controls for the
PCR analysis. PCR products from all 4 patient samples were submitted for Sanger
sequencing for the possible detection of SNPs in the KRAS gene. Results seen in
Figure 4.9f showed a single mutation found in patient 36 at the 37 th nucleotide,
where G was substituted for A; this denotes the G13S mutation, which results in a
glycine substitution for serine in the resulting protein product. Although direct
nucleotide sequencing is a well-established technique, the sensitivity was not
adequate for the detection of low abundant mutant copies in a high background of
wild type copies.
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Figure 4.8 Agarose gel electrophoresis of PCR products generated from (A)
RPMI-8226 cells and (B) CMMCs from 4 patient samples. PCR was run with 35
cycles with an initial denaturation step of 2 min and final extension for 7 min. Each
cycle consisted of: 94°C (30 s), 59°C (30 s), 72°C (40 s). The gel was stained with
ethidium bromide and run at 4.8 Vcm-1. (A) Gel electropherogram for PCR
performed on RPMI-8226 cells with; (a) no gDNA template; (b) gDNA template
from HT-29 directly (positive control); (c) gDNA from 20 RPMI-8226 cells; (d) gDNA
from 150 RPMI-8226 cells; (e) gDNA from 500 RPMI-8226 cells; and (f) gDNA from
750 RPMI-8226 cells. Lanes a-f contain 5 µL of DNA amplicons. (B) Gel
electropherogram for PCR performed on CMMCs obtained from 4 clinical samples
analyzed using the CMMC selection device: (a) No gDNA and used as a negative
control; (b) gDNA template from RPMI-8226 directly used as a positive control. (c)
gDNA from patient 35; (d) gDNA from patient 36; (e) gDNA from patient 37; e)
gDNA from patient 38. Positive controls consisted of harvesting either HT-29 or
RPMI-8226 cells from the culturing dish (~1,000 cells), lysing them, performing a
solid-phase extraction of the gDNA followed by PCR of the purified sample.

LDR coupled to PCR is a method that has been shown to detect single-point
mutations in DNA with sensitivities approaching 1 mutant copy in 4,000 wild type
copies and is thus better equipped to detect KRAS mutations from heterogeneous
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samples

compared

to

Sanger

sequencing.[62-64]

Briefly,

following

PCR

amplification of the gene fragment of interest, the amplicons are mixed with two LDR
primers, a common and discriminating primer that flank the point mutation of
interest. The discriminating primer contains a base at its 3’-end that coincides with
the single base mutation site. If the 3’ nucleotide of the discriminating primer is not
complementary to the mutation site being interrogated, ligation of the common and
discriminating primers does not occur. A perfect match between the 3’-end of the
discriminating primer to the target DNA does occur, ligation of the common and
discriminating primers occur and resultant LDR product length becomes the sum of
nucleotides from these two primers. LDR products are then detected using CGE
(capillary gel electrophoresis) based on differences in the electrophoretic mobility of
ligated versus unligated primers. In our experiments, purified PCR amplicons from
HT-29, RPMI-8226 and CMMCs from patients 35, 36, 37, 38 were used in the LDR
assay for the detection of possible KRAS mutations in codons 12 and 13.
Sequences used in this study for both discriminating and common primers for each
possible mutation were designed from Khanna et al. and are listed in Table 2. [63]
Genomic DNA from the HT-29 colorectal cell line was used as a negative control for
these studies as it is well documented that it bears no KRAS mutations. gDNA from
the RPMI-8226 cell line has been documented to be heterozygous, bearing both the
wild type allele as well as a KRAS mutated allele with the G12A (c12.2C) mutation.
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Figure 4.9 LDR and Sanger sequence analysis of sequence variations in the KRAS
gene for codons 12 and 13 with the gDNA secured from RPMI-8226 cells, HT-29 cells,
and CMMCs isolated from clinical samples. LDR consisted of 20 cycles. Initial
denaturation was performed at 95°C for 2 min. Each cycle consisted of: 95°C (30 s);
60°C (2 min); and 4°C as a final hold. LDR products were analyzed using CGE
performed at a capillary temperature of 60°C with an initial denaturation step prior to
injection at 90°C for 3 min. CGE injection was performed at 2.0 kV for 30 s and
separation was done at 6.0 kV. CGE electropherograms for various samples are
shown in (A-F). LDR product peaks are represented with an asterisk *. (A) shows the
49 nt LDR product denoting the G12A mutation found in RPMI-8226; (B) and (D) show
no LDR products at the c12.2 C locus for HT-29 and patient 35, respectively; (C)
shows a 54 nt LDR product denoting the G12S mutation for patient 35; and (E) shows
a 42 nt product denoting the G13D mutation for patient 36. DNA size markers of 20
and 80 nt were co-electrophoresed with the LDR products. (F) Sanger sequencing
trace for gDNA secured from patient 36 at codons 12 and 13 with an additional peak at
c13.1A denoting the presence of mutant copies bearing the G13S mutation.
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Results from the CGE electropherograms (Figure 4.9a-e) indicated the presence of
a 49 nt LDR product in the RPMI-8226 analyses denoting the G12A mutation (Figure
4.9a) while no LDR products were seen in the HT-29 analysis (Figure 4.9b) for all
mutant primer sets tested; these results are in agreement with reported studies.[40] A
summary of the LDR products observed from the 4 patient samples analyzed are
presented in Table 4.3. Multiple KRAS mutations were found in all of these samples
indicating the heterogeneous nature of the cells captured from the respective blood
samples. Patients 35 and 38, whom were known to have active MM, showed multiple
LDR products as well as higher band intensities compared to patients 36 and 37
indicating higher fractions of KRAS mutant copies in their gDNA than patients 36 and
37, who were classified with the SMM (see Figure 4.8). These results are in agreement
with early studies that indicated the frequency of these activating RAS mutations are
associated with advanced stage MM compared to earlier stages of MM.[57, 61]

Table 4.3 KRAS mutational analysis on clinical samples
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4.4 Conclusion
In this study, we have demonstrated the use of a polymer-based microfluidic
device that has the capability to select CMMCs directly from whole blood as a
potential diagnostic tool for MM. This device was able to isolate CMMCs, which are
mesenchymal type cells, at a recovery of ~71% directly from whole blood using
CD138 as the selection antigen. The CMMC selection device required no sample
preprocessing, such as the lysis of RBCs, minimizing CMMC loss. We have
previously demonstrated the scalability of this device and therefore, it could be
reconfigured to process larger volumes of blood (7.5 mL) so as to provide higher
number of cells for extensive molecular profiling studies. [24] The ability to perform
on-chip immunophenotyping as well as clonal testing was demonstrated for CMMCs
selected and underscores its potential use in prognostic investigational studies for
MGUS, SMM and active MM disease states. Preliminary clinical data presented here
on SMM and active MM demonstrates the device sensitivity to the disease state.
Future studies will also include MGUS group of patients in the clinical studies and
focus on patient monitoring for drug targeting studies and gene expression profiling
for MM clinically relevant markers.
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CHAPTER 5. FUTURE STUDIES: DEVELOPMENT OF A MODULAR WORKSTATION
FOR CTC GENOTYPING
5.1 Background
Until recently, affinity based technologies focused on CTC detection and analysis
have primarily targeted the EpCAM antigen for the specific capture of epithelial based
CTCs in blood circulation. However, growing trends on CTC based studies have
indicated the existence of tumor cells bearing other additional phenotypes. In
particularly, it has been suggested that CTCs expressing invasive phenotypes downregulate and lose their epithelial antigens (including EpCAM) partly by a process called
the epithelial-to-mesenchymal transition, EMT. [1-3] It has also been hypothesized that
in some epithelial-based cancers, like mCRCs, CTCs consist of different subpopulations that may have a continuum of phenotypes besides the epithelial one. [1, 4,
5] Therefore, the ability to enrich different CTC sub-populations may be compromised if
only EpCAM is used as the selection target. [6, 7] It is critical to consider the use of
orthogonal selection agents that target, for example, invasive phenotypes, to better
predict early and/or metastatic disease. Therefore, it will be necessary to use a
combination of mAb for CTC selection.
We will generate CTC selection strategies that will recover with high efficiency
two different CTC phenotypes. One antigen is associated with an epithelial phenotype,
EpCAM(+), and the other is directed at a more invasive phenotype, seprase(+), a serine
protease localized in the invadapodia. Seprase, which is an integral membrane
gelatinase protein, has been shown to be involved in degradation of the ECM and
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enhance tumor growth and proliferation. Seprase is differentially expressed on the
invading front of human malignant tumor cells, especially localized within the
invadopodia. Chen and co-workers have developed an invasion-based assay that
consists of a collagen adhesion matrix (CAM) to collect CTCs by their ability to invade
and ingest the CAM, which is enabled by seprase. [8-10] Seprase has been found to be
overexpressed on tumor cell surfaces in >90% of human epithelial cancers; [11] it is
highly expressed in CRC and PDAC tissues. [12]
The use of microfluidics for the selection and enumeration of CTCs from clinical
samples has been reported. [13-18] However a system for the recovery of CTCs from
whole blood, their enumeration and correlation of phenotype with genotype for particular
CTC sub-populations has yet to be reported. The development of an integrated
workstation that can offer these capabilities is paramount because molecular
information obtained from CTCs can generate clinical information that cannot be
garnered from enumeration data alone. We will use two selection targets, seprase and
EpCAM, for this workstation to select CTCs that have an invasive and/or epithelial
phenotype, respectively. The CTC selection units will be configured into thermoplastic
modules integrated with other task-specific modules to build a fluidic bio-processor,
which is an integral component to the workstation acquiring molecular and phenotype
data on CTCs (Figure5.1).
The challenge with genotyping gDNA from CTCs is the low copy number of the
assay’s input. This is especially true for mCRC, which typically show low yields of
CTCs. [19] Indeed, most studies invoking molecular profiling of CTCs have used
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reverse transcription PCR with mRNA surrogates because of their higher copy number .
[20, 21] [22, 23] CTC analysis of gDNA for mCRC demands minimal sample handling to
reduce sample loss and contamination. The proposed workstation will target these
issues. We will detect point mutations in KRAS, BRAF and PIK3CA genes isolated from
CTCs of mCRC patients using the modular workstation equipped with a fluidic bioprocessor that can carry out highly multiplexed assays using PCR/LDR. [24-27]
Collaborative work between the Soper and Barany laboratories has demonstrated that
PCR/LDR assays can be carried out in microfluidic architectures, [26, 28] but these
systems have not been utilized for CTC molecular profiling. We will employ a
continuous readout strategy using molecular beacon probes formed from an LD R and
FRET with CCD time-delayed integration, CCD-TDI, [29] detection.
In Chapter 2, we developed a modular microfluidic system that could isolate,
enumerate and phenotype CTCs. [30] To improve and build upon this system, our future
objective would be to develop a modular workstation that will select circulating tumor
cells (CTCs) from two orthogonal sub-populations can provide phenotypic and
genotypic information about CTCs using CRC and PDAC as case examples ( see
Figure 5.1). The innovative concepts in this workstation will include: (1) Serial
arrangement of two CTC selection modules targeting seprase(+) and/or EpCAM(+)
CTCs. To improve CTC recovery, nano-texturing of the channel walls and floors will be
accomplished using 3D molding. [29] To release the CTCs from the antibody-decorated
selection surface, we will investigate bifunctional oligonucleotide linkers, which will have
a nucleotide that can be cleaved enzymatically or photolytically. (2) An addressable 2D
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cell array composed of a multi-layered structure with valving and fluidic layers
possessing excellent optical properties and a laser to eject the cells individually from
specific addresses of the array. (3) Integration of molecular processing strategies of
CTCs using an automated work flow in a closed architecture with continuous readout.

Figure 5.1 Schematic of the bio-processor, an integral component of the CTC
workstation. The bio-processor is composed of modules for CTC affinity selection
(Seprase and EpCAM), impedance sensor (CD), cell array with valving fluidic layer,
SPE module, and imaging module for the real-time monitoring of molecular beacons via
FRET produced as a result of a successful LDR. The fluidic motherboard also contains
continuous flow thermal reactors for lysis, PCR and LDR. The PCR is multiplexed
containing primers for the appropriate gene fragments to be interrogated. The LDRs are
spatially multiplexed with each thermal reactor monitoring a specific locus. While the
system shows a 6-plex LDR, this can be scaled for higher multiplexing as needed. The
workstation also contains a scanning microscope for phenotyping cells in the 2D array,
the imaging microscope for CCD-TDI readout, thermal control units, electronic control
boards for data processing, and fluid handling hardware (syringe pumps), which are not
shown.
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5.2 Enrichment of Invasive and Epithelial Phenotype CTCs from Whole Blood
using Serially Arranged Modules Positioned on a Fluidic Motherboard

One of the main aspects of CTC enrichment is to achieve maximum yields due to
their rare occurrence in blood.

The design, fabrication and evaluation novel CTC

selection modules that contain 3D nanotextures in thermoplastic channels (PMMA or
COC) decorated with antibodies targeting different CTC sub-populations will be
determined. These modules will be arranged serially on a fluidic motherboard. We will
also investigate the use of oligonucleotide bifunctional linkers to increase the load of
mAb to the selection bed surface and provide a flexible and simple approach to release
the CTCs from the selection surface.
5.2.1

Bi-functional Linkers

We will incorporate, oligonucleotide bifunctional linkers with a modified nucleotide
base engineered into them that can be cleaved enzymatically or photolytically to release
CTCs

following

selection.

Bifunctional

linkers

will

consist

of

single-stranded

oligonucleotides of varying lengths and sequence content, containing a primary amine
at the 5’ end and a thiol group at the 3’ end. The polymer surfaces (substrate and cover
plate) will be UV-activated following hot embossing. The two pieces will then be
compression-sealed at room temperature and the bifunctional oligonucleotide injected
into the fluidic network in the presence of EDC/NHS (Scheme 5.1). This is followed by
thermal fusion bonding of the cover plate to the substrate near the Tg of the substrate
(~105oC for PMMA). Figure 5.2 shows a fluorescence scan of PMMA that has been UVactivated and covalently linked to an oligonucleotide through its 5’ amino group using
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EDC/NHS chemistry. As can be seen, both before and after thermal treatment, the
amount of oligonucleotide remains constant due to the thermal stability of the
oligonucleotide and its inability to be buried into the substrate when heated. Following
thermal fusion bonding of the assembled cover plate, the antibody, which has been
treated

with

succinimidyl

trans-4

(maleimidymethyl)

cyclohexane-1-carboxylatate

(SMCC), reacts with the thiol groups (Scheme 5.1).

Scheme 5.1 Single-stranded oligonucleotide bifunctional linkers used for
covalently attaching mAbs to polymer surfaces bearing accessible carboxylic
acids. The oligonucleotide linkers (see upper left) can contain any sequence,
but is shown with a string of ~15 dT units that do not contain a primary amine so
as not to be cross-linked to the surface. X1,2 can be a uracil or photocleavable
residue as seen in the upper right. Following device incubation with target cells,
they can be released from the selection surface.

The strategy provides the ability to use different cleavable entities that are
engineered into the oligonucleotide linker, such as a photocleavable or dU residue;
these residues can be cleaved using light or a USER enzyme system, respectively
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(Figure 5.2). For a dU residue, we can use the urasil-specific excision reagent that
consists of uracil DNA glycosylase (UDG) and Endonuclease VIII to remove the dU
residue

Figure 5.2 Effect of thermal fusion bonding on the stability of oligonucleotide
bifunctional linkers. After modified oligonucleotide linkers were covalently attached
to UV-activated PMMA, the PMMA was (A) heated to 107ºC for 20 min or (B) not
heated. The fluorescence intensity profiles from a vertical section of two spots
(see dotted yellow line) in (A) and (B) are shown in (C). To interrogate the stability
of the attached oligonucleotide linkers, solution complements to the linkers
bearing a fluorescent reporter were hybridized to the linkers. As can be seen in
(C), no difference in the fluorescence intensity resulted. (D) UV-activated PMMA
reacted with EDC/NHS coupling reagents and a single-stranded oligonucleotide
linker containing a 5’ amino group and Cy3 at its 3’ end. A single dU residue was
added internally to the linker. After coupling, the linker was subjected to the USER
system, which cleaves the linker at the dU residue. The loss of fluorescence is
indicative of the cleavage. Spot (a) is a linker with no dU residue, while spot (b)
contained the dU residue in the linker
5.2.2

Nanotextured Surfaces

Previous research has shown that nano-texturing can improve recovery of CTCs
or other cell types on nanopillars, [31-35] roughened PDMS[36] or silica nanobeads.
[37] Nano-texturing increases the number of anchoring points for protrusions emanating
from the CTC surface. [35] However, in all reports, nano-texturing was done only to the
floor of the selection devices. We have developed an innovative replication-based
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technology that will allow integration of topological nanostructures into microfluidic
channels in 3D. [37-39]A schematic showing the processing strategy is depicted in
Figure 5.3 and is based on polymer 3D molding, which enables the rapid production of
3D patterns over large areas with high throughput and at low-cost. One of the key
components for the process is the use of a flexible intermediate stamp with the desired
nanostructures that can conformally mold into non-planar surfaces. PDMS was chosen
as the intermediate stamp because it can stretch during the 3D fabrication process and
return to its original dimensions following embossing. Figure 5.3 presents SEMs for 3D
molded structures where nano-bumps (~200 nm in diameter x 100 nm height) or micropumps (~6 µm in diameter x 5 µm height) were formed on the floor and side-walls of a
fluidic channel equipped with a cover plate. While the cover plate was not subjected to
nano-texturing, it could also contain these structures
We will fabricate a test device for evaluating different nano-texturing modalities
and operating conditions to optimize CTC recovery, especially for cells with the
antigenic targets positioned on sub-cellular protrusions. The test device will consist of
microchannels 150 µm wide and 30 µm deep. These channel dimensions are based on
our previous data showing these dimensions provide high recovery of CTCs.[13]
However for this test device, we will switch the depth and width from previous versions
to produce low aspect ratio channels to permit interrogation of UV-activated channels
for both their chemical (XPS, confocal fluorescence microscopy, water contact angle
measurements) and topographical (AFM, SEM) characteristics. We will also evaluate
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the ability to mold these 3D structures in high aspect ratio channels (150 µm deep; 30
µm wide).

Figure 5.3 The top panel shows the process strategy for performing 3D molding
using a PDMS intermediate molding tool containing nano-textures. The finished nanotextured chip is shown with ridges, but the nano-structure architecture can be altered
through lithographic changes imposed on the PDMS intermediate molding tool. (A-C,
E) SEM images of PMMA CTC selection channels containing nano-textures with
bumps that range from 200 nm (A-D) to 5 µm (E). (D, F) Fluorescence microscope
images of nano-textured channels that were sealed with a cover plate using solventassisted bonding. Fluorescein was used as the dye seed in a 1X TBE buffer (pH =
8.5). These images demonstrate no leakage following cover plate bonding. For S EMs
(A, E), the CTC device was sealed with a cover plate, dipped in liquid N2 and fractured
so as to produce a cross section of the nano-textured channel to show the integrity of
the nano-features. In (A), the nano-texture structures are not visible at the
magnification used but can be seen in (B), before cover plate bonding; (C), after clover
plate bonding. In (E), the features are clearly visible.
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5.2.3

Seprase and EpCAM

The ability to enrich sub-populations of CTCs using mCRC and mPDAC as
models will be investigated. The sub-populations will be selected based on Seprase and
EpCAM expression. Figure 5.4 shows expression differences between several selected
cell lines. We will generate two CTC selection modules; the bed of one module will be
decorated with mAb for Seprase (D8, D28, etc.) and the other module will contain antiEpCAM antibodies. Both modules will be interconnected to the fluidic motherboard of
the workstation in a serial arrangement (Figure 5.1). To initially evaluate the serial
selection process, we will use Hs5427T (Seprase(+)) and SW620 (EpCAM(+)) cell lines
seeded into a buffer to serve as positive controls. Because of the modular set-up of the
system, we can investigate the selection of Seprase(+) and EpCAM(+) CTCs in each
module to understand cross-reactivity. Following the positive control experiments, the
cell lines will be seeded into “normal” blood to determine leukocyte infiltration during this
dual-selection process. Finally, the serial selection process will be used to evaluate
CTC sub-type numbers in mCRC and mPDAC patients.

Figure 5.4 Expression differences of Seprase and EpCAM for various cancer cell lines
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5.3 Generation of an Addressable 2-Dimensional (2D) Cell Array for
Immunophenotyping via Fluorescence Imaging

After the affinity selection of CTCs, we need to immunophenotype them using an
automated workflow strategy with minimal sample handling. In addition, we may want to
address groups of CTCs that have a common phenotype, or even individual CTCs to
correlate phenotypes with genotypes. We should note that because of the CTC
selection process from whole blood, we will have already sorted CTCs based on two
divergent phenotypes, Seprase(+) and EpCAM(+).
5.3.1 Dual Electrode Pair Impedance Sensor
We have developed an impedance sensor that can detect CTCs based on size to
discriminate them from interfering leukocytes and other materials. [13, 17, 40, 41] The
sensing was accomplished using a resonance impedance measurement employing a 40
kHz waveform, which produced signal amplitudes dominated by the cell size. Figure 5.5
provides results for SW620 cells spiked into buffer. [13, 17, 40] Also shown are
leukocytes that were isolated from a buffy coat and measured using impedance
sensing. There was some overlap in the signal amplitudes between the two cell types;
the misclassification frequency was ~15%. We will look to improve the discrimination
between interfering cells and CTCs by adding an additional measurement channel. We
will use our existing sensor and place another electrode pair in series operating at a
higher frequency, which has been coined single-cell impedance cytometry. [43]
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Figure 5.5 Single-cell electrical impedance detection. (A) Histograms for
impedance response for leukocytes (blue bar) and SW620 cancer cells (red
bar). (B) SW620 (red) and leukocyte (blue) cell size measured optically. (C)
Plot of impedance response, phase and magnitude, as a function of the
voltage frequency applied to the electrodes. Taken from ref.[42] with
permission. (D) New electrode design in which thin films electrodes are
deposited on both top and bottom plates.

The high frequency impedance measurement can provide information about the
intracellular and cell membrane composition; [42, 44, 45]

the low frequency

measurement provides information about cell size (Figure 5.5). Scatter plots can be
constructed from signal amplitudes from each sensor .[43] For example, the x-axis will
consist of cell impedance amplitudes for an 100 kHz channel while the y-axis plots
impedance amplitudes at >1 MHz. [46] We can also monitor electrical phase shifts,
which can provide cell viability information.
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5.3.2 2D Cell Array
In most cases, microfluidic chips for the positive selection of CTCs carry out
fixation, permeabilization, staining and rinsing on the selection surface and thus need to
scan the entire selection bed in three dimensions, significantly increasing processing
time. [15, 47, 48] To eliminate this, our 2D cell array will define the position of a single
cell within the array once it has been released from the selection bed
Several examples of cell arrays using microfluidics have been reported that
consist of microwells with the cells entrapped using magnetic [49] , dielectrophoretic
[50-53] ,hydrostatic [54], optical [55, 56]

or confinement [57]

forces. Here, we will

generate a low-density 2D microwell array module for immunophenotyping CTCs with
the ability to individually address each pixel of the array. We do not require high density
arrays because the sample has already undergone pre-selection
In Chapter 3, we presented a 2D cell array as an imaging module where CTCs
released from the HT-CTC module were collected and stained with fluorescently labeled
markers for phenotype identification. [58] Collection efficiencies of 96% for fixed cells
and 85 % for live cells were obtained; however, the collection efficiency for CTCs from
patient samples was 72%, indicating a loss through suction, or infiltration of leukocytes
with similar dimensions to CTCs. This module was interfaced to the staining and
imaging module via capillaries which may account for dead volume that may lead to
sample loss. For the modular workstation, the 2D cell array will adopt a different format
with additional features.
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The proposed cell array consists of microwells positioned in an X by Y
arrangement (Figure 5.6A). Each well will be approximately 25 µm deep with a diameter
of 25 µm because these dimensions are slightly larger than most CTCs; a well aspect
ratio of 1 can typically accommodate a single cell.[59] The microwells will be laserdrilled through a suspended polymer membrane made by double-sided hot embossing.
The bottom of each microwell will be sealed against a three-layer structure made from
fluorinated ethylene propylene (FEP), which possesses good transmissivity at most
optical wavelengths. Each row of the array will contain a microchannel underneath that
is terminated with a valve, Figure 5.6B. [60] After bonding of the FEP layers to PMMA,
laser ablation can be used to drill through the FEP top plate to allow hydrodynamic
access to each well of the array. The microwells will be made from PMMA because of
its good biocompatibility and minimal amounts of non-specific adsorption it shows. The
valving and microchannels layers will use FEP because of its relatively large elongation
at break value [60],and its Tg, which is close to PMMA. FEP’s Tg allows it to be
thermally fusion bonded to PMMA. FEP has a refractive index of 1.344, which is similar
to that of water. Therefore, the holes created on the bottom of each microwell will not
degrade image quality. An additional advantage of FEP is that it has a higher Young’s
modulus than PDMS so when applying a slight negative pressure, it will not pull the
membrane onto the valve seat; these valves are normally open and a solenoid will close
them.
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Figure 5.6 (A) Schematic of the 2D cell array. The array consists of microwells made
from PMMA and a transparent FEP layer (3 layers) that serve as the fluidic, valving
and through-hole units for this module. (B) Fabrication method for the polymer valves;
this is accomplished using 2-sided embossing and laser drilling. The small arrows
show the flow direction when the valve is open. To close the valve, a mechanical
solenoid is used.[29] (C) Cross-sectional view of the microwell with the FEP layers
serving as the well floor with access hole to the fluidic network. The total force (F T)
acting on the cell to resist movement is gravity (F G), hydrodynamic (if applied, F H) and
Stokes (FS). For a HeLa-type cell, FT ≈ FG ≈ 29.9 pN. For a 1064-nm laser beam of
modest intensity, a scattering force, F S, will be able to eject the cell from this well. F H is
applied using either positive or negative operation of a syringe pump and valves,
poised on the backside of this module (they are not visible in this schematic).

The module works by imposing a low flow of a cell suspension across the
microwell array. Cells can be injected into the well by gravity and/or a small negative
pressure applied to each well through the FEP fluidic layer. The entrapped cells within
the wells have been fixed, permeabilized and stained prior to release from the selection
surface and can be imaged using a 4-color microscope. The microscope we will use for
phenotyping CTCs will have a mercury arc lamp, a filter cube to select the appropriate
filter set and a CCD transducer. The microscope will be mounted on an XYZ motorized
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translational stage. [61] We will use the standard panel to characterize CTCs including
DAPI (blue), CD45 (FITC; green), and cytokeratins (phycoerythrin; red). If we require a
fourth antigen in the panel to determine Seprase(+) cells expressing EpCAM or a
cancer stem cell marker, we can use AlexaFluor 680. The microscope can image the
array through an access port machined into the fluidic motherboard from the backside
(see Figure 5.1).
To address each microwell of the 2D cell array, we will investigate the use of
radiation pressure produced by a 1064-nm Nd:YAG laser fiber coupled to the scanning
microscope.[62-66] For a laser beam that is not tightly focused, a scattering force will
typically exceed the gradient force and thus propel the cell along the optical axis.
Therefore, when the microscope is placed in line with a well, radiation forces will eject a
cell from that well when this force exceeds FT (Figure 5.6C). To assist in the ejection of
cells from a well and keep the laser power low to avoid thermal effects, we can also
open the valve along a row of the array to apply a slight positive FH. To evaluate cell
ejection, we can monitor the array in real time using the imaging microscope.
To test the operational metrics of this module, we will use SW620 and Hs2857T
cell lines. For the initial experiments, the cells will be visualized using brightfield
microscopy to determine cell entrapment efficiency. Both the cell suspension flow rate
and negative pressure applied through the FEP fluidic layer will be investigated to
optimize the entrapment process as well as the ejection process.
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5.4 Integration of Fluidic Modules for Continuous Molecular Processing of
CTCs even at the Single-Cell Level

We will expand on the use of a molecular assay for detecting point mutations in
gDNA using PCR/LDR with FRET readout. [67, 68] In our previous publications using
this assay for CRC, only HT29 and LS180 cell lines were used and not CTCs isolated
from clinical samples. Specifically, we will detect the presence/absence of point
mutations in KRAS, BRAF and PIK3CA using PCR and spatial multiplexing with
different primer pairs for the LDR for processing all mutations from a single input, and
thus, requiring only a single color. Spatial multiplexing involves splitting the PCR
products into equal volumes and feeding this into a series of LDR continuous flow
thermal reactors (linear amplification). Each reactor will be seeded with LDR primers
specific for the locus being interrogated. The donor/acceptor dye pair we will use is
Cy5/Cy5.5 due to the relatively large Förster radius associated with this dye pair (61.7
Å) and the red emission of the acceptor, Cy5.5 (λem ~700 nm), which reduces
background fluorescence improving the signal-to-noise ratio in the measurement. [69,
70] In addition, the donor/acceptor dyes will be attached to the 3’ and 5’ ends of LDR
generated molecular beacons using a 3-carbon spacer to provide optimal energy
transfer efficiency. [68] This assay is attractive for mass-limited samples because of the
two stages of amplification used, PCR and LDR.
5.4.1

PCR/LDR/FRET Assay for the Detection of KRAS Point Mutations
For this task, we will integrate the modules for molecular processing of mCRC

CTCs extracted from the 2D cell array either as groups or individuals based on their
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phenotype. This phase of the project builds from our recent publication concerning the
molecular profiling of mycobacterium tuberculosis bacterial cells as detailed in the
preliminary results. [29] However, instead of using the universal array as the readout
platform for the PCR/LDR, we will employ a continuous readout format using LDR
formation of molecular beacons and spatial multiplexing with CCD-TDI readout . The
modules that we will utilize for this phase of the processing pipeline include: (1)
Continuous flow thermal reactors for CTC lysis, PCR and LDR. Polycarbonate will be
used as the substrate for the motherboard due to its high Tg, minimizing microstructure
deformation during

thermal processing

and

its large elongation at break to

accommodate valves [29] (2) SPE module made from polycarbonate that possesses a
high density of microposts formed during the embossing step used to make the fluidic
network The choice of polycarbonate here is predicated on the fact that this material,
when exposed to 254 nm UV-light, generates a surface with a high propensity to let
nucleic acids condense on its surface when a cell lysate is suspended in polyethylene
glycol and NaCl. The attractive feature of the SPE module is that multiple cells can be
sequentially lysed and immobilized to the extraction bed to analyze a group of cells.
All modules will be interconnected to the motherboard using low-dead volume
interconnects laser-drilled into the module and motherboard and conformally sealed
with plastic tubing.[29] This gives us the ability to disconnect any module from the
motherboard and replace it with a new module. In addition, we have the flexibility i n
choosing which modules may be needed for the specific assay. Dummy modules
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connecting input/output ports can be inserted into the motherboard to eliminate
unnecessary processing steps.
5.5 Optical Read Out Module
In this task, we will generate an optical readout module for molecular beacon
probes that are produced from the LDR continuous flow thermal cyclers. A diagram of
the fluidic module for this purpose is depicted in Figure 5.7A. It consists of an
embedded polymer waveguide and fluidic channels placed orthogonal to the waveguide
embedded into the cover plate of this module; the evanescent field is used to excite
fluors in the fluidic channels. We have generated a similar polymer waveguide that was
made from COC and embedded into a PMMA substrate. [71]

Unfortunately, the

refractive index difference between the waveguide core (COC) and the cladding
(PMMA) was minimal so the penetration depth of the evanescent field into the adjacent
fluidic channel was small (~100 nm) when light was launched into the waveguide near
the critical angle. In this application, we will use FEP as the cladding material for the
core COC waveguide. The refractive index of FEP is 1.344 compared to 1.48 for PMMA
and 1.53 for COC. Therefore, the penetration depth of the evanescent field using FEP
should be on the order of 500 nm. With a higher penetration depth of the evanescent
field, we can produce sampling channels for this optical reader that are on the order of 2
µm wide with a depth (0.5-1.0 µm) that can be produced using optical lithography and
generate high sampling efficiency of the LDR-generated molecular beacons. [72] Also,
the channel width is sufficient to fit a series of channels within the field-of-view of a high
collection efficiency microscope objective; therefore, no scanning is required improving
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the duty cycle. [73] We have prepared channels in various polymers consisting of these
dimensions (Figure 5.7B). In the present application, we will require the appropriate
number of channels to interrogate all of the relevant mutations, with one channel
serving as a positive control. The molding tool to fabricate this module will be prepared
via UV-LiGA.
The COC core waveguide is situated in a guide channel hot-embossed into the
FEP cover plate. A PDMS stencil containing a cavity defining the coupling prism is
placed on top of the FEP cover plate reversibly sealed to the PDMS stencil. A COC
melt, which utilizes a solvent for COC that does not damage FEP, is allowed to fill the
cavities defined by the PDMS stencil and FEP channel. For the PMMA-embedded
waveguide, we used toluene as the solvent for COC. For FEP, we will initially test
toluene, but other solvents can be investigated as well. Following removal of PDMS
stencil, the FEP cover plate is bonded to the FEP fluidic substrate.
For reading fluorescence generated when molecular beacons flow over the
planar COC waveguide, we will use an imaging CCD camera operated in TDI mode,
which provides better signal-to-noise ratio and higher duty cycle compared to a
snapshot operational mode for the CCD. [72] The gain in the signal-to-noise ratio for
TDI versus a snapshot scales with N1/2, where N is the number of pixels along the shift
axis.
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Figure 5.7 (A) Schematic of the optical readout module that consists of input
connects to accept the output of each LDR thermal reactor, which are poised on the
motherboard. This module consists of a cover plate with an embedded COC planar
waveguide and readout channels that are approximately 2 µm in width and 350-500 nm
in depth at the detection zone (evanescent excitation of solution molecular beacons).
(B) Molding tool is prepared via UV-LiGA.

In our previous work using CCD-TDI readout, double-stranded DNA stained with an
intercalating dye was monitored; however, the excitation beam was launched at the side
of a microchannel array instead of using a waveguide.
5.5.1

Characterization and Clinical Application of the Modular Work
Station

One challenge in evaluating new technologies is the limited predictive value of
traditional preclinical models, such as tumor cell lines. [74]

Primary human tumor

xenograft models have been proposed as a significant advancement over conventional
xenograft models. Unlike cell lines where there is dependence on various subpopulations that are able to survive on a plastic dish, PDX tumors retain the
heterogeneity from which they were derived. Recent reports suggest that patient tumors
directly explanted into immunocompromised mice exhibit response rates to cytotoxic or
targeted therapies similar to that seen in humans. In this phase of the project, we will
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use human tumor xenografts for evaluating the ability of the workstation to select
various sub-populations of CTCs to learn about CTC numbers for each selection
phenotype (seprase and EpCAM) for mCRC and mPDAC
We will design PCR and LDR primer sets for codons 12 (6 loci) and 13 (1 locus)
in KRAS for genotyping mCRC CTCs using PCR/LDR with FRET readout. Prof. Francis
Barany will be the consultant in guiding our primer design for PCR/LDR. [26, 27, 75, 76]
We will also design primer sets for the BRAF V600E mutation (1 locus) and PIK3CA
mutations in the p85, C2, helical and kinase domains (2 loci; exons 9,20).[77].
We will first isolate and analyze CTCs from established PDXs using the
workstation. Each mCRC PDX represents an individual patient tumor and will be
expanded to 5 mice per PDX to account for variability. As our mCRC PDXs have been
characterized for KRAS and BRAF mutations, we will select 5 KRAS mutant (mt)
(codons 12 and 13), 5 KRAS wild-type (wt) and 2 BRAF mt mCRC PDX. We will
evaluate an additional 10 KRAS wt mCRC PDX for PIK3CA mutations. As the expected
frequency of mutations in PIK3CA is 30%, we anticipate the analysis of 15 KRAS wt
mCRC PDX will be sufficient to detect 3-5 PIK3CA mts. All PDX blood draws (~500 µL,
left ventricle) will be analyzed for KRAS, BRAF, and PIK3CA mutations using PCR/LDR
and compared to our known analysis of mutations from the human tumor tissue and
correlated to the phenotype. We will also compare the KRAS, BRAF and PIK3CA
mutations in EpCAM(+) and seprase(+) mCRC CTCs.
We will next evaluate the utility of the workstation prospectively in patients with
mCRC. On average, 6-8 patients with mCRC undergo operations at our institution each
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month. Our PDX Program will allow us to perform a prospective validation of CTCs in
patients and compare our mutational analysis of driver genes with the matched deidentified tumors. We will prospectively collect matched blood and biopsies from 60 deidentified patients. We calculate this sample size will be needed to detect at least 1
patient tumor with a BRAF mutation. [77] DNA from tumor specimens will be analyzed
using validated PCR/LDR assays. Comparisons between bench-top and the workstation
genotyping of CTCs will be carried out throughout the course of this study. The metrics
for operational performance will consist of CTC limit-of-detection to get quality genotypic
data for CTC sub-populations, sample loss and potential contamination issues. For
bench-top genotyping, CTC modules will be operated as stand-alone units.[78] Due to
the configuration of the fluidic motherboard and the cleavable linkers we are employing,
we can collect separately seprase(+) and EpCAM(+) CTCs into microfuge tubes for
bench-top processing.
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